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Abstract
María del Sol Jiménez, Ph. D. 
Department of Chemistry
University of Kansas 
July 2007 
The use of ring-closing metathesis (RCM) for the construction of small,
medium and large rings has become a powerful tool in organic chemistry.  The 
application of this reaction for the construction of sulfur heterocycles (S-heterocycles)
as potential pharmacological targets has become a major focus in our laboratories.
The goal of this dissertation is to demonstrate the application of RCM for the 
construction of a variety of sulfur heterocycles including sultams, cyclic sulfamides,
cyclic sulfamoyl carbamates and cyclic sulfamoyl ureas with the ultimate goal of 
biological screening.  The successful synthesis of 6- to 11-membered ring S-
heterocycles using this method will be discussed.
The first project described in this dissertation involves the use of RCM for the
construction of 6-membered ring sultams with multiple handles for further 
functionalization and library development. The utility of these sultams as versatile 
scaffolds for a variety of diversification reactions using solution-phase chemistry will 
be explained.  Also, the successful application of ROMP-derived reagents developed 
in our laboratories as facilitated protocols for diversification strategies and subsequent 
library development will be discussed.
iii
The second project describes the use of RCM for the facile construction of 
sulfamide analogs of the HIV protease inhibitor DMP 323.  The accomplishment of 
both symmetric and unsymmetric cyclic sulfamides will be discussed. Also, efforts 
towards the synthesis of N-hydroxy cyclic sulfamides will be presented. 
The third project describes the use of RCM for the construction of 
9-membered ring sulfamoyl ureas and 9- to 11-membered ring sulfamoyl carbamates.
iv
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Chapter 1 
Introduction: Synthetic Approaches to Sultams 
1
1.1 Sulfonamides: An Important Class of Medicinal Agents 
The purpose of this chapter is to review the literature for the preparation of 
sultams, which are the cyclic versions of sulfonamides.  A brief and general 
introduction of the biological relevance of acyclic sulfonamides will be used to
preface the topic. 
1.1.1 Introduction 
The sulfonamide moiety (-SO2NHR) has become an important pharmacophore
in medicinal chemistry; its origin, however, was the result of mere coincidence.  The 
sulfonamide story began in the early 1900’s, with the discovery of azo dyes, which 
were widely used in the production of fibers and textiles.  Widespread use quickly 
prompted efforts to improve its properties.  It was found that the introduction of the
sulfonamide group (-SO2NH-) gave dyes superior stability to light, greater water 
solubility during application, and greater fixation to fibers.1  In 1933, a research group 
out of Germany, ignored the myth that bacterial infections could not be cured by 
drugs, and began testing the action of various dyes against streptococcal infections in
mice.  To their delight, the red dye prontosil was found to be an effective agent,2  and 
further studies demonstrated its applicability in humans.  Moreover, biological studies 
involving prontosil revealed that it acted as a pro-drug, which is metabolized in the 
body into the chemotherapeutically active sulfanilamide (Figure 1.1).  This important
discovery led to its clinical use for the treatment of bacterial infections.  Subsequently,
many compounds related to sulfanilamide have been synthesized and referred to as 
2
sulfonamides.  Currently, over 30 agents containing the sulfonamide moiety are under 
clinical use.
Figure 1.1 Chemical stucture of prontosil and sulfanilamide
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1.1.2 Biological Properties of Sulfonamides
Due to its extensive biological profile, the sulfonamide moiety gained
widespread use in medicinal chemistry.  Chemical studies involving pKa
measurements have revealed that this versatile entity is comparable to the carboxyl
group and therefore, it has been utilized as a carboxyl isostere.1   Studies have shown
that sulfonamides serve as non-hydrolyzable amide surrogates, making them an ideal
functional group in the synthesis of peptidomimetics.3-7  It has been observed that the
introduction of the sulfonamide moiety induces an increase in metabolic stability 
towards protease-catalyzed degradation of peptidosulfonamides.8  For this reason,
they have been used as transition-state analogues for amide bond hydrolysis, and have 
found applications as potential HIV protease inhibitors.5, 6  Biological studies 
performed with histamine H3 receptor antagonists revealed that the in vitro profiles of 
sulfonamides were superior to the corresponding amide analogs.9-11
Sulfonamides contain a high density of hydrogen bond donor and acceptor 
sites, which allow them to coordinate to amino acid residues located at the active sites
of enzymes.9  The sulfonamide moiety is also associated with increased
bioavailability and increased water solubility relative to other polar groups 
3
(e.g. amides).9 These interesting properties have promoted the incorporation of the 
sulfonamide group into a growing number of compounds, many of which have 
demonstrated biological activity. 
Sulfonamides have found extensive use as both carbonic anhydrase and 
matrix metalloproteinase inhibitors, which are a family of zinc containing enzymes
implicated in a number of diseases such as arthritis and cancer.12, 13  Studies 
performed on sulfonamides revealed that inhibition of these enzymes is brought about 
by their ability to mimic the tetrahedral transition state when binding to catalytic zinc
ions located at the active site of the enzymes.14-16  A model study that supports this
coordination is presented in Figure 1.2.
Figure 1.2 
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Sulfonamides have also shown antibacterial, diuretic, hypoglycemic,
antithyroid, and most recently, antitumor activity.17  Representative examples of 
biologically active sulfonamides are shown in Figure 1.3 including the antibacterial
agent sulfathiazole,18 the carbonic anhydrase inhibitor acetazolamide19 which has 
been clinically used for more than 45 years, the anticancer agent E7070 which is 
currently in advanced clinical trials,20 the HIV protease inhibitor amprenavir,21 and
4
most recently Viagra (Sildenafil),22 one of the most marketable drugs used for male
erectile dysfunction. 
Figure 1.3 Biologically active sulfonamides
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Only two examples of naturally occurring sulfonamides have been reported to 
date.  Altemicidin,23 isolated from the actinomycete strain Streptomyces sioyaensis,
has shown tumor cell growth inhibition and psammaplin C,24 isolated from the marine
sponge Psammaplysilla purpurea (Figure 1.4).  With the sparcity of naturally
occurring sulfonamides, in conjunction with the attractive biological features of 
sulfonamide-containing compounds described so far, synthetic efforts towards the 
construction of compounds containing this functionality have been pursued.  In many
cases, their syntheses have been accomplished from readily available starting
materials.
Figure 1.4 Naturally occurring sulfonamides
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1.1.3 Synthetic Approaches Toward Sulfonamides
The usual way of preparing sulfonamides is by treatment of sulfonyl chlorides 
with ammonia or amines (Reaction 1, Scheme 1.1).25  Treatment with ammonia gives 
primary sulfonamides, while primary and secondary amines give N-alkyl
sulfonamides and N,N-dialkyl sulfonamides respectively. Alternatively, sulfonamides
can be prepared from the corresponding sulfinyl chlorides, which are coupled with 
amines to form sulfinamides and then oxidized into sulfonamides (Reaction 2,
Scheme 1.1).26  In cases where the sulfonyl chloride is not commercially available it 
Scheme 1.1
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can be prepared from the respective sulfonic acid or their sodium salts using 
chlorinating agents such as PCl5, POCl3, SOCl2, phosgene, or triphosgene (Reaction 1, 
Scheme 1.2).26  Aromatic sulfonyl chlorides can be prepared by treatment of aromatic
rings with chlorosulfuric acid (ClSO2OH) (Reaction 2, Scheme 1.2).
27
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1.2 Sultams: Cyclic Sulfonamides 
1.2.1 Biological Properties  of Sultams 
Cyclic sulfonamides (sultams) although not found in nature28 have also found
applications in drug development.  Examples of biologically active sultams include
the antiepileptic agent Sulthiame,29 the antiinflamatory agent Ampiroxicam,30
Brinzolamide31, 32 for the treatment of glaucoma, S-2474,33 a new anthiarthritic drug
candidate that is now under clinical trials, HIV-1 inhibitors34, 35 selective inhibitors of
Calpain I,36  and most recently PBTD’s37  which are a new class of candidates for the 
treatment of chronic myelogenous leukemia (CML) (Figure 1.5).
Figure 1.5 Biologically active sultams 
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In addition to their medicinal value, sultams have been successfully used as
chiral auxiliaries,38, 39 reagents,40-42 artificial sweeteners (i.e. saccharin),43 and
agricultural agents.44  For example, the well known Oppolzer sultam 1.1 has been
utilized in numerous asymmetric reactions (Reaction 1, Figure 1.6),38, 39 sultam 1.2
has been used as a stereoselective oxidizing agent (Reaction 2, Figure 1.6)42 and 
7
sultam 1.3 has found application as an electrophilic fluorinating agent to provide 
monofluorinated ketones (Reaction 3, Figure 1.6). 40, 41   In agriculture, sultams have 
been used as herbicides.44
Figure 1.6 Sultams used as reagents in organic chemistry
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Despite the importance of sultams in medicinal and synthetic chemistry,
methods to access these important compounds in an enantiomerically and
diastereomerically pure fashion are still limited.
1.2.2 Synthesis of Sultams via Intramolecular Reactions 
The following sections describe the most relevant methods that have been 
utilized to synthesize sultams, all of them based on intramolecular processess.  The 
most common methods reported to date include the Heck reaction, Diels-Alder
cycloaddition, 1,3-dipolar cycloaddition, base and acid-promoted cyclizations, radical
8
cyclizations, rhodium (Rh)-catalyzed cyclizations and ring-closing metathesis (RCM). 
Other more recently reported methods such as metal-catalyzed cyclizations involving
gold (Au) and copper (Cu) will also be discussed.  Although a variety of 
intramolecular cycloaddition reactions for the synthesis of sultams will be presented,
considerable emphasis will be given to RCM cyclization, which is the key synthetic 
method used to access a variety of sulfur heterocycles (S-heterocycles) throughout
this dissertation.
1.2.2.1  Heck Reaction 
A number of cyclization methods relying on C-C bond forming strategies 
have been reported for the synthesis of sultams.  Of particular interest is the Heck
reaction, where catalytic amounts of Pd, a suitable ligand and a base are utilized.45, 46
In 2005, Metz and coworkers used the intramolecular Heck reaction for the synthesis
of ?-methylene-?-sultams as potential cysteine protease inhibitors and demonstrated
the use of these S-heterocycles as Michael acceptors with different sulfur
nucleophiles.47  Cyclic and acyclic allyl amines were used to synthesize the
sulfonamide substrates applying the general method described before (Reaction 1, 
Scheme 1.1).  Initially, cyclization of the sulfonamide substrates was performed under
two different catalytic conditions: standard conditions (Method A: 5 mol % Pd(PPh3)4,
Et3N (2 equiv.), MeCN, reflux, 2 h) and Method B (5 mol % Pd(OAc)2, 11 mol % 
P(o-Tol)3, Bu4NCl (2 equiv.), Na2CO3 (2 equiv.), MeCN, reflux, 1 h) which has been
successfully utilized by Minnaard and coworkers for the synthesis of lactams
(Scheme 1.3).48
9
Scheme 1.3 
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Although the desired cyclized products were obtained under these reaction 
conditions, a mixture of byproducts resulting from double bond migration was
observed (Scheme 1.3).  To circumvent this problem, a variety of silver and thallium
additives were investigated.  Silver(I) additives have been documented to play a 
crucial role in the Heck reaction by increasing reaction rates, preventing deactivation
of the catalyst, minimizing double bond isomerization of the products and enhancing 
enantioselectivity. 45  The silver salts act as effective halide scavengers, switching the
Heck reaction from a neutral to a cationic pathway through dissociation of the halide.
Thallium salts, although highly toxic, have also been used as halide scavengers in the
Heck reaction through a similar pathway.45  The optimized conditions for the 
cyclization of sulfonamides 1.4-1.7 (Scheme 1.4) were obtained in the presence of 10 
mol % Pd(OAc)2 as the catalyst, 11 mol % of P(o-Tol)3 as the ligand, and 2 equiv. of 
thallium acetate (TlOAc) as an additive in refluxing MeCN for 3-5 h.  The resulting
sultams were obtained in good yields (64-75%) as the only products (Scheme 1.4).
In contrast to N-benzyl sulfonamides 1.4-1.7 sulfonamides containing a free 
N-H bond failed to cyclize under the optimized reaction conditions, even under 
prolonged reaction times (5 days in refluxing acetonitrile). 
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Scheme 1.4 
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While Metz and coworkers were able to use the Heck reaction for the 
synthesis of monocyclic and bicyclic sultams, Evans and coworkers applied the same
synthetic strategy towards the synthesis of tricyclic sultams, which were later
converted to pyrrolidines and piperidines.49  Although using the identical palladium
catalyst as Metz and coworkers [Pd(OAc)2], no additive seemed to be necessary to 
perform the reaction.  Treatment of the aromatic sulfonamide in Scheme 1.5 with 10 
mol % Pd(OAc)2 in the presence of 20 mol % PPh3, K2CO3 (2 equiv.) and DMF at 
110 °C for 15 h afforded tricyclic sultam 1.8 in very good yield (87%).
Scheme 1.5 
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However, in a number of cases, the product arising from double bond 
isomerization was obtained.  Further reduction of sultam 1.8 led to the synthesis of 
aryl-substituted pyrrolidines.  This sequence was adapted to the synthesis of the 
enantiomerically pure 2-phenylpyrrolidine structures present in many natural and
nonnatural aza sugars (Figure 1.7).50
Figure 1.7 
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Analogous to the work reported by Metz, Vasudevan and coworkers utilized a 
Heck coupling reaction for the synthesis of bicyclic aromatic sultams such as 1.1051
(Scheme 1.6).  Sulfonamide 1.9, generated via an aza-Baylis-Hillman reaction with 2-
bromo-4-(trifluoromethyl)benzenesulfonamide, 4-methoxybenzaldehyde and methyl
acrylate,  underwent intramolecular Heck coupling with 5 mol % Pd(OAc)2, 2 mol % 
P(o-tolyl)3, and Et3N in THF at 160 °C for 1 h to afford the conformationally strained
bicyclic sultam 1.10 in moderate yield (60%) (Scheme 1.6).  Although this procedure 
afforded the desired bicyclic sultam, high temperatures were required.
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1.2.2.2  Diels-Alder Cyclization
The Diels-Alder reaction has been fairly utilized for the synthesis of bicyclic 
sultams.  In 1996, Metz and coworkers reported the synthesis of ?- and ?-sultams via
the Diels-Alder cycloaddition reaction starting from N-benzylaminoalkyl substituted 
furans.52  Benzylamines 1.11 and 1.12 were prepared from their respective racemic
alcohols by nucleophilic displacement of their tosylates with benzylamine.  These
amines were then treated with vinylsulfonyl chloride, forming the sulfonamide
intermediates 1.13 and 1.14 that readily underwent the cycloaddition reaction to
provide bicyclic sultams 1.15 and 1.16 in high yields as a mixture of diastereomers
(Scheme 1.7). 
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The cyclization reaction was also performed with sulfonamides 1.17-1.19,
featuring a three atom tether connecting the furan and dienophile moieties (Scheme 
1.8).  In contrast to vinyl sulfonamides 1.13 and 1.14, (Scheme 1.7) sulfonamides
1.17-1.19 did not undergo cyclization during their preparation.  Although no ring 
closure was observed for 1.17 (R=H) in refluxing toluene, an equilibrium mixture of 
1.18-1.21 and 1.19-1.22 was attained at this elevated temperature, with the best 
conversion achieved for 1.22 (R = Bn, 91% yield).
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The application of high pressure (13 kbar in CH2Cl2 at room temperature) was 
also examined.  These reaction conditions were applied to the Diels-Alder cyclization
of sulfonamides 1.23 and 1.24 and the results compared to the reaction performed
under refluxing toluene (Table 1.1).53
Table 1.1 Intramolecular Diels-Alder reaction of sulfonamides 1.23 and 1.24
R2
R
1
Bn
S
N
O
O
1.23, R1 = R2 = H
1.24, R1 = R2 =Me
H
H
R2
R1
S
N
O
O
Bn
+
H
H
R2
R1
S
N
O
O
Bn
1.25 1.26
Conditions A:
13 kbar, CH2Cl2, rt
Conditions B:
toluene, BHT, reflux
Reaction Conditions R1, R2 1.25:1.26 ratio % Yield 
A H 1.0 : 1.6 79
B H 1.0 : 1.0 76
A Me 1.0 : 1.9 81
B Me 1.6 : 1.0 61
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The radical scavenger BHT proved beneficial for the reaction performed
under refluxing toluene by suppressing side reactions at elevated temperatures.  From 
the results shown in table 1.1, it is evident that the yields of the cyclization products 
improved at higher pressures.  These conditions also favored the formation of the 
endo product, whereas at atmospheric pressure there is no endo/exo discrimination.
When the same reaction conditions were applied to cyclic 1,3-diene 1.27 (Table 1.2),
the adduct 1.28 is formed preferentially over 1.29 at atmospheric pressure and is 
enhanced at higher pressures. 
Table 1.2 Results of the Diels-Alder cycloaddition of sulfonamide 1.27
Me
Bn
O2S
N
1.27
+
1.28 1.29
Conditions A:
13 kbar, CH2Cl2, rt
Conditions B:
toluene, BHT, reflux N
S S
N
O
O
BnBn
O
O
Reaction Conditions 1.28 : 1.29 ratio % yield 
A 30.3 : 1.0 93
B 9.3 : 1.0 77
The same study was reported for the synthesis of enantiopure 5- and 6-
membered ring sultams containing a chiral auxiliary attached to the nitrogen atom.54
In this case, the cycloaddition performed at higher pressures was associated with a 
higher asymmetric induction and higher overall yields than the reaction performed at
ambient pressure. These results suggest that higher pressure conditions are necessary
to improve the yields and selectivities of the cyclized products.
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In 2001, Wright and coworkers applied the thermal Diels-Alder reaction to the 
synthesis of bicyclic sultam histamine H3 receptor antagonists.
55  The trienes utilized 
for the intramolecular Diels-Alder reaction were obtained from condensation of N-
Boc-methanesulfonamide with different aldehydes followed by alkylation.  The 
cyclization reactions were performed at 145 °C in toluene in a sealed tube for two to 
three days (Scheme 1.9).  Lower temperatures, such as toluene at reflux were not
successful.  Even though prolonged reaction times were required, the cyclized
adducts were obtained in good to excellent yields.
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Sultams have also found use as tethers for the synthesis of natural products.
In 1999, Overman and coworkers utilized tetracyclic sultam 1.31 (Scheme 1.10), 
generated via an intramolecular Diels-Alder reaction, during the total synthesis of the
natural product (+)-aloperine.56  Deprotonation of methanesulfonamide 1.30 with 
LHMDS in the presence of diethyl chlorophosphate, followed by the in situ addition 
of ethyl glycoxylate, readily generated sultam 1.31 in a 3.4:1 ratio of cycloadducts
(Scheme 1.10).  The SO2 group was intended to be removed from the cycloadducts 
under reductive conditions, proving that this entity could also serve as a removable
tether in organic synthesis.  Many of the attempted reductive conditions failed to 
cleave the SO2 tether either at the N-S or C-S bonds.  Only one of the reductive 
conditions tried worked (sodium or lithium in refluxing ammonia), albeit providing
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the desired product in minimal quantities.  These results contrast the observations 
made by Evans and coworkers where they successfully removed the SO2 moiety
under metal reductive conditions en routes to aryl substituted cyclic amines.49  Due to
the failure of this synthetic route, a different tether approach was used to synthesize 
(+)-aloperine.
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1.2.2.3  Copper-Catalyzed Cyclizations
In 2000, Dodd and coworkers reported a new strategy for the synthesis of 
various sultams based on intramolecular copper catalyzed nitrene delivery.57  Their
study showed the first intramolecular copper-catalyzed aziridination of primary
sulfonamides via an iminoiodinane intermediate.  Both linear and aromatic
sulfonamides were utilized as starting materials.  The linear sulfonamides were 
synthesized in three steps via published protocols starting from the respective alkyl
bromides. The benzenesulfonamides used were synthesized via a two-step protocol 
involving an ortho-metalation step followed by acidic cleavage of the sulfonamide
N-t-butyl group.  A variety of aliphatic and aromatic sulfonamides were treated with 
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iodobenzene diacetate [PhI(OAc)2] and potassium hydroxide in methanol, affording
the respective iminoiodinane intermediates, which upon purification via simple
extraction were treated with catalytic copper triflate in MeCN to afford the
corresponding sulfonamide aziridines 1.31-1.36 in moderate to good yields (Scheme
1.11).
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As expected, the cyclization of the allyl iminoiodinane intermediate (n = 1) 
failed to form the strained 4-membered ring bicyclic sultam 1.31, while the 
cyclization of the 5-hexene iminoiodinane intermediate (n = 4) gave exclusively the 
allylic insertion product instead of the aziridine.  These copper-catalyzed C-H 
insertion products have been rarely observed in analogous intramolecular
aziridination reactions.  In the case of the benzene sulfonamides, the vinyl
iminoiodinane intermediate (n = 0) failed to give the respective aziridine 1.34 under 
the same reaction conditions.  The desired aziridine was only observed via bromine-
catalyzed aziridination in the presence of phenyltrimethylammonium tribromide
(PTAB).  For more sterically hindered benzene sulfonamides (R = Me), the desired
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aziridine 1.36 was achieved in good yield (80%).  Similar yields for the cyclization 
step were obtained when the reaction was performed using the N-chloramine salts of 
the respective linear and benzene sulfonamides, followed by addition of catalytic 
quantities of  PTAB.58
Ring opening of various aziridines was accomplished in the presence of
different nucleophiles such as alcohols, thiols, Grignard reagents and benzylic amines
to afford five-, six-, and seven-membered ring functionalized sultams in good to
excellent yields (Scheme 1.12).  Non-aromatic aziridines led to exclusive opening at 
the more substituted carbon to provide sultams 1.37-1.39 in good to excellent yields 
(62-92%), while aromatic aziridines reacted at the less substituted carbon to afford
functionalized sultams 1.40 and 1.41 in good yields (60% and 62%, respectively). 
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The cyclization of sulfonamides catalyzed by copper(II) acetate has also been 
reported.  In 2004, the Chemler group reported the synthesis of tetracyclic sultams via 
oxidative cyclization promoted by copper(II) acetate in the presence of base (Scheme
1.13).59  The best reaction conditions for the oxidative cyclization reactions were 
realized at elevated temperatures (120 °C) in a pressure tube with polar solvents such
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as MeCN and DMF.  The resulting aromatic sultams were obtained in relatively good 
yields (69-71%). 
Scheme 1.13 
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A variety of arylsulfonyl-o-allylalanines bearing different para- and meta-
substituents in the sulfonyl aromatic ring were studied to determine the scope of the 
reaction.  It was found that the yields and selectivities of the products obtained were 
dependent on the substituent present in the aromatic ring.  With electron donating 
groups (Me, OMe) at the para-position of the sulfonamide group, the reaction 
proceeded in moderate to good yields (43-73%), leading to the exclusive formation of 
the para-tetracyclic sultam (para-product).  However, meta-substitution led to a 
mixture of regioisomeric products as shown in Scheme 1.14.  The same results were 
observed for meta-substituted chlorine substrates.
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Two interesting results were obtained during the course of their study.  When
meta-substituted nitrosulfonamide was used, the product obtained was exclusively the 
ortho product.  With para-substituted bromosulfonamide the ortho-cyclized product 
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obtained lacked the bromide functionality.  All these cases provided exclusively the 
ortho product, albeit low yields (~25%) except in one case, when addition of DMSO
dramatically increased the yield to 54%.  The rate-enhancing effects of DMSO in
Pd(II)-catalyzed reactions appears to be associated with its palladium-coordination
activity.  Having both soft (S) and hard (O) ligand donor atoms seems to facilitate the
reduction-oxidation cycling between Pd(II) and Pd(0) in this type of reactions.60
 1.2.2.4  Gold-Catalyzed Cyclization
In early 2006, the first example for the synthesis of sultams catalyzed by 
gold(I) phosphine complexes was reported.61  This study showed the intramolecular
amination of unactivated alkenes under both thermal conditions and microwave
irradiation.  The best reaction conditions were obtained using 5 mol % of 
(PPh3)AuCl/AgOTf in toluene at 60-100 °C for 12-72 h (Table 1.3).  A variety of 
sulfonamides were subjected to these reaction conditions providing the respective 
sultams in excellent yields (88-100%).  The reaction was successful even when steric 
hindrance was present at the double bond as shown in sultam 1.42 (Table 1.3).  To 
shorten the reaction times, all the reactions were performed under microwave
irradiation at 140 °C in DCE and the results compared to the reactions performed
under thermal conditions.  A considerable reduction in reaction time (less than 1 h)
was observed for these new reaction conditions (Table 1.3).  This new methodology
seems promising for further study towards more elaborate sultams and its application 
towards the synthesis of enantiopure sultams.
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Table 1.3 Gold(I)-catalyzed cyclization under thermal and microwave conditions
S
NHR
O O
n
5 mol % (PPh3)AuCl/AgOTf
toluene, 100 oC, 12-72 h
S
NR
O O
n
n = 0, 1, 2
R = H, Et, tBu
88-100% yield
?? conditions:
140 oC, DCE, 10-40 min.
or
Substrate Product
Thermal Cond. 
Time (h) % Yield
µ? Cond. 
Time (min.) % Yield 
S
NHEt
O O
S
N
O O
Et
24 95 40 90
S
NH2
O O
S
N
O O
H
1.42
12 99 10 100
S
NH2
O O
S
N
O O
H
72 95 40 95
1.2.2.5   Rhodium-Catalyzed Cyclizations 
Inspired by the work of DuBois and Breslow involving intramolecular
amidation reactions of saturated C-H bonds catalyzed by rhodium (II) dimers and 
recent work by Dodd57 showing copper-catalyzed aziridination of sulfonamides (see 
Scheme 1.11, vide supra), Che and coworkers studied the intramolecular aziridation
of sulfonamides catalyzed by rhodium (II) dimers such as Rh2(OAc)4 to provide the 
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corresponding aziridines in excellent yields62 (Scheme 1.15).  From previous work in
their laboratories it was observed that a combination of PhI(OAc)2 and primary
sulfonamides (ArSO2NH2) could be used as the nitrogen source in intramolecular
amidation reactions.  Further studies addressed to both aromatic and aliphatic 
sulfonamides revealed that the intramolecular aziridination was also possible with
PhI(OAc)2 as the oxidant when catalyzed by Rh2(OAc)4.  The best results for the 
intramolecular aziridination were obtained using Rh2(OAc)4 (0.02 equiv.), PhI(OAc)2
(1.5 equiv.) and Al2CO3 (2.5 equiv.) in refluxing CH2Cl2 for 3 h.  The generality of 
this protocol was demonstrated using a variety of unsaturated sulfonamides to provide 
the aziridine products in excellent yields and conversions (Scheme 1.15). 
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In a single case, the aziridine was not detected when aliphatic sulfonamides
were used.  Instead, vinylic sultam 1.43, arising from C-H bond insertion, was 
isolated (Scheme 1.16).  Dodd and coworkers have reported similar results.57
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The enantioselective synthesis of aromatic sultams described in Scheme 1.15 
is an area of great interest. Screening of a variety of chiral rhodium catalysts revealed
that 1.44 gave the best enentioselectivities with values up to 76% ee in good to 
excellent yields (Figure 1.8).63   Replacing the catalyst with the more robust 
ruthenium porphyrine complex 1.45 resulted in a dramatic drop in enantioselectivity
for the best case presented (65% yield and 9% ee).64  Similar attempts were
performed by Fruit and coworkers for the synthesis of both aliphatic and aromatic
amines catalyzed by chiral dirhodium complexes in the presence of PhI(OAc)2 and
MgO.65  However, these reaction conditions provided the chiral sultams with 
selectivities up to 66% ee when using 1.46 as catalyst.
Figure 1.8 
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1.2.2.6   Radical Cyclizations
Free radical cyclization reactions have been employed for the construction of 
C-C bonds and have found application towards the synthesis of sultams. The 
cyclization of ally vinyl sulfonamides has been achieved using indium as a single-
electron transfer radical initiator.66  When sulfonamide 1.47 was subjected to the
radical cyclization reaction using indium (2 equiv.) and various alkyl halides in water, 
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the desired sultams were obtained in good yields without the formation of byproducts,
although a cis/trans mixture was observed (Scheme 1.17).
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It was found that indium is an excellent radical initiator in aqueous solvents, 
providing the best yields (84%) in only 4 h.  In biphasic systems (H2O-CH2Cl2) the 
yields dropped substantially (42%) and the reaction required longer times (48 h). 
The same reaction was applicable to sulfonamides bearing an imine terminal,
such as hydrazone 1.48 (Scheme 1.18).  In this particular case, a large amount of 
indium (10 equiv.) was required for the success of the reaction, providing the
respective hydrazine sultams in good to excellent yields (42-93%) as a cis/trans
mixture.  Even in biphasic solvent systems (H2O-CH2Cl2), the reaction proved 
successful with this substrate, providing isopropyl sultam (R = iPr) in 93% yield.
Scheme 1.18 
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In 1999, the first example of the synthesis of bridgehead bicyclic sultams was
reported by Paquette and coworkers.67  A variety of ?-halomethylsulfonamides were 
heated with tri-n-butyltin hydride (Bu3SnH, 1.2 equiv.) and AIBN (0.07 equiv.) in
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benzene to provide a mixture of products, one arising from simple reductive 
dehalogenation, and the second one being the desired bridgehead sultam (Table 1.4).
Table 1.4 Intramolecular radical cyclization of various ?-halomethylsulfonamides
NXH2CO2S
n
n = 1-4
X = Cl, Br
Bu3SnH
AIBN
benzene
NCH3SO2
n
+
S N
O
O
n
reductive
dehalogenation
br idgehead
sultam
Sulfonamide
Reduction  product 
(% yield) 
Bridgehead sultam
(% yield) 
NClH2CO2S
1.49
NH3CO2S
(74%) S
N
O
O
1.50 (0%)
1.51
NBrH2CO2S
(47%)
NH3CO2S
S
NN
S
O
O
+
(16%) 1.52 (7%)
O
O
NBrH2CO2S NH3CO2S
(12%)
N
S
O
O
(69%)
NBrH2CO2S NH3CO2S
(10%)
N
S
O
O
(79%)
N
BrH2CO2S
N
H3CO2S
(49%)
N
S
O
O
(37%)
Only in the case of sulfonamide 1.49, the desired cyclization product 1.50 was not 
achieved, presumably due to the increased ring strain encountered in the formation of 
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this bridgehead sultam.  In the case of sulfonamide 1.51, the formation of bridgehead 
sultam 1.52 resulted from competing 6-endo C-C bond formation.  Table 1.4 shows 
the products and yields obtained under these reaction conditions.
That same year (1999) Paquette and coworkers realized the intramolecular
cyclization of radicals generated from ?-halomethylsulfonamides to synthesize 
sultams.68  Although it has been documented that ?-sulfonyl radicals can be difficult 
to generate69 and lack stability,70, 71 various ?-halomethylsulfonamides cyclized to
sultam 1.53 (Scheme 1.19) via generation of the respective ?-sulfonamidyl radical 
when reacted with Bu3SnH, (1.1-3.0 equiv.) and AIBN (0.07-0.47 equiv.) in benzene 
in more than 85% yield. 
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A variety of ?-halomethylsulfonamide homologs were also subjected to the 
radical cyclization reaction.  Depending on the double bond chain length, competition
pathways between the respective endo or exo cyclization modes gave rise to a mixture
of sultams.
A cascade RCM/isomerization reaction followed by a sequential radical 
cyclization has been implemented by Piva and coworkers for the synthesis of tricyclic
sultams.72  Sulfonamides 1.54 and 1.55 were subjected to the RCM reaction using 
Grubbs first generation catalyst (Cat. B), followed by double bond migration with 
sodium hydride (NaH), giving the corresponding sulfonamides in excellent yields 
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(Scheme 1.20).  These new products were subjected to the radical cyclization reaction 
in the presence of tris(trimethylsilyl)silane (TTMSS) and AIBN to form the 
respective tricyclic sultams in good yields (52-62%).
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With these results in hand the authors performed the same reaction sequence
in a one-pot procedure with sulfonamide 1.56 (Scheme 1.21).  Although a mixture of
sultam 1.57 and sulfonamide 1.58 were obtained, the one-pot procedure proved useful
for the synthesis of tricyclic sultams providing the desired compound 1.57 with yields
comparable to the stepwise protocol.
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Some examples of radical cyclization reactions via irradiation of sulfonamides
with PhI(OAc)2 and I2 in the presence of a tungsten lamp have also been reported.
73, 74
This synthetic pathway has been useful for the synthesis of benzosultams73 and
saccharine derivatives74 in moderate to excellent yields.
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1.2.2.7   1,3-Dipolar Cycloadditions
Interested in the biological profile offered by sultams, Chiacchio and 
coworkers pursued the synthesis of annulated sultams via 1,3-dipolar cycloaddition
reactions.75  The synthesis of the cyclization precursor was attained from L-amino
acids via a three-step sequence.  Treatment of aldehyde 1.59 with N-substituted
hydroxylamines (R3 = Me, Bn) under basic conditions afforded the nitrone
intermediate which readily underwent a 1,3-dipolar cycloaddition to form the
respective bicyclic sultams in good yields and complete diatereoselectivity based on 
NMR analysis of the crude products (Scheme 1.22).  The excellent 
diastereoselectivity of the cycloaddition step was shown to be dependent on the
stereocenter at the ?-position of the sulfonamide (R1).
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1.59
 In addition to N-substituted hydroxylamines, primary amines and hydrazones 
were used in the cycloaddition reaction, providing the respective bicyclic sultams in
good yields.
1.2.2.8   Base-Promoted Cyclizations
One of the most popular methods to synthesize sultams has been base-
promoted cyclization.  An interesting example published by Proudfoot and coworkers 
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makes use of substituted saccharins as precursors, followed by ring expansion.76  The
synthesis of the saccharide derivatives 1.61 and 1.62 began with the introduction of a
dimethylcarbamoyl group in sulfonamide 1.60 (Scheme 1.23).  Under basic 
conditions ortho-lithiation of sulfonamide 1.60 followed by addition of iodomethane
or iodine provided the methyl or iodo derivatives which subsequently closed under 
the basic conditions to afford the saccharine derivatives 1.61 and 1.62 in acceptable
yields (62% and 44% respectively) after workup.  Saccharins 1.61 and 1.62 were then 
transformed into oxicams by ring expansion with methyl chloroacetate and NaHMDS.
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In 1996, Liskamp and coworkers explored a solid-phase approach towards the 
synthesis of peptidosulfonamides.77  Initial attempts using the Merrifield resin as the
solid support proved problematic.  To circumvent these problems, the resin was 
switched to Tantagel, since better solvation is possible and therefore, close to
homogeneous reaction conditions can be obtained.  The resin of choice was 
introduced in the early steps of the synthesis via coupling with an amino acid. 
Further reaction with an alkyl sulfinyl chloride followed by oxidation provided 
sulfonamide 1.63.  Boc-deprotection of sulfonamide 1.63 with TFA in DCM, 
followed by washing with Et3N (Scheme 1.24), and heating the reaction mixture for 5
days in the presence of Et3N afforded, upon removal of the resin by filtration, the 7-
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membered ring sultam 1.64 in only 21% yield.  The cyclization step serves a dual role 
in this reaction by simultaneously generating the sultam while cleaving the resin.
Even though this reaction provides a facile route to cyclic peptidosulfonamides using
a solid support approach, room for optimization is evidenced by the low reaction
yields.
Scheme 1.24 
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In 2004 Postel and coworkers performed a study for the base-promoted
cyclization of a series of enantiomerically pure spiro (4-amino-5-H-2,3-
dihydroisothiazole-1,1-dioxide) ring systems on sugar templates with the goal of 
accessing a novel range of aza analogs of TSAO nucleosides (ATSAOs, Figure 1.9).78
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These carbanion-mediated cyclizations were investigated in the presence of 
different bases (K2CO3, Cs2CO3, n-BuLi and LDA). It was observed that the success 
of the reaction depended upon the compatibility of the base with the substituents 
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present in the sulfonamide substrate.  For example, conversion of the N-methyl and 
N-benzyl sulfonamides (R2) in Scheme 1.25 into the respective aminosultams was
successfully achieved in good to excellent yields (59-99%) using Cs2CO3 (1 equiv.) 
as the base in refluxing MeCN for 1-2 h.
Scheme 1.25 
O
O
O
BnO
NC
N
R2S
R1
O O
Cs2CO3
CH3CN
O
O
O
S
N
O O
R2R
1
BnO R
1 = H, R2 = Bn (65%)
R1 = Me, R2 = Bn (87%)
R1 = Ph, R2 = Me (99%)
R1 = H, R2 = Me (59%)
R1 = Ph, R2 = Bn (77%)
H2N
R1 = H, Me, Ph
R2 = Me, Bn
However, when the analogous N-methyl- or N-benzyl-5-O-benzoyl derivatives 
(Scheme 1.26) were used as substrates, the expected cyclized products 1.65 and 1.66
were obtained.  In addition, the basic conditions employed promoted hydrolysis of the 
benzoate to give the corresponding sultams 1.67 and 1.68 via Michael addition into
the enamine followed by hydrolysis.  Sultams 1.69 and 1.70 were obtained as a result
of intramolecular benzoyl transfer (Scheme 1.26). 
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When the ?-benzyl substrates (Bn-SO2NR) were used (Scheme 1.27), the
desired cyclized products were obtained in excellent yields (R = Me, 98%; R = Bn, 
99%) using the same reaction conditions as described above (Scheme 1.26).  It seems
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that the success of the reaction is also dependent upon the alkyl group located ? to the
sulfonamide functionality. 
Scheme 1.27 
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Interestingly, under similar reaction conditions (Cs2CO3 in CH3CN) the 
unsubstituted (N-H) sulfonamides (Scheme 1.28) failed to provide the desired 
cyclized products.  It is possible that deprotonation of the acidic proton from the
nitrogen atom of the sulfonamide group forms the corresponding insoluble salt,
thereby generating a heterogenous reaction mixture and impeding the cyclization step. 
However, by using a lithiated base such as n-BuLi or LDA (1 equiv.), the resulting 
lithium salt was expected to be soluble in THF allowing for cyclization.  As predicted,
treatment of the unsubstituted (N-H) sulfonamides with n-BuLi or LDA (1 equiv.) in 
THF afforded the respective sultams in marginal to excellent yields (Scheme 1.28).
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O
O
O
BnO
NC
N
HS
R
O O
n-BuLi
or LDA
O
O
O
S
N
O O
HR
BnO
R = H, 99%
R = Me, 20%
R = Ph, 73%
H2N
THF, -10 oC
In summary, N-substituted alkylsulfonamides cyclized successfully to the 
respective sultams in the presence of Cs2CO3, whereas for sulfonamides containing a 
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free N-H bond, n-BuLi or LDA proved to be the base of choice for the cyclization 
step.
In 2006, Enders and coworkers described a flexible synthesis of various ?- and 
?-sultams.79  A key step for the formation of the enantiopure sultams was the 
diastereoselective 1,2-nucleophilic addition to the C=N double bond of the
hydrazonosulfonates.  In this approach a chiral auxiliary (SAMP) was used to induced 
diastereoselectivity in the sulfonamide (Table 1.5).  Chiral hydrazonosulfonate 1.71
Table 1.5 Yields and enantioselectivities obtained for chiral sultams 
S
c-HexO
O O
H
N
N
MeO
n
1.71
RM,
CeCl3
THF
S
c-HexO
O O
R
HN
N
MeO
n
S
Cl
O O
R
NH2
n
N S
H O
O
R
n
Et3N
R n
Sultam
(% yield) 
% eea
Et 1 70 78
nBu 1 99 87b
nHex 1 93 90b
Ph 1 77 93
Me 2 82 > 96b
nBu 2 100 93
nHex 2 100 93
Ph 2 72 99
        a Determined by GC on chiral stationary phase (Chirasil-dex) 
b In correlation with the de value of the corresponding hydrazines.
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was subjected to 1,2-addition by organocerium reagents to install the alkyl group. 
Initial attempts to perform the nucleophilic addition with highly basic organolithium 
or Grignard reagents resulted in the elimination of the sulfur component.  To avoid 
this problem, less basic but higher nucleophilic cerium reagents, formed by 
transmetallation of organolithium or Grignard reagents with dehydrated CeCl3 were
used.  Under these conditions, various hydrazines were obtained in good to excellent 
yields (77-99%) and high diastereoselectivities (78 to > 96%).  Further 
transformations provided the sulfonyl chlorides which cyclized to the respective
sultams under basic conditions (Et3N).  Five- and six-membered ring sultams were
obtained in good to excellent yields (70-100%) and high enantiomeric excess (78-
99%) with the six-memebered ring sultams providing the best ee’s (Table 1.5). 
An interesting example of base promoted cyclization to sultams was reported 
by Snieckus and coworkers.80  Attempted N-allylation of sulfonamide 1.72 under 
standard basic conditions (NaH, DMF, 0 °C), resulted in the exclusive formation of
sultam 1.73 (Scheme 1.29) via an uncommon sulfonamide to acetylene 5-exo-dig ring
closure.
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A similar reaction occurred via an intramolecular Michael addition between 
the sulfonamide moiety and the ?,?-unsaturated ester functionality in structure 1.75
(Scheme 1.30).81 When attempting to transform sulfonyl chloride 1.74 into its
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respective sulfonamide 1.75 by addition of a solution of ammonium hydroxide
(NH4OH), sultam 1.76 was obtained instead (Scheme 1.30).  A variety of crystalline
sultams resulted via this procedure albeit in low yields (14-45%).
Scheme 1.30 
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In 2003, Lee and coworkers reported a practical synthesis of sultams via 
sulfonamide dianion alkylation and the application of this method for the synthesis of 
chiral sultams as valuable chiral auxiliaries.82  The chiral sultams were readily 
synthesized from commercially available ?-amino alcohols.  Their synthetic study 
revealed that methanesulfonylation of ?-amino alcohols can be performed at both the
hydroxyl and amino termini in the presence of Et3N, followed by SN2 displacement
with sodium chloride (NaCl) in DMF to form sulfonamides in high yields (85-90%) 
(Scheme 1.31).  Cyclization to sultams was readily initiated with the in situ
generation of LDA83 by treatment of n-BuLi (2.2 equiv.) and diisopropylamine
(DIPA, 0.25 equiv.) at low temperatures (-50 °C).  Subsequent aging of the reaction 
mixture at 0 °C for 1h provided a variety of chiral 5-membered ring sultams in good
yields (68-75%) via this methodology. Based on the success of this synthetic
approach, Merck applied it a year later to the multi-kilogram synthesis of a 
?-secretase inhibitor as a potential target for the treatment of Alzheimer’s disease.84
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Morris and coworkers set out to synthesize a variety of cyclic sulfonamides as
potential sultam analogs of thromboxane A2 (TXA2) receptor antagonists.
85  Initial
attempts began with a Michael reaction between a benzyl ester and vinyl sulfone to
form the core substrate 1.77 (Scheme 1.32). Ester 1.77 was then converted to the 
amide via a three-step protocol, involving hydrolysis into the carboxylic acid 
followed by amination to afford the amide.  The cyclization event to 1.78 was
accomplished by the addition of KOtBu.  Although the expected cyclization product 
was obtained, the yields were not quite satisfactory (45%).  Finally, reduction of the
carbonyl group with NaCF3CO2BH3 provided sultam 1.79 in good yield (82%).
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Disappointed by the low yields provided via this route, an alternative 
synthesis was pursued in which the positions of the ester and sulfonamide moiety
were switched.  Cyclization of the sulfonamide (Scheme 1.33) provided the
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reaspective sulfimide in good yields in the presence of NaH (74%).  Further 
conversion to sultam 1.79 via reduction of the carbonyl proceeded in good yield.
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In 1991, Cooper86 reported a similar approach to Lee’s82 for the synthesis of
sultams.  The synthesis of aliphatic sultams was accomplished starting from 
2-aminoalcohols. N, O-dimesylates, prepared by mesylation of the amino alcohols 
with MsCl and pyridine were treated with BuLi to give the respective sultams in 
moderate to good yields (45-81%) (Table 1.6). 
Table 1.6 Results for the cyclization of N, O-dimesylates into sultams
HO
NHR1
R3
R
2
MsCl, pyr.
R
3
R2
NR
1
O
S
O O
S
O O
BuLi
hexane/THF
45-74%
N
S
O O
R
1
R2R3
R1 R2 R3 % yield of sultam
Bn H H 74%
    -(CH2)3- H 81%
Me Me Ph 45%
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Although BuLi deprotonates both hydrogens ? to the suylfonyl groups, only
the anion generated from the N-mesylate can react efficiently in the intramolecular
fashion to displace the O-mesylate, affording the cyclized products.
1.2.2.9  Acid-Promoted Cyclizations
In 2000, Merck Research Laboratories reported the acid-promoted cyclization 
to sultam 1.82, which is a side chain of the ?-lactam anti-MRSA (Methicillin-resistant
Staphylococcus aureus) antibiotic 1.83.87  This side chain was identified as an anti-
MRSA pharmacophore which was designed to be released upon opening of the 
?-lactam ring.  The synthesis to this sultam was initiated from cheap, commercially
available 1-methylnaphthalene.  Sulfonylation and amination, followed by nitration of
the aromatic ring afforded nitrosulfonamide 1.80 in modest yields. Cyclization to 1.81
was performed using a one-pot hydrogenation-cyclization reaction (Scheme 1.34). 
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Reduction of the nitro group to the amine was accomplished by standard
hydrogenation conditions (10% Pd/C, H2) in quantitative yield.  The
aminosulfonamide intermediate was then cyclized upon acidification with HCl at
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reflux for 3 h, providing sultam 1.81 in 85% yield and >99% purity after 
crystallization.
Lewis acids have also been utilized for the synthesis of sultams.  Katritzky
and coworkers reported the synthesis of 6-, 7-, and 8-membered ring aromatic sultams
via a Friedel-Crafts cyclization of ?-phenylalkanesulfamoyl chlorides.88  The Friedel-
Crafts intramolecular cyclization reaction of the sulfamoyl chlorides shown in 
Scheme 1.35 was carried out in the presence of AlCl3 in nitrobenzene.  After aqueous
workup, sultam 1.85 (n = 2, 69%) was obtained in high purity without the need for 
further purification, while sultams 1.84 (n = 1, 46%) and 1.86 (n = 3, 7%) required
further chromatographic purification.
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In order to improve the yields of the sultam ring system present in saccharins,
Snieckus and coworkers utilized an ortho metallation-cross coupling strategy,
followed by cyclization under acidic conditions, to provide saccharin sultams in good 
to excellent yields89 (Table 1.7).  The metallation-cross coupling strategy of the 
sulfonamides proceeded via addition of n-BuLi/TMEDA, followed by
N,N-diethylcarbamoyl chloride quench.  Without isolation, addition of TFA, followed
by treatment with HOAc provided the saccharin sultam systems shown in table 1.7 in 
modest to excellent yields (42-90%).
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Table 1.7 Yields obtained for the formation of various saccharin sultams
S
N
H
O O
G Ar
Ph
1. n-BuLi,
TMEDA
THF, 0 oC,
2. ClCONEt2
S
N
H
O O
G Ar
Ph
Et2N O
1. TFA, rt
10 min.
2.AcOH,
reflux
3. HCl
G Ar
S
N O
O
HO
% yielda of sultams G Ar
90 H Ph
57b H 2-naphthyl
42b Me Ph
88 OMe Ph
a Isolated and purified products.
b Yield over two steps
In 2006, Silvestri and coworkers synthesized a series of 7-membered ring 
sultams via a Pictet-Spengler type cyclization.37  Tricyclic sultam 1.88 was prepared 
in 51% yield via condensation between sulfonamide 1.87 and ethyl 
2,2-diethoxyacetate in the presence of catalytic amounts of p-toluenesulfonic acid
(PTSA) in refluxing absolute ethanol (100% EtOH) (Scheme 1.36).  Acylation of 
sulfonamide 1.88 with various chlorides in the presence of NaHCO3 and boiling 1-
bromo-3-chloropropane afforded the respective amides. Biological testing performed
on these compounds (also known as PBTDs) revealed that they are a new class of 
potential agents for the treatment of chronic myelogenous leukemia (CML). 
Derivatives of these promising compounds are currently being pursued in an effort to
find new candidates for the treatment of cancer. 
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1.2.2.10  Ring-Closing Metathesis (RCM) 
Ring-closing metathesis has emerged as a powerful synthetic tool for the 
formation of C-C bonds.  A variety of well-defined alkylidine-metal complexes
including the molybdenum complex A90 and the ruthenium complexes B91 and C92
are available for this transformation (Figure 1.10).  Even though molybdenum
catalyst A exhibits very high reactivity towards a wide range of substrates, it suffers 
from extreme sensitivity to moisture and air as well as decomposition upon storage. 
While catalyst B is both air and water stable and compatible with many functional 
groups, it is not active for the formation of tri- and tetrasubstituted olefins.92  The 
more active complex C has shown to be a powerful alternative, promoting the
cyclization of tri- and tetrasubtituted olefins.92
Figure 1.10 Ruthenium and molybdenum catalysts used for RCM
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Initially, RCM was mostly used for the formation of carbocycles, but has 
found great applicability for the synthesis of heterocyclic rings, including sulfur 
heterocycles.93  The RCM reaction has been used extensively for the formation of 
small to medium-sized rings as well as macrocycles.  The mechanism by which this
intramolecular C-C bond forming process takes place has been the topic of intensive
study.  The accepted RCM mechanism94 is presented in Scheme 1.37.  This pathway
is initiated by the dissociation of a phosphine ligand to form a reactive 14-electron
complex capable of coordinating an olefin.  A [2+2] cycloaddition leads to the
formation of a metallocyclobutane intermediate.95  A [2+2] cycloreversion releases an 
ethylene molecule followed by a second [2+2] cycloaddition to form another, more
sterically congested metallacyclobutane.  A final [2+2] cycloreversion affords the 
cyclized product and regenerates the active catalytic species.
Scheme 1.37
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Presented below is a summary of the RCM approaches that have been
reported for the synthesis of sultams.  Using this synthetic method, various ring-size
sultams (5-, 6-, 7-, 8-, 9- and 15-membered ring) have been obtained.  RCM routes to
sulfamides and sulfamoyl carbamates will not be covered in this section as they are
the basis of further discussions later in this dissertation. 
The first report of the use of RCM for the efficient synthesis of sultams
appeared in 1999 by Hanson and coworkers.96  Novel 5-, 6-, and 7-membered ring 
allyl- and vinylsultams with different substituents at the nitrogen atom were 
accomplished using Grubbs first generation catalyst (Cat. B) (Figure 1.10).
Styrenesulfonyl chloride and allylsulfonyl chloride proved to be ideal precursors to 
synthesize vinylsulfonamides and allylsulfonamides, respectively (Table 1.8).
During the synthesis of allylsulfonamides, a minor product corresponding to 
vinylsulfonamide was observed.  This product, arising from double bond 
isomerization of the allylsulfonamide during the base promoted allylation procedure 
was circumvented using benzylallylamine as the coupling partner with the 
allylsulfonyl chloride.  The RCM products were obtained in good to excellent yields 
using 6 mol % of catalyst B (Figure 1.10) in refluxing CH2Cl2 at concentrations
ranging from 0.01-0.02M.  Interestingly, the cyclization of electron deficient olefins
proved successful under the cyclization reaction conditions. It is worth mentioning
that the cyclization of the sulfonamides bearing a free N-H was not deleterious to the 
performance of the catalyst, providing the respective cyclized products in excellent
yields (90%). 
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Table 1.8 Results for the RCM cyclization of styrene and allylsulfonamides 
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N
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n
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CH2Cl2
S
N
O O
R
1
n
n
S
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O O 1. R1NH2, Et3N
CH2Cl2
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S
N
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R1
n
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Cat. B
CH2Cl2
S
N
O O
R
1
n
Br n
R1 n % Yield of RCM 
H 1 90
Bn 1 88
Bn 2 65
(CH)CH2iPr(CO2CH3) 1 90
H 1 90
Bn 1 91
Bn 2 91
(CH)CH3(CO2Et) 1 87
In addition to these results, a strategy employing both RCM and Ring-
Opening Metathesis Polymerization (ROMP) has been developed for the synthesis of 
oligimeric sultams.97  The RCM precursors were synthesized following the same
synthetic protocol as described in Table 1.8.  Alkyl-substituted and amino ester-
derived sulfonamides proved to be suitable substrates for the RCM reaction (Scheme
1.38).  Cyclization to sultams 1.89 and 1.90 was carried out in excellent yields in the 
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presence of catalyst B (Figure 1.10), followed by subsequent Diels-Alder cyclization 
with cyclopentadiene under Lewis acid catalysis to form norbornenyl sultams as a 
mixture of separable diastereomers.  The endo diastereomers 1.91 and 1.92 readily
underwent ROMP with 1-20 mol % catalyst B (Figure 1.10) followed by quenching
with ethyl vinyl ether to provide oligomeric sultams.
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Snieckus has described a directed ortho metalation-RCM approach for the 
synthesis of 7-, 8-, 9- and 15-membered ring sultams.80  Aromatic p-toluene
sulfonamides, bearing N-substituents (R = Et, allyl) underwent cyclization in good to 
excellent yields.  The RCM reaction afforded 8- and 15-membered ring sultams
(Scheme 1.39) using 10 mol % of catalyst B (Figure 1.10) in CH2Cl2 at rt for 16h.
Dilute conditions (0.002M) were used for the cyclization step in order to avoid
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dimerization as a result of cross-metathesis. The same ring-closing protocol proved 
useful for the synthesis of 9-membered oxygen-containing sultams (Scheme 1.39). 
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The eight-membered ring sultams (n = 1, R = Et, H) were obtained in 
excellent yields (90-96%) while the 15-membered sultam (n = 8, R = Et) was
obtained in good yield (64%) as a cis:trans mixture as determined by 1H NMR.  In 
the nine-membered ring oxygen-containing sultams, the low yield obtained for the 
unsubstituted sultam (R = H, 33%) was attributed to isolation difficulty due to low 
solubility.
An enyne metathesis methodology was used for the synthesis of diene 1.93
(Scheme 1.40).80  In this case the ene-yne precursor was exposed to similar RCM 
conditions as described above (Scheme 1.39) in the presence of an ethylene 
atmosphere in order to favor the formation of diene 1.93 (Scheme 1.40).  This diene 
proved useful for further Diels-Alder cyclization with maleic anhydride, forming
polycyclic sultam 1.94 in good yields. 
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Two different RCM-cleavage strategies have also been implemented for the
synthesis of sultams.  In the first one, the RCM catalyst is bound to a polymer
whereas the second strategy relies on polymer bound-substrates.  In the first approach, 
a polymer bound RCM catalyst (Cat. D) (Scheme 1.41) developed by Barrett and 
coworkers98, 99 has been utilized to synthesize 7-membered ring sultams with the 
ultimate goal of being incorporated into combinatorial chemistry and
peptidomimetics.100  The desire to use catalyst D for the generation of these entities
arose from the difficulty of removing the ruthenium residues from the typical RCM 
reaction in conjunction to the difficulty of recycling the ruthenium catalyst from the 
reaction mixture.  Exposure of the Boc-protected sulfonamide in Scheme 1.41 to 5
mol % catalyst B (Figure 1.10) or D in 1,2-dichloroethane (0.04M) provided the 
desired sultam in good yields (79% and 84% respectively).  The RCM also proceeded
efficiently at rt in 30 min. with the sulfonamide containing a free N-H bond using
catalyst B or D, affording the respective 7-membered ring sultam in excellent yields
(93% and 95% respectively).  It is worth mentioning that the RCM reaction with
catalyst D was accompanied by the addition of 1-hexene to the reaction mixture in
order to facilitate the regeneration of the catalyst.
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The cyclized products using catalyst D were obtained pure without any
residual ruthenium after a single chromatographic purification.  Although catalyst D
can be regenerated for further use via simple filtration, subjection to the RCM 
reaction conditions with recovered D resulted in a less active catalyst as evidenced by
the lower yields obtained (46% yield for R = Boc and 54% yield for R = H). 
The second RCM-cleavage strategy has been applied to resin-bound
sulfonamides, where the RCM reaction was effectively used to cleave the cyclized
7-membered ring sulfonamide from the resin.101, 102  Double-armed and single-armed
polystyrene precursors 1.95 and 1.96 were used to test the efficacy of this method.
The RCM-cleavage strategy (Scheme 1.42) was performed with 2.5-5 mol % of cat. B
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(Figure 1.10) to afford the 7-membered ring sultam in good yields.  The addition of 
an olefin co-factor (1-octene) to the reaction mixture resulted in a decrease in the 
yield of the cyclized product as well as a decrease in the crude purity.  Investigations
revealed that a double-armed linker was not necessary, therefore a variety of flexible 
single-armed linkers were used to obtained three different N-substituted sultams in 
moderate yields using only 5 mol % of catalyst B (Scheme 1.43). 
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The synthesis of a variety of bicyclic sultams as constrained proline analogs
has been achieved by Hannesian and coworkers via RCM,28 culminating in the 
synthesis of sultam 1.106 as a weak thrombin inhibitor (Scheme 1.44).  Three types
of bicyclic sultams varying in size of the sultam ring (5,5; 6,5; and 7,5) have been
synthesized by this method (1.100-1.102) from sulfonamides 1.97-1.99 in good to 
excellent yields (Scheme 1.44).  The RCM reaction was performed using 3-6 mol % 
of catalyst B (Figure 1.10) in refluxing CH2Cl2.  While sulfonamide 1.100 (n = 0) was
obtained in only 22% yield using catalyst B, the reaction with the more reactive
catalyst C on the TBDPS protected ether 1.103 dramatically increased the yield of the 
product to 79%.  Sultams 1.101 (n = 1) and 1.102 (n = 2) were obtained in excellent 
yields using catalyst B.  Sulfonamide 1.104 containing an O-TBDPS protecting group 
50
was cyclized to sultam 1.105 using 3 mol % of B and further used to obtain the 
thrombin inhibitor analog 1.106.
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A simple protocol for the rapid construction of sultams fused to a ?-lactam
ring as presented in Table 1.9 has been reported by Metz and coworkers as 
?-lactam sulfonamide hybrids.103, 104  The ?-lactams used were synthesized according
to a published procedure and then converted to the N-sulfonyl derivatives.  Initial 
attempts to cyclize vinylic sulfonamides (R = H, entry 1) and (R = Me, entry 2) with 
5 mol % of catalyst C (Figure 1.10) in refluxing CH2Cl2 were unsuccessful.  It is 
believed that enhanced ring strain of the bicyclic products might be an impeding
factor.  However, subjecting the allylic homologs (R = H, Me, entry 3 and 4) to the 
same RCM conditions afforded the desired bicyclic sultams in good to excellent 
yields (56% and 82%, respectively) as crystalline solids.  The yields obtained for the
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RCM reaction are presented below (Table 1.9).  The best results were obtained for the
seven-membered ring annelated sultams (n = 2, entry 5 and 6) regardless of the
substituent present at the 4-position of the ?-lactam ring.  While six- and eight-
membered ring sultams (R = Me, entry 4 and 8) were isolated in good yields (82%
and 63%), cyclization to furnish the unsubstituted counterparts (R = H, entry 3 and 7) 
were less efficient, providing much lower yields (56% and 28%, respectively). 
Table 1.9 Results for the RCM reaction towards fused sultams
N
O
R
S
O
O
n
5 mol % C
CH2Cl2, reflux
N
SO
O O
R
n
4
Entry R n % Yield of 
sultam
1 H 0 0
2 Me 0 0
3 H 1 56
4 Me 1 82
5 H 2 98
6 Me 2 97
7 H 3 28
8 Me 3 63
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In 2006, Paquette and coworkers demonstrated the successful application of 
the RCM reaction for the synthesis of seven-membered ring sultams en routes to 
bicyclic sultams having a sulfur atom at the apex position.105  This is the first report
for the synthesis of bridgehead sultams of this nature.  Initially, RCM to sulfonamide
1.107 was envisioned to be incorporated as the last step leading to the formation of 
bridgehead sultam 1.108.  This route began as a five-step sequence to afford the RCM
precursor 1.107 (Scheme 1.45).  Subjection of this diene to RCM conditions failed to
provide bicyclic sultam 1.108.  The inability to perform the cyclization was attributed 
to a combination of ring strain and steric effects.
Scheme 1.45 
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A solution to this problem was to rework the route to 1.108 by performing the 
RCM reaction at an earlier stage of the reaction sequence.  With this in mind,
sulfonamide 1.109 was subjected to the RCM reaction using only 1 mol % of catalyst
B (Figure 1.10) to deliver sultam 1.110 in more than 90% yield (Scheme 1.46).
Submission of the RCM product 1.110 to base-promoted cyclization readily formed
bridgehead sultam 1.108 in high yield (95%). 
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The synthesis of nine-membered ring peptidosulfonamides, although less 
prevalent in literature, has been achieved via RCM by Liskamp and coworkers.106
Coupling of sulfonyl chloride with allyl amine in the presence of a weak base,
followed by deprotection and subsequent reaction with acryloyl chloride provided the 
RCM precursor 1.111 (Scheme 1.47).  The ring closure was performed using 20 
mol % of catalyst C (Figure 1.10) in 1, 1, 2-trichloroethane as the solvent (10 mM).
Interestingly, ?,?-dichlorotoluene was added to the reaction mixture in order to 
reduce the inactivation of the catalyst.  Unexpectedly, the dimeric 18-membered ring 
was the product obtained.
Scheme 1.47 
S
N
O O
N
H H
O
N
S
N
O O
H
O
H
20 mol %Cat. C
TCE
?,?-dichlorotouene
S
N
N
S
N
N
O
O
H
O
H
O
O
H
O
H
1.111
1.112
Further efforts to obtain the 9-membered ring sultam 1.112 by running the 
reaction under more diluted conditions (1 mM) were unsuccessful.  It seems that the 
formation of the 18-membered ring is more favorable than the corresponding
9-membered ring for this particular substrate. 
To facilitate the RCM reaction to a cyclic peptidosulfonamide structure,
carbamate 1.113 was prepared.  Subjection of 1.113 to the same RCM reaction 
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conditions as described in Scheme 1.47 failed to give the desired 
9-membered sultam, forming instead a product arising presumably from ring opening 
by ?-elimination (Scheme 1.48). 
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Failed attempts to obtain the desired 9-membered ring sultams forced the 
authors to synthesize other RCM precursors keeping in mind that the sulfonamide
moiety will facilitate a conformation in which the terminal alkenes will be favored to 
undergo ring closure.  Switching the protecting group at the nitrogen from Cbz to 
o-NBS [the o-NBS-protecting (o-nitrobenzenesulfonyl) groups are less likely to 
accept a proton, therefore preventing ?-elimination] was expected to facilitate the 
cyclization reaction.  Using the same synthetic approach as explained before, three 
different sulfonamides (table 1.10, entry 1-3) were prepared in good yields and
subjected to the RCM conditions using 10 mol % of catalyst C (Figure 1.10) to form 
the respective cyclic peptidosulfonamides in moderate to good yields (Table 1.10).
These results indicate that peptidosulfonamides with different R1 and R2 groups are 
readily accessible via this method.  These cyclic peptidosulfonamides were further 
incorporated into a peptide sequence to obtain ?-turn mimetics.
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Table 1.10 RCM approach towards sultam peptidomimetics
S
N
O O
N
o-NBS R2
N
S
N
O O
R
2
o-NBS
Cat. C
TCE
?,?-dichloro-
touene
R1
R1
Entry R1 R2 % yield of sultam
1 H Bn 60
2 CH3 Cy 47
3 CH(CH3)2 (CH2)5CH3 48
1.3  Synthesis of Other Sulfur Heterocycles
The ability of the sulfonamide moiety to serve as a non-hydrolyzable amide
surrogate, in conjunction to the successful application of the RCM reaction for the 
synthesis of sultams, has prompted efforts towards the synthesis of other sulfur 
analogs that can perhaps show biological activity.  Sulfonamide analogs of interest 
include cyclic sulfamides, cyclic sulfamoyl carbamates and cyclic sulfamoyl ureas
(see sections 1.3.2-1.3.5).
1.3.1 Cyclic Sulfamides 
Sulfamides are compounds containing a sulfone functionality flanked by two 
nitrogen atoms (R-NSO2N-R
1).  Although a variety of biologically active cyclic 
sulfamides have been reported, the sulfamide analogs of the HIV protease inhibitor
DMP 323 (Figure 1.11) have been of much interest in our group. 
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1.3.2  DMP 323 and Related Analogs 
 In 1994, scientists at DuPont Merck Laboratories reported the development of 
a variety of highly potent HIV protease inhibitors.107  Based on X-ray
crystallographic data which shows that HIV PR exists as a C2-symmetric dimer,
DuPont Merck initially pursued the synthesis of nonpeptidic C2-symmetric inhibitors
with the hope of combining adequate potency with oral bioavailability.  A variety of 
promising inhibitors were synthesized and screened, out of which the seven-
membered ring urea DMP 323 exhibited good activity against HIV PR (IC90 = 57 
mM) (Figure 1.11).107  Despite its good oral bioavailability in animals, phase I 
clinical trial studies were disappointing, resulting in the withdrawal of the molecule
as a consequence of high blood level variability in humans.108  The more water 
soluble candidate DMP 450109 (Figure 1.11) was then synthesized showing an
improved pharmacokinetic profile in humans during its phase I clinical trials.
However, its promising therapeutic value was hindered by high plasma protein 
binding.109  As a result, the search for new candidates with improved
pharmacokinetics became an ongoing effort.
Figure 1.11 Cyclic ureas DMP 323 and DMP 450
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Extensive SAR studies have been concentrated on determining the effect of
varying the P1/P1'/P2/P2' residues in DMP 323 (Figure 1.12).  This has allowed for a 
better understanding of its interaction with the enzyme, facilitating the development
of new analogs with improved pharmacokinetic properties.  It was found that varying 
the P1/P1'/P2/P2' residues in DMP 323 significantly influence inhibitory potency by 
accentuating hydrophobic (P1/P1'), hydrogen bonding (P2/P2') and catalytic aspartate
(diol functionality) interaction with the enzyme.  It has also been of major interest to 
determine the absolute stereochemistry of its four contiguous stereocenters (4R, 5S,
6S, 7R)110 in order to make possible the synthesis of related analogs with improved
potency.
Figure 1.12 General features of the cyclic ureas developed by DuPont Merck 
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1.3.3  Sulfamide Analogs of DMP 323 
While the cyclic ureas have been of much interest, studies conducted 
independently by DuPont Merck Laboratories scientists,111 Hallberg and coworkers 
112-115 and Karlén and coworkers116 revealed that sulfamide analogs of DMP 323 also
display inhibitory activity (Figure 1.13).  In addition, unsymmetric urea117-120 and 
sulfamide116 derivatives of DMP 323 were also studied due to their potential to
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exhibit different solubility and inhibitory profiles relative to their C2-symmetric
counterparts.
Figure 1.13 Symmetric and unsymmetric sulfamide analogs of DMP 323
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1.3.4  Synthetic Approaches Towards Sulfamide Analogs of DMP 323 
The synthesis of C2-symmetric sulfamide analogs of DMP 323 commenced
with bisepoxide 1.114 as the key intermediate.  For the preparation of bisepoxide 
1.114 a four-step protocol was followed starting from commercially available 
L-mannonic ?-lactone (Scheme 1.49). 108, 112   Bisepoxide 1.114 was subjected to ring
opening, Mitsunobu alkylation, and various protection-deprotection protocols to
afford diazides 1.115 and 1.116.  Reduction of these diazides under standard 
hydrogenation conditions (H2, 10 % Pd/C) afforded the respective diamines.  The 
crude reaction mixture of the diamines was treated with sulfamide in pyridine to form
sulfamides 1.117 and 1.118.  Benzylation with NaH, followed by O-MEM group
removal with dry HCl in ether-methanol provided the sulfamide analogs of DMP 323 
(R1 = OPh) and (R2 = CH2Ph) in 18% and 16% overall yield, respectively from 
bisepoxide 1.114.  This reported route required 12 overall steps to get to the desired
C2-symmetric sulfamides in low overall yields.  It is worth mentioning that this
synthetic route incorporates the sulfamide moiety at the late stages of the synthesis. 
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The synthesis of unsymmetric sulfamide analogs of DMP 323 have also been 
reported.116  These analogs have been achieved by simple N-alkylation of sulfamides
1.117 and 1.118 (Scheme 1.49) under basic conditions.  However, this protocol 
provided a mixture of products including the desired unsymmetric analogs as well as
the symmetric analogs and recovered 1.117 and 1.118.
Based on our previous success on the ring-closing metathesis strategies to
cyclic sulfamide peptidomimetics (Scheme 1.50),121 we envisioned to implement the
RCM reaction to obtain both symmetric and unsymmetric sulfamide analogs of DMP 
323.  A detailed explanation towards this endeavor will be discussed in Chapter 3. 
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1.3.5  Cyclic Sulfamoyl Carbamates and Sulfamoyl Ureas 
Cyclic sulfamoyl carbamates and sulfamoyl ureas are among another class of 
S-heterocycles of much interest in our group.  Sulfamoyl carbamates (Figure 1.14) 
have been primarily used as important synthetic intermediates in the synthesis of 
unsymmetric sulfamides93, 121, 122 and sulfahydantoins.123  These compounds have 
been studied as acetyl-CoA:cholesterol O-acyl-transferase (ACAT) inhibitors124 in 
conjunction with sulfamoyl ureas (Figure 1.14).  While examples of acyclic
sulfamoyl carbamates are prevalent in the literature, reports of their cyclic 
counterparts are still limited, with only two examples, 1.119 and 1.120 reported to
date (Figure 1.15).125
Figure 1.14 Representative structures of sulfamoyl carbamates and sulfamoyl ureas 
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Sulfamoyl ureas (Figure 1.14) have been shown to be important hypoglycemic
agents,126-129 ACAT inhibitors,124 and herbicides.130, 131 Although large libraries of
sulfamoyl  ureas have been synthesized, cyclic sulfamoyl ureas have been largely
unexplored, with only one report in literature containing structures 1.121 and 1.122
(Figure 1.15).132
A detailed explanation of the RCM approach utilized to access a variety of 
cyclic sulfamoyl carbamates and sulfamoyl ureas will be covered in Chapter 4.
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Figure 1.15 Examples of cyclic sulfamoyl carbamates and sulfamoyl ureas 
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Conclusions
Based on the important properties encountered in sulfonamides, sultams, and 
related sulfur analogs, the synthesis of more novel variants should be explored in 
hopes of generating promising candidates for the treatment of life threatening
illnesses affecting humanity such as cancer and AIDS.  With a variety of synthetic
methods described so far for the facile construction of sultams, the RCM reaction 
seems very promising for the facile access to a variety of S-heterocycles.  With the 
effectiveness of the RCM reaction for the quick construction of S-heterocycles, the
generation of important pharmacologically active targets containing this functionality 
is within reach.
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Chapter 2 
A Facile RCM Strategy to Functionalized Sultams: Development of Scaffolds with 
Multiple Handles for Diversification and Library Development 
76
The aforementioned broad spectrum of biological activity displayed by 
sulfonamides, sultams and related sulfur heterocycles described in the introductory
chapter (Chapter 1) has prompted us to develop new methods for their synthesis. 
This in turn has opened opportunities for the development of diversification strategies 
for the production of their corresponding libraries.  Sulfonamides, sulfamides,
sulfamoyl carbamates and sulfamoyl ureas outlined in chapter 1 represent ideal
functional moieties that can serve as nonhydrolyzable amide surrogates.  When
coupled with additional desirable chemical features, they represent promising
peptidomimetic scaffolds for library production.  Our interest in the construction of 
novel S-heterocycles has recently led us to assemble a series of related sultams using
a strategy based on RCM, which is the basis of this chapter. The facile assembly via 
RCM and versatility of a key ?-hydroxy vinyl sultam (2.11) are the cornerstone of 
this approach.
2.1  Synthetic Strategies Towards Sultam Scaffolds
Our proposed strategy towards the synthesis of a diverse array of sultam
scaffolds hinges on several key points, including: (1) multi-gram scale synthesis of
allyl sulfonyl chloride which will be used as a sulfur linchpin for the installation of
the sulfonamide moiety, (2) installation of additional complexity via Mitsunobu
reaction with enantiomerically pure building blocks, (3) cyclization utilizing the 
RCM reaction and subsequent manipulation en route to a key ?-hydroxy vinyl sultam, 
and (4) incorporation of both solution phase strategies and ROMP-derived reagents 
for the diversification of each scaffold (Scheme 2.1).  The simplicity of this approach
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has enabled the production of sultam scaffolds in multi-gram scale using 6-7 step
solution phase protocols.  The development of "scaffolds from scaffolds", where a 
common core structure can give access to a variety of diversified products is also of 
primary aim. An example of one of the sultam scaffolds of interest containing 
multiple handles for diversification and library development is shown in Figure 2.1. 
Polymer-assisted solution phase chemistry will be made possible through the
employment of high-load, immobilized ROMP reagents that have been produced on 
large scale in our laboratories.  Overall, our ultimate aim is to utilize this strategy
towards the generation of novel sultams with biological and synthetic utility. 
Figure 2.1 Scaffold of interest and possible diversification reactions 
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Our synthetic strategy to access sultam scaffold 2.11 (Figure 2.1) is outlined 
in Scheme 2.1.  A retrosynthetic analysis towards this endeavor suggested the use of 
the readily prepared allyl sulfonyl chloride (2.1)1 as the starting material of choice 
(Scheme 2.1).  Conversion of sulfonyl chloride 2.1 into sulfamoyl carbamate 2.3 will 
set the stage for the installation of chiral building blocks via Mitsunobu alkylation.
Use of RCM will allow for the generation of sultam scaffolds of general structure 2.6.
Diastereoselective osmium-mediated dihydroxylation, subsequent carbonate 
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formation and base-promoted elimination of the cyclic carbonate 2.10 will yield the
desired C(4)-?-hydroxy vinyl sultam 2.11.  This scaffold was envisioned to be 
transformed into a variety of other complex structures using established protocols in 
our previous work related to P-sugars,2  as well as new protocols developed within 
this dissertation.
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Our strategy towards sultam 2.6 began with the multi-gram production of allyl 
sulfonyl chloride (2.1) following the two-step protocol developed by Belous and
coworkers1 (Scheme 2.2).  Thus, conversion of allyl sulfonyl chloride (2.1) into
sulfamoyl carbamate 2.3 was achieved via a two-step sequence that involved 
amination of 2.1 using anhydrous ammonia in ether to form sulfonamide 2.2,1
followed by Boc-protection of sulfonamide 2.2 via slow addition of di-tert-butyl
dicarbonate (Boc2O) in the presence of Et3N in CH2Cl2 at rt.
3  This process provided 
sulfamoyl carbamate 2.3 in excellent yield (96%) along with a minor byproduct 
(less than 4% yield) arising from bis-protection. Both compounds were easily
separable by column chromatography.  The introduction of the Boc group in 
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sulfamoyl carbamate 2.3 served a dual purpose: (1) as a labile protecting group that 
can be easily removed at any stage for further diversifications, and (2) as a group that
proved to be essential in lowering the pKa of the N-H (pKa ~ 4) in sulfamoyl
carbamate 2.3 for further Mitsunobu alkylation.  Mitsunobu reaction of sulfamoyl
carbamate 2.3 was performed with the readily prepared, chiral, nonracemic alcohol 
2.4, obtained from the condensation of trimethyl sulfonium ylide (Me2S=CH2) with
(S)-benzyl glycidyl ether,4 in the presence of DIAD and PPh3 in THF at rt to generate
diene 2.5 in good yield (78%).  During the optimization of the Mitsunobu reaction it 
was observed that the yield of diene 2.5 was dependent upon the concentration of the 
reaction.  When the reaction was performed under dilute conditions (0.05M), diene 
2.5 was obtained in the highest yield (78%) due to the formation of the product 
primarily originated from the desired SN2 pathway rather than the competing SN2'
route.  However, performing the reaction at higher concentrations (0.1M or higher),
resulted in a significant decrease in yields (40-51%) and an increase in the formation
of a byproduct arising from a SN2' pathway as clearly evidenced by TLC and 
confirmed by NMR analysis.  With diene 2.5 in hand, we concentrated our efforts on
the cyclization step to generate sultam 2.6.  Initial attempts to perform the RCM 
reaction with diene 2.5 using CH2Cl2 or ClCH2CH2Cl (DCE) as solvents under 
refluxing conditions resulted in unsuccessful RCM.  However, cyclization of diene 
2.5 using toluene as the solvent under refluxing conditions afforded the desired 
product 2.6.
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Various RCM conditions were studied and the results shown in Table 2.1. 
The optimized conditions for the RCM reaction were realized in the presence of 
5 mol % of Grubbs second generation catalyst (cat-C)5 in refluxing toluene under 
dilute conditions (0.01-0.005M), to provide sultam 2.6 in 87% yield (entry 3, Table 
2.1).  Performing the RCM reaction with the Grubbs first generation catalyst (catalyst
B)6 resulted in comparable yields, although higher catalyst loadings as well as longer
reaction times were required (entry 4, Table 2.1).  Removal of residual ruthenium was 
achieved using DMSO according to the method of Georg.7
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Table 2.1 Results obtained for the RCM reaction with diene 2.5
S
N
OBn
OO
S
N
OBn
O O
O
O
O
O
RCM
conditions
2.5 2.6
Entry RCM Conditions % yield RCM Product 
1 5 mol % Cat. C
CH2Cl2, 45 °C 
NR
2 5 mol % Cat. C
ClCH2CH2Cl, 83 °C 
NR
3 5 mol % Cat. C
toluene, 110 °C 
87%
4 10 mol % Cat. B
toluene, 110 °C 
84%
 Molecular modeling8 was performed in order to provide insight into the 
outcome of the RCM reaction.  It was observed that the presence of vicinal 
disubstitution at N-2 (SO2N-Boc) and C-3 (CH2OBn) in diene 2.5 forces the terminal
olefins to be oriented in opposite directions (Figure 2.2).  This unfavorable 
conformation necessitated the use of a higher boiling point solvent, refluxing toluene,
for successful RCM.  In contrast, the RCM reaction for diene 2.7 possessing a free 
sulfonamide N-H (SO2N-H) should proceed at lower temperatures since molecular
modeling revealed that the olefins in diene 2.7 are in close proximity to each other. 
In order to test this hypothesis, the Boc group was removed from sulfamoyl
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carbamate 2.5 (Scheme 2.2) under acidic conditions using TFA9 in CH2Cl2 at rt to
afford diene 2.7 in excellent yield (93%), which was then readily cyclized to sultam 
2.8 in high yield (92%) using 5 mol % of catalyst C5 in refluxing CH2Cl2.  It is worth 
mentioning that the presence of a free N-H bond in sulfonamides 2.7 did not
negatively affect the performance of the catalyst during the RCM reaction as is
sometimes the case with allylic amides possessing free N-H bonds.10
Figure 2.2 Molecular modeling performed for dienes 2.5 and 2.7
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Efforts towards the desired C(4)-?-hydroxy vinyl sultam 2.11 continued with
dihydroxylation of sultam 2.6 (Scheme 2.3).  Thus, osmium-catalyzed
dihydroxylation11 of sultam 2.6 in the presence of NMO and citric acid in a  mixture
of acetone and water as solvents resulted in the formation of the cis-diol 2.9 in high
yield (96%) and excellent diastereoselectivity (dr > 99:1).  The absolute configuration 
of diol 2.9 was unambiguously confirmed by X-ray crystallography (see Appendix). 
Sultam 2.8 containing a free N-H was also subjected to identical dihydroxylation 
conditions to afford diol 2.12 in high yield (94%) as a mixture of inseparable 
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diastereomers (dr ~ 8:1).  With the high diastereoselectivities obtained for diol 2.9,
we continued our synthetic route to sultam 2.11.  Thus, diol 2.9 was  protected as the
carbonate 2.10 in excellent yield (90%) using triphosgene and pyridine in CH2Cl2.
12
Base-promoted elimination of carbonate 2.10 with Et3N in refluxing CH2Cl2 afforded 
C(4)-?-hydroxy vinyl sulfonamide 2.11 in high yield (91%). 
Scheme 2.3 
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Removal of the Boc-group using the aforementioned acidic conditions (TFA, 
CH2Cl2)
6 afforded 2.13 as a crystalline solid in high yield (91%).  Single crystal
X-ray analysis of sultam 2.13 confirmed the absolute configuration (Scheme 2.4) 
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2.2  C(4)-?-hydroxy Vinyl Sultam: A Versatile Scaffold
 With C(4)-?-hydroxy vinyl sultam 2.11 in hand we proceeded to perform a
variety of diversification strategies using solution phase protocols as outlined in 
Scheme 2.5.  Thus, initial O-functionalization via Mitsunobu reactions of vinyl 
sultam 2.11 using different substituted phenols as nucleophiles was attempted.  It is
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worth mentioning that the Mitsunobu reaction of 2.11 proceeded only with phenols 
bearing electron withdrawing groups.  Mitsunobu alkylation of sultam 2.11 using 
DEAD and PPh3 in THF at rt was successful when using p-nitrophenol as the
nucleophile (Scheme 2.5) to afford O-diversified sultam 2.14 in moderate yield (45%).
However, Mitsunobu reaction with phenol or meta-tert-butylphenol failed to provide 
the respective O-diversified sultam, while Mitsunobu reaction with para-
bromophenol afforded only traces of the desired product. 
We then turned our attention to the introduction of nitrogen at the C(3) 
position in efforts to obtain amino alcohols. Consequently, vinyl sultam 2.11 was
treated with trichloroacetonitrile (Cl3CCN) in the presence of catalytic amounts of 
DBU in CH2Cl2 to afford trichloroacetimidate
2
2.15 in excellent yield (96%).  Further 
treatment of 2.15 with TFA in CH2Cl2 at rt afforded amino alcohol 2.16 in 97% yield
(Scheme 2.5).
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We also explored the addition of isocyanates to vinyl sultam 2.11 in attepts to 
form bicyclic sultams.  Treatment of 2.11 with phenyl isocyanate (PhNCO) and Et3N
in CH2Cl2 at reflux afforded sultam 2.17 in good yield (64%) via conjugate addition
into the vinylic double bond (Scheme 2.5).  Interestingly, when isopropyl isocyanate 
(iPrNCO) was utilized under identical conditions, prolonged reaction times were 
necessary in order to obtain the cyclized product 2.18 in good yield (78%).
We then turned our attention towards the possibility of performing conjugate 
addition of nucleophiles at the C(3) position of vinyl sultam 2.11.  Previous work 
reported by Roush and coworkers13 has revealed that vinyl sulfonamides are excellent
Michael acceptors of sulfur nucleophiles.  Based on the success of this report, we 
attempted the addition of various thiols at C(3) of vinyl sultam 2.11 (Scheme 2.5). 
Addition of thiophenol (PhSH)  to sultam 2.11 in the presence of catalytic amounts of 
Et3N in CH2Cl2 at rt
14 afforded sultam 2.19 in good yield (84%) as a mixture of 
inseparable diastereomers (dr ~ 6:1) as determined by 1H NMR.  With the success of
this reaction, different thiols were explored.  Interestingly, addition of phenylmethane
thiol (PhCH2SH) under the identical reaction conditions afforded sultam 2.20 in 
quantitative yield (100%) as a separable mixture of diastereomers with improved
diastereoselectivity (dr ~ 10:1).  Addition of butane thiol resulted in the formation of 
sultam 2.21 in 88% yield as a mixture of inseparable diastereomers (dr ~ 4.5:1).
2-methylpropane-2-thiol [(CH3)3CSH], however, failed to undergo Michael reaction 
under the same reaction conditions, presumably due to steric factors. 
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An interesting result was obtained during the course of this study.  When ?-
hydroxy sultam 2.11 was subjected to basic reaction conditions using 1.1 equiv. of
Cs2CO3 in THF at 60 °C for 1 h, an unexpected product originating from Boc-group
migration onto the alkoxide providing sultam 2.22, was isolated in 71% yield (Table 
2.2).  Schreiber and coworkers have previously reported a similar Boc-group 
migration event.15  In order to determine the extent of the Boc-group migration, a 
variety of bases were studied.  Interestingly, it was observed that Boc-group 
migration also occurred in the presence of K2CO3 (entry 2, 76%) and NaH (entry 3, 
91%).  However, subjecting sultam 2.11 to 1.1 equiv. of Et3N in CH2Cl2 at reflux for 
1 h resulted in complete recovery of 2.11.  These results open the door for further 
diversification reactions with sultam 2.22.  Diversification efforts utilizing sultam
2.22 will be pursued in the near future.
Table 2.2 Results for Boc migration observed in sultam 2.11
S
N
O O
Boc
OH
2.11 2.22
OBn
base S
N
O O
H
OBoc
OBn
Entry Base % yield of 2.22
1 Cs2CO3 71%
2 K2CO3 76%
3 NaH 91%
4 Et3N 0%
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We have also been interested in the installation of alkyl groups at the ?-
position of sultam 2.11 with the final goal of incorporating different functional groups 
throughout the periphery of the ring.  In order to accomplish this, we reasoned that
the introduction of an excellent leaving group such as a phosphate16 at the oxygen
atom of the hydroxyl group will favor this process.  With the leaving group in place, it
was expected that conjugate addition with organocuprates will introduce the desired
alkyl group at the ?-position of 2.11.  Thus, coupling of (MeO)2P(O)Cl with sultam 
2.11 in the presence of N-methylimidazole in CH2Cl2 at 0° C afforded allylic 
phosphate 2.23 in excellent yield17 (97%) (Scheme 2.6).  Conjugate addition of ethyl 
cuprate to 2.2318 was performed by adding an excess (10 equiv.) of diethylzinc 
cuprate to phosphate 2.23, affording sultam 2.24 in good yield (74%). This product 
was further dihydroxylated under osmium-catalyzed conditions11 to afford cis-diol
2.25 in good yield (79%). 
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With the success of the reaction sequence presented in Scheme 2.6, we turned
our efforts to performing a diversification/cuprate addition strategy.  This approach
involving deprotection via removal of the N-Boc group, followed by benzylation at 
the new free N-H site, followed by organocuprate addition will generate sultam 2.28
(Scheme 2.7).  Initial attempts to remove the Boc group in sultam 2.23 using TFA in 
88
CH2Cl2 resulted also in the hydrolysis of the phosphate moiety.  We therefore turned 
our attention to exploring milder reaction conditions that will remove the Boc group
while leaving the phosphate moiety untouched.  To our delight, treatment of sultam 
2.23 with 1-1.5 equiv. of FeCl3
19 in CH2Cl2 at rt for 30 min. afforded, after aqueous
workup, sultam 2.26 in good yield (60%).  Attempted N-benzylation of sultam 2.26
under basic conditions (BnBr, Cs2CO3, THF, 65 °C) did not afford the desired N-
benzyl sultam 2.27.  Instead, a product lacking both the phosphate moiety as well as
the N-benzyl group was isolated and later confirmed to be aziridine 2.29 via NMR
analysis.  This product was presumably the result of direct nucleophilic displacement
at C(4) bearing an excellent leaving group.   Failed attempts to obtain sultam 2.28 via
this route led us to abandon this reaction sequence.  In addition, studies concerning
this remarkable internal SN2 displacement are underway. 
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With the successful generation of scaffold 2.11 and its multiple diversification
reactions performed, efforts were directed at the diversification of scaffold 2.8 as 
outlined in Scheme 2.8.  Thus, alkylation of nitrogen using benzyl bromide and 
Cs2CO3 in THF at 80 °C for 30 min. afforded sultam 2.33 in good yield (86%).  This 
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reaction was successfully performed with a variety of benzyl bromides to afford the 
respective benzylated sultams in good to excellent yields (64-94%).  Formation of
conformationally constrained sultams was also of much interest.  Simultaneous
removal of the benzyl group and double bond in sultam 2.8 was accomplished via 
hydrogenation20 to afford sultam 2.31 in good yield (79%).  Formation of carbamate
2.34 was accomplished in moderate yield (48%) using triphosgene in pyridine.12
Alternatively, the olefin may be conserved through removal of the benzyl group with 
TMSI21 to afford sultam 2.30 in moderate yield (47%). Subsequent formation of 
carbamate 2.32 proceeded in good yield (53%).  Overall, sultam 2.8 represents a 
simple scaffold from which to generate diversified compounds with chemical and 
potential biological utility. 
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Our next diversification strategy was concentrated on sultam 2.9 as outlined in
Scheme 2.9.  Reaction of diol 2.9 with benzaldehyde and p-TsOH in refluxing
benzene22 provided acetal 2.35 as a mixture of separable diastereomers (dr ~1:1) in a 
combined yield of 66%.  Monoacylation of diol 2.9 was then performed.  Thus,
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reaction of diol 2.9 with benzoyl chloride23 and Et3N in CH2Cl2 at 0 °C afforded
sultam 2.36 in moderate yield (50%).  We then turned our attention to the synthesis of 
unexplored sugar-like sultams.  Thus, treatment of diol 2.9 with TFA in CH2Cl2
afforded sultam sugar 2.37 in 88% yield, while treatment with 5 equiv. of FeCl3 in 
CH2Cl2 at rt for 1 h afforded the respective sultam triol as a single baseline spot by
TLC.  Aqueous workup was necessary to quench FeCl3, however, the polarity of the
resulting triol has thus far hampered isolation.  Efforts focusing on non-aqueous 
workup are underway. 
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So far, a concise RCM pathway for the generation of multi-gram quantities of
different scaffolds has been developed.  We have devised a "scaffold from scaffold"
strategy that has relied on the use of solution phase protocols for different
diversification strategies.  With the success of these diversification reactions we next 
explored the use of polymer supported reagents or ROMP reagents for 
implementation in diversification strategies and generation of sultam libraries. 
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2.3  Use of ROMP Reagents for Diversification Strategies and  Development of 
Sultam Libraries
With the success obtained so far with diversification reactions performed
using solution phase protocols we concentrated our efforts on the application of 
ROMP reagents previously developed in our laboratories to facilitate the generation
of combinatorial libraries.  The use of polymer-supported reagents will allow for the
generation of diversified products by using filtration as the sole method of 
purification, avoiding the need for column chromatography which is a typical 
bottleneck in conventional solution phase techniques.  We have previously reported 
the successful coupling of a variety of primary amines and alcohols with carboxylic 
acids using the coupling reagent OACC,24 which is our polymer version of DCC.  We 
have been able to successfully synthesize OACC in our laboratories in multi-gram
quantities and use it effectively in a variety of coupling reactions with cyclic
sulfamide scaffolds.25  We therefore explored the application of OACC to the 
coupling reaction of sultam 2.11 with different amino acids.  The coupling reaction of 
C(4) ?-hydroxy sultam 2.11 with Boc-protected (L)-valine and Boc-protected 
(L)-alanine was performed using OACC in the presence of catalytic amounts of 
DMAP in CH2Cl2 at rt for 12 h.  The commercially available basic resin
MP-carbonate was utilized to scavenge the excess amino acid used in the coupling 
reaction. Simple filtration via a plug of silica using 100% EtOAc as eluent
successfully afforded sultam 2.38 and 2.39 in excellent yields (92% and 100%,
respectively) and high purities (>84%) as determined by LC/MS (Scheme 2.10).
92
The same OACC coupling protocol was successfully performed using sultam 2.11
and carboxylic acids such as isovaleric acid and cyclopropane carboxylic acid to 
afford sultams 2.40 and 2.41 in excellent  yields (100%) and high purities (>80% by 
1H NMR).
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The successful application of OACC for the coupling reactions presented
above, in conjunction to the successful addition of thiols to sultam 2.11 presented in
Scheme 2.5, prompted our efforts towards the development of a one-pot protocol 
involving OACC coupling of sultam 2.11 with carboxylic acids followed by addition 
of thiols.  This strategy will provide a protocol for the bis-functionalization in a one-
pot procedure.  Thus, sultam 2.11 was subjected to OACC coupling with isovaleric 
acid under the same reaction conditions as explained before to generate sultam 2.40
(Scheme 2.11).   After the scavenging event with MP-carbonate and filtration through 
a silica plug with 100% EtOAc, sultam 2.40 was immediately treated with
phenylmethane thiol in CH2Cl2 at reflux for 12 h, followed by scavenging of the thiol 
nucleophile with OBAC,26 a ROMP-generated bis-acid chloride designed in our 
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laboratories for the scavenging of nucleophiles.  This procedure provided diversified 
sultam 2.42 in good yield (91%) and >80% purity based on 1H NMR as a mixture of 
inseparable diastereomers (dr ~ 6:1) after simple filtration through a plug of silica. 
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We have also been able to develop a variety of new ROMP-derived 
benzylating agents and showed its successful application towards the benzylation of
amines, phenols, benzenethiols, sulfonamides and sultams.27 Thus, sultam 2.8 was
benzylated by addition of 1.2 equiv. of the ROMP-derived benzylsulfonium salt in the
presence of Cs2CO3 (1.2 equiv.) and NaI (15 mol %) at 80 °C in CH2Cl2 for 4 h, 
followed by simple filtration through a silica plug using 100% EtOAc as eluent 
(Scheme 2.12).  The benzylated sultam 2.32 was obtained in good yield (84%) and
high purity (96%) as determined by GC/MS.  This protocol exemplifies the facile
Scheme 2.12 
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access to diversified sultams by utilizing ROMP-derived reagents where filtration is 
used as the sole method of purification. 
Our efforts were then concentrated on the possibility of polymerizing the 
sultam scaffold 2.11, followed by a diversification reaction involving addition of 
organocuprates and simple filtration to readily obtain ?-alkylated sultams. Thus, 
commercially available 5-norbornene-2-exo,3-exo-dimethanol was transformed into 
the respective norbornenyl monochlorophosphate tag 2.43 via coupling with freshly
distilled POCl3 in the presence of Et3N and DMAP in CH2Cl2 in good yield (50%) 
(Scheme 2.13).  The coupling reaction of norbornenyl monochlorophosphate tag 2.43
with sultam 2.11 under basic conditions utilizing N-methylimidazole in CH2Cl2,
afforded sultam 2.44 in an excellent 97% yield. Polymerization of the tagged sultam 
scaffold 2.44 was possible using 5 mol % of Grubbs first generation catalyst (cat-B)
in CH2Cl2 at reflux to obtain the polymer-bound sultam 2.45 in good yield (80%). 
This polymer-bound sultam was subjected to the aforementioned conjugate addition 
with various alkyl organocuprates to afford ?-alkylated sultams 2.24 (R = Et, 74%),
2.46 (R = Me, 65%) and 2.47 (R = iPr, 67%) in good yields and high purity (>90%) 
after simple filtration via silica plug with 100% EtOAc.
It was observed that the ROMP-derived phosphate played a dual role during 
the organocuprate-release event: (1) it served as an excellent leaving group for the 
conjugate addition of the organocuprate and (2) upon release, it served as a scavenger
to sequester the copper salts formed during the reaction conditions. 
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2.4 Synthesis of Seven-Membered Ring Vinylic Sultams 
The RCM strategy utilized for the facile assembly of six-membered ring
sultam scaffolds described in this chapter has prompted our efforts into extending this
methodology for the construction of seven-membered ring vinylic sultams as outlined 
in Scheme 2.14.  The synthesis of the desired seven-membered ring sultam 2.53
began with the multi-gram synthesis of styrylsulfonyl chloride (2.48) according to
Culbertson and coworkers.28  Conversion of 2.48 into the respective
styrylsulfonamide under basic conditions with NH4OH, followed by Boc-protection
with Boc2O,
3 afforded sufamoyl carbamate 2.49 in 94% yield.  Mitsunobu alkylation
with chiral, nonracemic alcohol 2.5029 in the presence of PPh3 and DIAD in THF at
room temperature provided chiral sulfonamide 2.51 in good yield (82%).  Boc-group 
removal utilizing TFA in CH2Cl2 at room temperature afforded sulfonamide 2.52 in 
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quantitative yield.  Facile RCM with 5 mol % of Grubbs second generation catalyst 
(Cat. C) in refluxing DCE afforded seven-membered ring vinylic sultam 2.53 in a
good 86% yield.  This new scaffold will be subjected to a variety of diversification
reactions in the near future.
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Conclusions
We have successfully synthesized a variety of sultam scaffolds in multi-gram
quantities taking advantage of allyl sulfonyl chloride as the "sulfur linchpin" and
RCM as the cyclization event. We have also demonstrated the chemical versatility
offered by these scaffolds through a variety of diversification reactions utilizing 
solution-phase protocols.  In addition, the use of ROMP-derived reagents developed
in our laboratories has proved advantageous for the generation of sultam libraries
using filtration as the sole method of purification. Using this developed synthetic 
approach, six-membered sultams with different groups around the periphery have 
been easily access in a concise manner and in excellent yields.  Biological evaluation
97
of these novel sultams is currently in progress and is expected to contribute to drug 
discovery.
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Chapter 3 
Ring-Closing Metathesis Approaches to Symmetric and Unsymmetric Sulfamide 
Analogs of DMP 323 and N-hydroxy Cyclic Sulfamides
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As part of our efforts to synthesize different sulfur heterocycles as promising
pharmacological agents, we considered the potential of utilizing the ring-closing
metathesis reaction as the key cyclization step for the synthesis of symmetric and
unsymmetric sulfamide analogs of the HIV protease inhibitor DMP 323 (Figure 3.1). 
It has been shown in the introductory chapter, (Chapter 1) that the RCM reaction can 
provide seven-membered rings in excellent yields.  Moreover, a concise route that can 
afford these analogs and display inhibitory activity with improved pharmacokinetics
seemed very attractive to our group. We therefore intended to explore an RCM
approach to synthesize sulfamide analogs of DMP 323 in a more concise manner,
where the final products can be obtained in good to excellent yields via a much
shorter route compared to the one outlined in Scheme 1.49 (Chapter 1) by Hallberg 
and coworkers.1  Presented in this chapter is our achievements towards the described
symmetric and unsymmetric sulfur analogs of DMP 323.  RCM efforts towards N-
hydroxy cyclic sultams as potential MMP inhibitors will also be discussed. 
Figure 1 Cyclic urea DMP 323 
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3.1  Introduction of  Sulfur Linchpins Using SO2Cl2 and CSI 
Our interest in sulfamides and related analogs has led us to develop an RCM
approach for the synthesis of symmetric and unsymmetric sulfamide analogs of DMP 
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323 (Figure 3.1).  This strategy stems from our previous success to access symmetric
and unsymmetric cyclic sulfamide peptidomimetics via a concise RCM strategy.2
The developed strategy makes use of the reagents sulfuryl chloride (SO2Cl2, Scheme
3.1) and chlorosulfonyl isocyanate (CSI, Scheme 3.1) as sulfur linchpins to produce 
the respective symmetric sulfamide and unsymmetric sulfamoyl carbamate building 
blocks that could be easily accessed via a three-component coupling protocol.  The 
sulfamide and sulfamoyl carbamate obtained can be further functionalized via 
Mitsunobu alkylation and simple alkylation procedures.  Further transformations will 
lead to the desired differentiated sulfamide analogs of DMP 323. 
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Overall, the strengths of these approaches lie in the ability to (1) exploit the 
versatility of both sulfamide and sulfamoyl carbamate building blocks to effectively 
serve as “robust S-linchpins” to allow a number of simple but powerful 
transformations to occur, (2) incorporate simple ester groups  (Scheme 3.2) as latent 
or masked olefins for subsequent cyclization using the RCM reaction, (3) effective 
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use of the Mitsunobu reaction with enantiopure alcohols (Scheme 3.2) and simple
alkylation reaction protocols to selectively install the desired side chain groups at the 
P1/P1' and P2/P2' periphery (Figure 3.1) of the cyclic sulfamides.  This strategy was
developed to allow for strategic placement of side-chain groups in each of the
P1/P1'/P2/P2' residues of the cyclic sulfamide with the ultimate goal of occupying the
active site of HIV protease.  The combination of the S-linchpin with non-racemic
chiral building blocks (Scheme 3.2) will be vital for the success of the developed 
route.
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3.2  RCM Route Towards Symmetric and Unsymmetric Cyclic Sulfamides 
We initiated our study with the synthesis of C2-symmetric sulfamide analogs
of DMP 323.  Our new route towards cyclic C2-symmetric sulfamides commenced 
with a two-directional chain synthesis to obtain sulfamide 3.1. Sulfamide 3.1 was
synthesized by the coupling reaction of L-leucine amino ester with sulfuryl chloride
(SO2Cl2) under basic conditions as previously reported in our group (Scheme 3.3).
2
Dialkylation of leucine-derived sulfamide 3.1 under standard conditions using BnBr 
in the presence of K2CO3 in MeCN at 70 °C gave the corresponding bis-benzylated
sulfamide 3.2 in excellent yield (99%).3  The homotopic ester moieties in C2-
symmetric sulfamide 3.2 were then converted to terminal olefins via a three-step 
protocol to afford bis-olefin 3.4. Subsequent reduction of the esters present in
sulfamide 3.2 with LiAlH4 cleanly produced diol 3.3 in quantitative yield (100%). 
Conversion of the diol moieties in 3.3 into the respective bis-aldehyde was achieved
in excellent yield (99%) via Swern oxidation.  This bis-aldehyde was carried on 
immediately without further purification to bis-Wittig olefination with PPh3CH2Br in 
the presence of BuLi to generate diene sulfamide 3.4. The efficiency of this three-step 
protocol further demonstrates the robust nature of the sulfamide group as it withstood 
a variety of reaction conditions to cleanly afford diene 3.4.  Ring-closing metathesis
with 5 mol% of Grubbs second generation catalyst [(ImesH2)(PCy3)(Cl)2-Ru=CHPh]
4
in refluxing CH2Cl2 proceeded smoothly to generate cyclic sulfamide 3.5 in 69%
yield. Dihydroxylation of cyclic C2-symmetric sulfamide 3.5 bearing homotopic
olefinic faces was achieved by treatment with catalytic amounts of OsO4 (3 mol %) in 
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the presence of NMO (1.2 equiv.) to produce cyclic sulfamide diol 3.6 in excellent
yield (99%).  Alternatively, epoxidation of sulfamide 3.5 using 4 equiv. of m-CPBA
successfully gave the epoxy sulfamide 3.7 in modest yield (52%, unoptimized).
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Our synthetic approach was then applied to unsymmetric cyclic sulfamides
bearing stereogenic centers in both the P1/P1' and P2/P2' positions.  This synthetic
pathway was successfully achieved as outlined in Scheme 3.4. Initially, a three-
component coupling reaction with tert-butyl alcohol, chlorosulfonyl isocyanate (CSI), 
and the valine-derived allylic amine salt 3.85,6 under basic conditions gave the 
corresponding sulfamoyl carbamate 3.9 in 71% yield (Scheme 3.4).  This building 
block, first developed by Montero and co-workers,7 contains two nucleophilic N-H 
sites of varying pKa’s that can be chemoselectively differentiated (eg. Mitsunobu 
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alkylation). Thus, sulfamoyl carbamate 3.9 was first alkylated at the carbamate N-H 
(pKa ~ 4) under Mitsunobu conditions using PPh3 and DEAD in THF at rt with either 
ethyl lactate or 2-hydroxy-4-methylpentanoic acid methyl ester to produce 3.10 and
3.11 in good yields (84% and 87%, respectively).  Methylation of the remaining
sulfamide N-H site in sulfamide 3.10 and 3.11 using MeI and K2CO3 in MeCN 
afforded sulfamides 3.12 and 3.13 in excellent yields (96-100%).  Boc-removal under
acidic conditions using TFA in CH2Cl2 at rt provided 3.14 and 3.15 in good to 
excellent yields (88-100%).  Subsequent allylation of sulfamides 3.14 and 3.15 with 
allyl bromide and K2CO3 in MeCN at 70 °C generated the metathesis precursors 3.16
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and 3.17 in synthetically attractive yields (88-100%).  RCM reaction with 3-5 mol%
of the first generation Grubbs catalyst [(PCy3)2(Cl)2Ru=CHPh]
8 under refluxing 
CH2Cl2 afforded the differentiated unsymmetric cyclic sulfamides 3.18 and 3.19 in
nearly quantitative yields (97%). Surprisingly, dihydroxylation of sulfamides 3.18
and 3.19 occurred with little stereoselectivity to yield an approximate 1.3:1 
diastereomeric mixture of diols 3.20 and 3.21 and 3.22 and 3.23 respectively in a
combined yield of 97%. 
Previous work in our group has demonstrated that osmium-mediated
dihydroxylation of seven membered ring sulfamide systems that are structurally
similar to sulfamide 3.19 (R1 = CH2iPr, R
2 = Me), occurred with good diastereofacial 
selectivity (dr = 5.9-11:1, Figure 3.2).9  In this previous study, it was found that the 
nature of the N-substituent adjacent to the isopropyl sidechain has a considerable
influence on the diastereoselectivity of the diol.  In the two cyclic sulfamide cases
studied, when R=H (3.24) good diastereoselectivity was observed in the product (dr = 
11.1:1.0).  However, the selectivity was significantly diminished in the
dihydroxylation of the benzyl substituted sulfamide 3.25 (dr = 5.9:1.0). When taken 
collectively, it appears that N-substitution on the cyclic sulfamide has a significant
effect on the diastereoselectivity of the dihydroxylation.  Preliminary molecular
modeling experiments suggest that N-substitution effects the orientation of the 
isopropyl group in cyclic sulfamide 3.25, leading to a decrease in diastereoselectivity.
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Figure 3.2 Diastereoselectivities obtained in the dihydroxylation step
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The methods outlined in Schemes 3.3 and 3.4 were exploited further in the 
synthesis of an unsymmetric sulfamide bearing differentiated P1/P1'/P2/P2' regions as 
shown in Scheme 3.5. Thus, benzylation of our previously reported unsymmetric 
sulfamoyl carbamate 3.262 under standard benzylation conditions (BnBr, K2CO3,
MeCN, 70 °C) provided benzylated sulfamide 3.27 in excellent yield (94%).
Removal of the Boc group under acidic conditions (TFA, CH2Cl2) proceeded in 
excellent yield (97%) allowing for further diversification at the newly formed free
N-H in sulfamide 3.28.  Installation of a PMB group under basic alkylating conditions 
with PMBCl and K2CO3 in MeCN at 70 °C proceeded without incident to generate
sulfamide 3.29 in good yield (77%).  Sulfamide 3.29 was then subjected to a two-
directional chain synthesis employing the aforementioned three-step transformation
of both ester groups into the corresponding olefinic groups for further RCM. Thus, 
reduction of the ester moieties with LAH (38%), followed by oxidation of the bis-
alcohol to the respective bis-aldehyde via Swern oxidation (99%), and conversion to
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the bis-olefin via Wittig olefination (Ph3PCH2Br and BuLi) produced the metathesis
precursor 3.31 in good yield (69%). RCM with 5 mol% (ImesH2)(PCy3)(Cl)2R=CHPh
proceeded smoothly to yield the unsymmetric sulfamide 3.32 in good yields (69%) 
bearing differentiated lipophilic side-chains that occupy the P1(Me), P1' (iPr), P2
(PMB), and P2' (Bn) positions.  Final osmium-mediated dihydroxylation afforded the 
sulfamide diol 3.33 in excellent yield (91%), but with only modest 
diastereoselectivity (dr = 3.9:1). 
Scheme 3.5 
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The final approach that we investigated is outlined in Scheme 3.6.  This new 
strategy employs the Mitsunobu reaction to install the stereogenic center occupying
the P1 position.  Initial three-component coupling with tert-butyl alcohol, CSI and L-
valine methyl ester afforded sulfamide 3.34, which now contains two N-H sites with 
different pKa’s that can be used for selective alkylation to install the desired
substituents at the periphery of the cyclic sulfamide.  Thus, Mitsunobu alkylation of 
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sulfamide 3.342 at the most acidic N-H site (pKa ~ 4) was possible with the readily 
prepared, chiral, nonracemic secondary allylic alcohol 3.35, derived from the 
condensation of trimethyl sulfonium ylide with (R)-benzyl protected glycidol,10 in the 
presence of DIAD and PPh3 in THF at rt to generate sulfamide 3.36 in 67% yield.  It 
is important to note that the Mitsunobu product primarily originated from the desired
SN2 pathway rather than the competing SN2' route. The solvent system chosen for this
transformation had minor influence upon the ratio of the two observed products as 
seen in the following examples: THF (9.3:1 3.36:SN2'), CH2Cl2 (8:1, 3.36:SN2') and
benzene (>10:1, 3.36:SN2') as determined by 
1H NMR integration of the crude 
reaction mixture.  Allylation of sulfamide 3.36 using identical allylation conditions as
described before (allyl-Br, K2CO3, MeCN, 70 °C) yielded sulfamide diene 3.37 in a
92% yield. RCM with 5 mol% of catalyst C produced the cyclic sulfamide 3.38 in 
excellent yield (96%). Removal of the Boc group with TFA in CH2Cl2 at rt (96%),
and benzylation under the previously described conditions (BnBr, K2CO3, MeCN, 
70 ° C) gave the desired cyclic sulfamide 3.40 in good yield (89%).  Finally, 
dihydroxylation with OsO4 (6 mol %) afforded the differentiated sulfamide diol 3.41
in good yield (70%) and with high diastereoselectivity (dr = 16:1), with the major
product tentatively assigned as the diastereomer resulting from dihydroxylation on the 
olefinic face opposite to the benzyloxymethyl group of the adjacent stereocenter. 
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3.3  RCM Approach Towards N-Hydroxy Cyclic Sulfamides 
The successful application of the RCM reaction for the construction of a 
variety of cyclic sulfamides containing different groups at the P1/P1' and P2/P2' 
positions has led us to investigate the generation of N-hydroxy cyclic sulfamides as
potential MMP inhibitors via the same synthetic pathway developed in our group.  As 
described in the introductory chapter (Chapter 1), matrix metalloproteinases (MMPs),
also called matrixins, are zinc-containing enzymes that are involved in the remodeling
and breakdown of extracellular matrix proteins.11  Studies have revealed that 
overexpression of the MMPs can lead to a number of serious diseases such as arthritis
and cancer.12,13  To date, over 20 MMPs are known, all of which contain a zinc-
binding group (ZBG) that is essential for inhibitory potency (Scheme 3.7).14
However, it has not yet been possible to identify specific inhibitors for each of the 
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MMP enzymes.  Therefore, the synthesis of N-hydroxy cyclic sulfamides as potential 
MMP inhibitors seems to be a viable goal.
Our efforts towards biologically active sulfur-containing compounds have led 
us to synthesize cyclic N-hydroxy sulfamides as potential MMP inhibitors.  We 
reasoned that the synthesis of cyclic sulfamides will provide conformational
restriction around the ZBG (in this case N-OH) which may increase the potency of 
these compounds towards MMP by promoting favorable enzyme/inhibitor
interactions.  The retrosynthetic pathway for the design of the conformationally
constrained sulfamide inhibitors of MMP is shown in Scheme 3.7. 
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The generation of the N-O-benzyl cyclic sulfamide 3.46 was achieved as
outlined in Scheme 3.8,15 beginning with a three-component coupling reaction with 
tert-butyl alcohol, CSI and O-benzyl hydroxylamine hydrochloride in CH2Cl2 under
basic conditions (Et3N) at 0 °C to afford sulfamide 3.42 in good yield (85%). 
Mitsunobu alkylation with ethyl lactate, PPh3 and DIAD in THF at rt afforded chiral 
sulfamide 3.43 in good yield (64%).  Removal of the Boc group under acidic 
conditions (TFA, CH2Cl2, rt) occurred in excellent yields (90-100%) to afford 
sulfamide 3.44, followed by simultaneous allylation at the two N-H sites under 
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standard conditions (allyl-Br, K2CO3, MeCN, 70 °C) to provide diene 3.45 in a 91% 
yield.  RCM with 6 mol % of catalyst C in refluxing CH2Cl2 proceeded smoothly to 
afford cyclic sulfamide 3.46 in excellent yield (97%).  Finally, hydrogenation was 
attempted in order to obtain N-hydroxy sulfamide 3.47.  Initial efforts to obtain 3.47
under hydrogenation conditions (H2, Pd/C, MeOH) were unsuccessful.  Instead of 
affording the desired product 3.47, a separable mixture of 3.48 (66%) and 3.49 (21%)
was isolated. 
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Two hydrogenation conditions were employed and the results are listed in
table 3.1.  Hydrogenation of cyclic sulfamide 3.46 using 5 mol % of Pd/C in EtOAc 
gave exclusively sulfamide 3.48 (entry 1, Table 3.1).  Similar results were obtained 
when performing the reaction under microwave conditions in the presence of
ammonium formate (HCO2
-NH4
+)16 (entry 2, Table 3.1). 
114
Table 3.1 Results obtained for the hydrogenation reaction
N N
S
O O
OBn
EtO2C
3.46
hydrogenation
conditions N N
S
O O
OBn
3.48
EtO2C
Entry Conditions % yield
1 H2, 5% Pd/C, EtOAc, rt 67
2 HCO2
-NH4
+, µ? 71
Unfortunately, all the hydrogenation conditions employed failed to provide 
the desired N-hydroxy cyclic sulfamide 3.47.  Utilization of other reagents such as 
TiCl4
17 will be explored in future efforts.
Conclusions
We have successfully synthesized a variety of symmetric and unsymmetric
cyclic sulfamides with varied substitution in their P1/P1' and P2/P2' periphery. These 
syntheses have been accomplished using CSI or SO2Cl2 to generate the ‘robust S-
linchpins’ in combination with Mitsunobu alkylations, simple alkylations, RCM, and
diastereoselective dihydroxylations. This synthetic protocol proved useful for the 
synthesis of N-hydroxy cyclic sulfamides.  Using this developed synthetic approach,
seven-membered sulfamides with different groups around the periphery can be easily 
accessed in a concise manner and in excellent yields.  Biological evaluation of these 
novel sulfamides is currently in progress and is expected to contribute to drug 
discovery.
115
References for Chapter 3: 
[1] Hultén, J.; Bonham, N. M.; Nillroth, U.; Hansson, T.; Zuccarello, G.; Bouzide, 
A.; Åqvist, J.; Classon, B.; Danielson, U. H.; Karlén, A.; Kvarnström, I.;
Samuelsson, B.; Hallberg, A. Cyclic HIV-1 Protease Inhibitors Derived from
Mannitol: Synthesis, Inhibitory Potencies, and Computational Predictions of 
Binding Affinities. J. Med. Chem. 1997, 40, 885-897. 
[2] Dougherty, J. M.; Probst, D. A.; Robinson, R. E.; Moore, J. D.; Klein, T. A.;
Snelgrove, K. A.; Hanson, P. R. Ring-Closing Metathesis Strategies to Cyclic
Sulfamide Peptidomimetics. Tetrahedron 2000, 56, 9781-9790. 
[3] Jun, J. H.; Dougherty, J. M.; Jiménez, M. S.; Hanson, P. R. New Strategies to 
Symmetric and Unsymmetric Cyclic Sulfamide Analogs of DMP 323: A 
'Sulfur Linchpin'/RCM Approach. Tetrahedron 2003, 59, 8901-8912. 
[4] Scholl, M.; Ding, S.; Lee, C. W.; Grubbs, R. H. Synthesis and Activity of a
New Generation of Ruthenium-Based Olefin Metathesis Catalysts
Coordinated with 1,3-Dimesityl-4,5-dihydroimidazol-2-ylidene Ligands. Org.
Lett. 1999, 1, 953-956. 
[5] Fehrentz, J.-A.; Castro, B. An Efficient Synthesis of Optically Active ?-(t-
Butoxycarbonylamino)-aldehydes from ?-Amino Acids. Synthesis 1983, 676-
678.
[6] Saari, W. S.; Fischer, T. E. A Convenient and Versatile Synthesis of Chiral 
Aliphatic and Allylic Amines. Synthesis 1990, 453-454. 
[7] Montero, J.-L.; Dewynter, G.; Agoh, B.; Delaunay, B.; Imbach, J.-L. Selective 
Synthesis of Sulfonylureas and Carboxysulfamides: A Novel Route to 
Oxazolidinones. Tetrahedron Lett. 1983, 24, 3091-3094. 
[8] Schwab, P.; Grubbs, R. G.; Ziller, J. W. Synthesis and Application of 
RuCl2(=CHR')(PR3)2: The Influence of the Alkylidene Moiety on Metathesis
Activity. J. Am. Chem. Soc. 1996, 118, 100-110. 
[9] McReynolds, M. D.; Sprott, K. T.; Hanson, P. R. A Concise Route to
Structurally Diverse DMP 323 Analogues via Highly Functionalized 1,4-
Diamines. Org. Lett. 2002, 4, 4673-4676. 
[10] Davoille, R. J.; Rutherford, D. T.; Christie, S. D. R. Homologation of Allylic 
Alcohols. An Approach to Cyclic and Acyclic Polyoxygenated Compounds.
Tetrahedron Lett. 2000, 41, 1255-1259. 
116
[11] Zhang, X.; Gonella, N. C.; Koehn, J.; Pathak, N.; Ganu, V.; Melton, R.; 
Parker, D.; Hu, S-H.; Nam, K-Y. Solution Structure of the Catalytic Domain
of Human Collagenase-3 (MMP-13) Complexed to a Potent Non-Peptidic 
Sulfonamide Inhibitor: Binding Comparison with Stromelysin-1 and 
Collagenase-1. J. Mol. Biol. 2000, 301, 513-524. 
[12] Scozzafava, A.; Supuran, C. T. Carbonic Anhydrase and Matrix
Metalloproteinase Inhibitors: Sulfonylated Amino Acid Hydroxamates with 
MMP Inhibitory properties Act as Efficient Inhibitors of CA Isoenzymes I, II,
and IV, and N-Hydroxysulfonamides Inhibit Both These Zinc Enzymes. J.
Med. Chem. 2000, 43, 3677-3687. 
[13] Decicco, C. P.; Seng, J. L.; Kennedy, K. E.; Covington, M. B.; Welch, P. K.;
Arner, E. C.; Magolda, R. L.; Nelson, D. J. Amide Surrogates of Matrix
Metalloproteinase Inhibitors: Urea and Sulfonamide Mimics. Bioorg. Med. 
Chem. Lett. 1997, 7, 2331-2336. 
[14] Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. H. Design and 
Therapeutic Application of Matrix Metalloproteinase Inhibitors. Chem. Rev. 
1999, 99, 2735-2776. 
[15] Jung, J. H.; Jiménez, M. S.; Hanson, P. R. Unpublished results. 
[16] Banik, B. K.; Barakat, K. J.; Wagle, D. R.; Manhas, M. S.; Bose, A. K. 
Microwave-Assisted Rapid and Simplified Hydrogenation. J. Org. Chem.
1999, 64, 5746-5753. 
[17] Inagaki, M.; Tsuri, T.; Jyoyama, H.; Ono, T.; Yamada, K.; Kobayashi, M.; 
Hori, Y.; Arimura, A.; Yasui, K.; Ohno, K.; Kakudo, S.; Koizumi, K.; Suzuki,
R.; Kato, M.; Kawai, S.; Matsumoto, S. Novel Antiarthritic Agents with 1,2-
Isothiazolidine-1,1-dioxide(g-Sultam) Skeleton: Cytokine Suppressive Dual 
Inhibitors of Cyclooxygenase-2 and 5-Lipoxygenase. J. Med. Chem. 2000, 43,
2040-2048.
117
Chapter 4:
Ring-Closing Metathesis Approaches to the Synthesis of Cyclic Sulfamoyl 
Carbamates and Sulfamoyl Ureas 
118
4.1 Sulfamoyl Carbamates and Sulfamoyl Ureas 
The recent growth of high-throughput screening for biologically active agents
has increased the demand for the development of diverse libraries of synthetic 
compounds.1-3 A growing area in combinatorial chemistry4-8 is the generation of 
novel scaffolds that are extremely advantageous from both a chemical and a 
biological point of view.9-13 The ability of the sulfonamide moiety, and related
analogs, to serve as non-hydrolyzable amide surrogates has opened the door for their 
use as key functional groups in the development of new scaffolds. A number of 
compounds based on this premise have been developed including, biologically active 
sulfonamides,14-16 sulfamides,17-19 sulfamoyl carbamates,20-22 sulfahydantoins,23 and
sulfamoyl ureas.24-27 Recently, novel libraries based on sulfonamide,28-32 sulfamoyl
urea,33 sulfahydantoin,34-35 and sulfamide36 scaffolds have been reported. Our interest 
in the development of new routes to access both phosphorus and sulfur-containing
heterocycles (P- and S-heterocycles)37 leads us to herein report a ring-closing
metathesis (RCM) approach37-41 to a diverse set of cyclic sulfamoyl carbamates and 
cyclic sulfamoyl ureas described in Figure 4.1.
Figure 4.1 Cyclic sulfamoyl carbamates and cyclic sulfamoyl ureas of interest 
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These compounds represent novel scaffolds possessing multiple points of diversity 
from which to produce combinatorial libraries, with the ultimate goal of biological
screening.
Sulfamoyl carbamates of general structure shown in Figure 4.2 have been 
primarily used as important synthetic intermediates in the generation of unsymmetric 
sulfamides37,42-43 and sulfahydantoins.44 Their popularity originates from their ease of 
synthesis utilizing the previously mentioned 3-component coupling with 
chlorosulfonyl isocyanate (CSI), and facile functionalization by standard alkylation
and Mitsunobu alkylation45-46 resulting in the facile production of linear sulfamoyl
carbamates,47-50 sulfahydantoins,44 and linear44,19 and cyclic sulfamides.37,42-43
Figure 4.2 General structure of linear sulfamoyl carbamates and ureas 
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As previously described in the introductory chapter (Chapter 1) sulfamoyl
carbamates and sulfamoyl ureas have been studied as acyl-CoA:cholesterol O-acyl-
transferase (ACAT) inhibitors.22 However, reports of cyclic sulfamoyl carbamates
are limited, and no examples of cyclic sulfamoyl carbamates of general structure 
shown in Figure 4.1 have appeared in the literature. 
Sulfamoyl ureas (Figure 4.2) have also been shown to be biologically 
active.22-27, 51-52  Large libraries of linear sulfamoyl ureas have been synthesized from
the 3-component coupling of two amine nucleophiles and CSI.  The chemical features
of the sulfamoyl urea group are different from that of a sulfamoyl carbamate.  Indeed, 
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the higher pKa of the urea N-H (pKa >10), compared to the carbamate N-H (pKa ~ 4), 
has hindered efforts to alkylate the urea N-H using the Mitsunobu reaction. Thus,
derivatization of these compounds has previously fallen solely to base-promoted
alkylation. Despite their importance as biological targets, cyclic sulfamoyl ureas have
been largely unexplored.
The emergence of ring-closing olefin metathesis (RCM)53-59 over the last 
decade has fundamentally changed the method of generating both carbocyclic and 
heterocyclic targets.58-59 Specifically, RCM has become an important and extremely
useful transformation for the facile construction of small-, medium-, and large ring-
containing systems.58-60 When coupled with the versatile nature of both sulfamoyl
carbamates and sulfamoyl ureas, several factors provided impetus for this
investigation, including: (1) the ease of synthesis and analog generation in both 
sulfamoyl carbamate and urea classes, (2) the convenience of using RCM to generate 
cyclic structures, (3) the ability of both sulfamoyl carbamate and urea moieties to
serve as surrogates for sulfamide or urea groups present in known biologically active 
systems, and (4) the correlation to the known biological activities of linear sulfamoyl
carbamates and ureas. 
4.2. RCM Approaches Toward Cyclic Sulfamoyl Ureas and Cyclic Sulfamoyl 
Carbamates
Previously, we have utilized sulfamoyl carbamate building blocks as 
synthetically valuable starting materials to generate a variety of unsymmetrical cyclic 
sulfamides related to the potent HIV protease inhibitors DMP 323 and DMP 450.43
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Our new route utilizes this functional group as the central ‘linchpin’ in an RCM 
methodology. The strength of this approach lies in the wide variety of 9- to 11-
membered cyclic sulfamoyl carbamates (Figure 4.3) and sulfamoyl ureas (Figure 4.3)
that can be accessed from the corresponding dienes. The focal points of this method
include the ability to: (1) use 3-component coupling of CSI, allylic alcohols and 
allylic amines to synthesize asymmetric sulfamoyl carbamates and sulfamoyl ureas, 
(2) functionalize the sulfamoyl carbamate nitrogen via a Mitsunobu reaction, (3) 
utilize base-promoted alkylation or the Mitsunobu reaction to functionalize the 
sulfamoyl urea nitrogen, and (4) generate novel cyclic sulfamoyl carbamates and 
sulfamoyl ureas utilizing RCM. 
Figure 4.3 Synthetic approach towards cyclic sulfamoyl carbamates and ureas
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Our initial efforts began with the 3-component coupling of allyl alcohol, CSI, 
and N-allyl (L)-valine methyl ester to produce the corresponding sulfamoyl carbamate
4.1 (Scheme 4.1).  Optimization of the reaction conditions led to the use of 1.2 equiv. 
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of Et3N to efficiently facilitate the formation of sulfamoyl carbamate 4.1 in 79% yield.
Sulfahydantoin formation via intramolecular cyclization between the carbamate
nitrogen and the ester group was thwarted under these optimized conditions. Next, it 
was synthetically desirable to functionalize the carbamate nitrogen in 4.1. Though 
base-promoted alkylation of sulfamoyl carbamates with K2CO3 was a viable option, 
the Mitsunobu reaction was employed because of its versatility and to reduce possible
hydantoin formation. Subjection of 4.1 to Mitsunobu conditions using benzyl alcohol
(BnOH), DEAD and PPh3 in THF at rt gave sulfamoyl carbamate 4.2 in excellent
yields (89-92%). 
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The initial attempts to cyclize diene 4.2 using Grubbs first generation catalyst
[(PCy3)2(Cl)2Ru=CHPh] (cat-B)
61-63 in CH2Cl2 (0.009 M) resulted in the formation of
9-membered cyclic sulfamoyl carbamate 4.3 in only 33% yield, with a major
byproduct (~30% yield) tentatively assigned as the dimer arising from cross-
metathesis (X-MET).  The difficulty in confirming such a product was the result of
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carbamate C–N bond rotamers that are present in the cross metathesized product.
Proton NMR experiments on these sulfamoyl carbamates conducted at 50 °C failed to
overcome the rotational barrier. RCM using the more active second generation
catalyst [(IMesH2)(PCy3)(Cl)2Ru=CHPh] (cat-C)
69 in CH2Cl2 (0.009 M) resulted in
the formation of the desired 9-membered cyclic sulfamoyl carbamate 4.3 in 69%
overall yield, with no detectable dimer formation via X-MET.  This newly formed
sulfamoyl carbamate represents the first example of RCM on this class of compounds
and highlights the potential for library production utilizing more elaborate alcohols at 
the initial coupling and subsequent Mitsunobu alkylation steps. 
With a general route to cyclic sulfamoyl carbamates in hand, analogous cyclic 
sulfamoyl carbamates were synthesized using benzylamine and other (L)-amino
esters as represented in Table 4.1. Coupling with CSI and allyl alcohol afforded 
sulfamoyl carbamates 4.4-4.6 in good yields (85-90%). Benzylation of sulfamoyl
carbamates 4.4-4.6 via the Mitsunobu reaction with BnOH, DEAD and PPh3 in THF
afforded metathesis precursors 4.7-4.9 in 81-92% yields. RCM with 6 mol% of cat-C 
gave cyclic sulfamoyl carbamates 4.10-4.12 in modest yields (40-52%).  Removal of 
residual ruthenium was achieved using DMSO according to Georg.65  Surprisingly,
although these yields were marginal (40-52%), no X-MET dimer was observed,
prompting us to further optimize the RCM reaction. 
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Table 4.1: RCM route to 9-membered ring sulfamoyl carbamates 
Entry
3-component
coupling product 
(% yield) 
Mitsunobu product 
(% yield) 
RCM Product 
(% yield)
1
O N
H
S
N
O OO
Ph
4.4 (90%)
O N
S
N
O OO
Ph
Bn
4.7 (92%)
N
S
N
O
O O
O
Bn
Ph
4.10 (40%)
2
4.5 (85%)
O N
H
S
N
O OO
CO2Me
4.8 (87%)
O N
S
N
O OO
CO2Me
Bn
N
S
N
O
O O
O
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4.11 (51%)
CO2Me
3
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O N
H
S
N
O OO
CO2Me
Ph
4.9 (81%)
O N
S
N
O OO
CO2Me
Ph
Bn
N
S
N
O
O O
O
Bn
4.12 (52%)
CO2Me
Ph
In the second route shown in Scheme 4.2, the 3-component coupling reaction
was carried out with various olefinic alcohols of varying chain length, CSI, and (L)-
phenylalanine methyl ester to produce the corresponding sulfamoyl carbamates 4.13-
4.15 in good yields (56-86%). The Mitsunobu reaction with PMBOH, DIAD and 
PPh3 in THF was employed to regioselectively install the PMB moiety at the 
carbamate position (pKa ~ 4) in sulfamoyl carbamates 4.13-4.15 to afford PMB-
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protected sulfamoyl carbamates 4.16-4.18 in good to excellent yields (79-97%).
Allylation of the PMB-protected carbamates 4.16-4.18 under standard conditions 
(allyl bromide and K2CO3 in MeCN under reflux) produced RCM precursors 4.19-
4.21 in high yields (90-99%). Subjection to RCM conditions using 10-20 mol % of
cat-C in refluxing DCE (0.005 M) gave the corresponding 9-, 10-, and 11-membered
cyclic sulfamoyl carbamates 4.22-4.24 in good yields (65-87%). 
Scheme 4.2 
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The initial examples outlined in Schemes 4.1 and 4.2 utilized simple
Mitsunobu benzylation to install diversity at the sulfamoyl carbamate. Installation of 
side chains bearing stereogenic centers, as previously shown in the synthesis of
unsymmetric sulfamides,42-43 were next pursued as outlined in Scheme 4.3. Thus, 
alkylation of sulfamoyl carbamate 4.25 with naturally occurring (S)-ethyl lactate
under Mitsunobu conditions (DIAD, PPh3 in THF, rt), generated alkylated sulfamoyl
carbamate 4.26 in 65% yield. Simple allylation under standard conditions provided
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diene 4.27 in good yield (68%), followed by RCM in refluxing DCE to afford cyclic 
sulfamoyl carbamate 4.28 in good yield (70%) containing both valine and alanine 
side chains at the periphery. 
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Subsequent efforts were focused toward the exploration of a similar three-step
protocol to generate 9-membered cyclic sulfamoyl ureas (Scheme 4.4).  Benzylamine
was chosen as the initial test substrate, due to potential problems with sulfahydantoin
formation from the use of amino esters, vide infra. Coupling of 2 equiv. of
benzylamine with CSI gave linear sulfamoyl urea 4.29 in 90% yield (Scheme 4.4). 
As with the sulfamoyl carbamates, functionalization of the urea nitrogen with a
benzyl group was desirable. Unfortunately, sulfamoyl ureas were unable to undergo 
Mitsunobu benzylations under standard DEAD or DIAD conditions. Initial attempts
at benzylation using DBU and NaH were found to be surprisingly ineffective despite
literature precedent,22 yielding no noticeable benzylated product. Utilizing our 
previous method to alkylate sulfamides (BnBr, K2CO3, MeCN) resulted in the
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formation of benzylated sulfamoyl urea 4.30, albeit in a modest 58% yield.  RCM of 
4.30 proved to be efficient as 6 mol% cat-C in CH2Cl2 (0.01 M) afforded 9-membered
cyclic sulfamoyl urea 4.31 in 74% yield.  Importantly, no product arising from
X-MET was observed. This result represents the first known example of RCM on a
sulfamoyl urea template, and opens opportunities to diversification strategies. 
Scheme 4.4 
N
S
N
N
O O
Bn
O
Bn
4.31
N N
H
S
N
O OO
4.29
Ph
NHBn
Et3N,CH2Cl2, 0
oC
N
S
Cl
O O
C
O
BnBr, K2CO3
MeCN, 70 oC
58%
RCM, 6 mol % C
CH2Cl2, 40
oC, 10h
90%
Ph
N N
S
N
O OO
4.30
PhPh
Bn
Bn
74%
With a method for the generation of cyclic sulfamoyl ureas in hand, the 
synthesis of sulfamoyl ureas utilizing allylated aminoesters was explored. 
Sulfahydantoin formation, arising from attack of the sulfamoyl urea nitrogen into the 
sulfamide amino ester forming hydantoin 4.35, was of major concern (Scheme 4.5).
Thus, our initial use of excess base in the initial 3-component coupling reaction 
generated sulfahydantoins 4.35-4.37 as a significant byproduct.  In addition, the 
sulfamoyl ureas were found to cyclize the substrates to the sulfahydantoins 4.35-4.37
at rt with excess Et3N in solution and in small amounts during purification via column
chromatography.
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Despite these concerns, our initial 3-component coupling reaction with a 
variety of allylated amino esters and CSI produced sulfamoyl ureas 4.32-4.34 in good 
overall yields (Scheme 4.6).  Furthermore, optimal results were obtained with 1.2
equiv. of Et3N and 2.2 equiv. of the amino ester. Lowering the equivalents of the 
amino ester gave a complex mixture of product, sulfahydantoin and sulfamoyl
chloride. For stability reasons, benzylation was therefore utilized as a means of both
protection and functionalization. The standard K2CO3 promoted benzylation of 4.32-
4.34 resulted in moderate yields of benzyl-protected RCM precursors 4.38-4.40 (43-
65%).
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Surprisingly, these conditions produced only minor amounts of the sulfahydantoin 
despite elevated temperatures, with no single entry yielding more than 5% of
hydantoin byproduct.  Metathesis of the amino ester-derived sulfamoyl ureas 
provided consistent results as treatment of dienes 4.38-4.40 with 6 mol% of cat-C
afforded the desired cyclic sulfamoyl ureas 4.41-4.43 in good yields (71-81%).
Importantly, no byproducts arising from X-MET were observed. 
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An alternate route to benzylation was sought in order to circumvent problems
associated with generating benzylated sulfamoyl ureas. We felt that if a Mitsunobu
reaction could be initiated at the sulfamoyl urea nitrogen, the potential for 
derivatization would greatly improve. The difficulty is encountered in the inability of 
the DEAD/PPh3 complex to deprotonate the sulfamoyl ureas containing a less acidic 
N-H moiety. Mitsunobu reactions with higher pKa nucleophiles have been realized
with the advent of 1,10-(azodicarbonyl) dipiperidine-tributylphosphine (ADDP)66 as a 
more powerful DEAD equivalent. To test the efficacy of this method, benzylamine-
derived sulfamoyl urea 4.29 was subjected to modified Mitsunobu conditions with 
ADDP, to afford benzylated sulfamoyl urea 4.30 in 52% yield (Scheme 4.7).  To our 
knowledge, this is the first example of a Mitsunobu reaction using a sulfamoyl urea as 
the nucleophile.  Though the yield was less than that obtained via standard alkylation
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conditions, these results are encouraging.  In addition to nitrogen protection,
utilization of more elaborate nonracemic secondary alcohols will provide an excellent 
pathway for diversification of these sulfamoyl ureas.
Conclusions
We have described the first synthesis of both cyclic sulfamoyl carbamates and
ureas utilizing the RCM reaction. This method represents an extension of our success
with our recent sulfamide research and a new direction in the synthesis of novel S-
heterocycles. Further research on sulfamoyl carbamates will focus on 
functionalization of the sulfamoyl carbamate nitrogen utilizing secondary allylic 
alcohols and amines in the 3-component coupling reaction to generate a variety of 
novel sulfamoyl carbamates and sulfamoyl ureas. In addition, the Mitsunbou reaction 
will be optimized and exploited as an important means to functionalize the sulfamoyl
ureas.  Biological screening and further refinement of these compounds will be 
pursued.
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Chapter 5 
Experimental
138
All reactions were carried out in flame-dried glassware under argon.  Toluene, THF,
Et2O, and CH2Cl2 were purified by passage through a purification system (Solv-Tek) 
employing activated Al2O3. Et3N was distilled from CaH2.  Flash column
chromatography was performed with Merck silica gel (EM-9385-9, 230–400 mesh).
Thin layer chromatography (TLC) was performed on silica gel 60F254 plates 
(EM-5715-7, Merck).  All amino acid precursors were purchased from Advanced 
Chem Tech. 1H and 13C spectra were recorded in CDCl3, MeOD or Acetone-d6 on 
either a Bruker DRX-400 or a Bruker AM-500 spectrometer operating at 400/100
MHz and 500/125 MHz, respectively.  High-resolution mass spectrometry (HRMS) 
and FAB spectra were obtained on a VG Instrument ZAB double-focusing mass
spectrometer.  Infrared data was obtained on a Nicolet 320 Fourier Transform 
Infrared Spectrophotometers. Melting points were obtained on a Thomas Hoover
capillary melting point apparatus. Optical rotations were carried out on a Rudolph
Automatic Polarimeter (AUTOPOL IV). 
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tert-butyl allylsulfonylcarbamate (2.3) 
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To a solution of allyl sulfonamide 2.2 (500 mg, 4.13 mmol) in CH2Cl2 (5.2 mL) was
added DMAP (50 mg, 0.41 mmol) and Et3N (459 mg, 4.53 mmol, 0.63 mL), followed 
by the dropwise addition of a solution of Boc2O (1.04 g, 4.75 mmol, 1.09 mL) in 
CH2Cl2 (8.3 mL) over 15 min. with stirring.  The reaction was stirred at rt for 2.5 h 
after which the solvent was removed.  To the crude mixture was added 1N HCl (25
mL) and the solution extracted with EtOAc (4 × 50 mL).  The organic layer was 
washed with water (25 mL) and brine (25 mL), dried over MgSO4, filtered and the
solvent removed under reduced pressure.  Flash chromatography (SiO2, 3:1 
Heptane/EtOAc) afforded 851 mg (93%) of carbamate 2.3 as a yellow oil, which
solidified to a crystalline yellow solid when left in the fridge. A small amount of the
bisprotected product (46mg, 4%) was also isolated.
Analytical data for 2.3: TLC Rf = 0.32 (1:1 Heptane/EtOAc); Mp = 43-45 °C;
1H NMR (400 MHz, CDCl3) ? 6.97 (s, 1H, N-H), 5.90 (dddd, J = 17.4, 10.1, 7.4, 7.4
Hz, 1H), 5.49 (dd, J = 10.1, 1.0 Hz, 1H), 5.44 (dd, J = 17.0, 1.2 Hz, 1H), 4.11 (d, J = 
7.4 Hz, 2H), 1.51 (s, 9H); 13C NMR (100 MHz, CDCl3) ? 149.8, 124.8, 124.5, 84.1, 
56.6, 27.7; FTIR (neat) 3242, 3094, 2982, 1742, 1641 cm-1; HRMS (M+Na)+ calcd 
for 244.0619, found 244.0610.
140
(R)-tert-butyl allylsulfonyl(1-(benzyloxy)but-3-en-2-yl)carbamate (2.5) 
S
N
O O
O
O
O
Ph
To a solution of allylic alcohol 2.4 (120 mg, 0.67 mmol), sulfamoyl carbamate 2.3
(149 mg, 0.67 mmol) and PPh3 (228 mg, 0.87 mmol) in THF (13.4 mL) at rt was 
added DEAD (152 mg, 0.87 mmol, 0.14 mL) dropwise via syringe and the reaction 
stirred at rt until complete by TLC (usually < 1 h).  Flash chromatography (SiO2, 6:1 
Hexane/EtOAc) afforded 219 mg (79%) of sulfonamide 2.5 as a yellow oil.
Analytical data for 2.5: TLC Rf = 0.63 (2:1 Heptane/EtOAc); [?]  = -9.70
(c = 1.125, CHCl
25
D
3)
1H NMR (400 MHz, CDCl3) ? 7.27-7.19 (m, 5H), 5.92 (ddd, J = 
17.2, 10.4, 6.5 Hz, 1H), 5.78 (dddd, J = 17.4, 10.1, 7.4, 7.4 Hz, 1H), 5.29 (dd, J =
9.9,1.0 Hz, 1H), 5.26 (dd, J = 17.1, 1.0 Hz, 1H), 5.23 (dd, J = 17.3, 1.0 Hz, 1H), 5.16 
(dd, J = 10.4, 1.0 Hz, 1H), 4.96-4.90 (m, 1H), 4.52 (d, J = 11.8 Hz, 1H), 4.44 (d, J = 
11.8 Hz, 1H), 4.16 (dd, J = 13.8, 7.6 Hz, 1H), 4.05 (dd, J = 13.7, 7.2 Hz, 1H), 3.84 
(dd, J = 9.6, 8.8 Hz, 1H), 3.59 (dd, J = 9.7, 6.2 Hz, 1H), 1.43 (s, 9H); 13C NMR (125 
MHz, CDCl3) ? 151.0, 137.8, 134.0, 128.4, 127.7, 127.7, 124.7, 124.6, 118.5, 84.6,
73.0, 69.9, 59.3, 58.4, 28.0; FTIR (neat) 3088, 3030, 2978, 2930, 2868, 1726, 1639, 
1497 cm-1; HRMS (M+Na)+ calcd for  C19H27NO5SNa 404.1508, found 404.1527. 
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1,2-thiazine-N-carboxylic acid-3,6-dihydro-(3R)-[(phenylmethoxy)methyl]-1,1-
dimethylethyl ester-1,1-dioxide (2.6)
S
N
O O
O
O
OBn
To a solution of diene 2.5 (2.5 g, 6.55 mmol) in degassed toluene (655 mL) was
added Grubbs second generation catalyst (Cat. C) (278 mg, 0.328 mmol) in one 
portion and the reaction heated at reflux for 3 h.  The solvent was removed under 
reduced pressure, CH2Cl2 (50 mL) added and the residual ruthenium removed by 
addition of DMSO (1.28 g, 16.4 mmol, 1.16 mL) and stirring at rt for 12 h.  Flash 
chromatography (SiO2, 3:1 Hexane/EtOAc) afforded 2.0 g (87 %) of sultam 2.6 as an 
ivory solid.
Analytical data for 2.6: TLC Rf = 0.33 (2:1 Heptane/EtOAc); Mp = 68-73 °C;
[?] = + 120.4 (c = 0.955, CHCl25D 3);
1H NMR (400 MHz, CDCl3) ? 7.34-7.27 (m, 5H), 
6.01 (dddd, J = 10.8, 4.0, 1.6, 1.6 Hz, 1H), 5.78 (dddd, J = 10.4, 5.6, 2.8, 1.6 Hz, 1H), 
5.27-5.24 (m, 1H), 4.55 (s, 2H), 3.92 (dddd, J = 16.4, 2.4, 2.4, 2.4 Hz, 1H), 3.78 (d, J
= 6.4 Hz, 2H), 3.77-3.72 (m, 1H), 1.49 (s, 9H); 13 C NMR (125 MHz, CDCl3) ? 150.5, 
137.8, 128.3, 127.6, 127.6, 126.8, 118.3, 84.6, 73.2, 70.7, 60.0, 50.3, 27.8; FTIR 
(neat) 2980, 2928, 2866, 1722, 1454 cm-1; HRMS (M+Na)+ calcd for  C17H23NO5SNa
376.1195, found 376.1212. 
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(R)-N-(1-(benzyloxy)but-3-en-2-yl)prop-2-ene-1-sulfonamide (2.7) 
S
N
O O
O
H
Ph
To a solution of diene 2.5 (330 mg, 0.87 mmol) in CH2Cl2 (3 mL) was added an 
excess of TFA (1 mL) dropwise via syringe and the reaction stirred at rt until all 
starting material was consumed (~30 min).  The reaction mixture was quenched with 
15 mL of saturated NaHCO3 and extracted with CH2Cl2 (4 × 25 mL).  The organic
layers were combined, dried over Na2SO4, filtered and concentrated under reduced
pressure. Flash chromatography (SiO2, 3:1 Heptane/EtOAc) afforded 227 mg (93%) 
of sulfonamide 2.7 as a light yellow oil.
Analytical data for 2.7: TLC Rf = 0.70 (1:1 Heptane/EtOAc);  [?] = +4.65 
(c = 0.817, CHCl
25
D
3);
1H NMR (400 MHz, CDCl3) ? 7.38-7.28 (m, 5H), 5.90 (dddd, J = 
17.2, 10.0, 7.2, 7.2 Hz, 1H), 5.83 (ddd, J = 17.2, 10.4, 6.8 Hz, 1H), 5.38 (dd, J = 10.8, 
1.0 Hz, 1H), 5.37 (dd, J = 17.2, 1.0 Hz, 1H), 5.35 (dd, J = 17.2, 1.0 Hz, 1H), 5.26 (dd, 
J = 10.4, 1.0 Hz, 1H), 4.81 (d, J = 7.5 Hz, 1H), 4.56 (d, J = 11.9 Hz, 1H), 4.51 (d, J = 
11.8 Hz, 1H), 4.17-4.11 (m, 1H), 3.73 (dd, J = 6.7, 6.0 Hz, 1H), 3.60 (dd, J = 9.5, 4.1 
Hz, 1H), 3.50 (dd, J = 9.5, 5.4 Hz, 1H); 13C NMR (100 MHz, CDCl3) ? 137.3, 135.4,
128.4, 127.8, 127.7, 125.7, 123.7, 117.7, 73.2, 72.3, 57.9, 56.1; FTIR (neat) 3283, 
3086, 3030, 2921, 2862, 1641 cm-1; HRMS (M+Na)+ calcd for C14H19NO3SNa
304.0983, found 304.1003. 
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(R)-2H-1,2-thiazine, 3,6-dihydro-3-[(phenylmethoxy)methyl]-1,1-dioxide (2.8) 
S
N
O O
H
OBn
In a procedure similar to the preparation of sultam 2.6, a solution of sulfonamide 2.7
(217 mg, 0.77 mmol) in degassed CH2Cl2 (154 mL) was treated with Grubbs second
generation catalyst (Cat. C) (33mg, 0.039 mmol) and the mixture subjected to the 
RCM reaction. Removal of the residual ruthenium with DMSO, followed by
purification via flash chromatography (SiO2, 3:1 Heptane/EtOAc) afforded 180 mg
(92%) of sultam 2.8 as an ivory solid.
Analytical data for 2.8: TLC Rf = 0.12 (2:1 Heptane/EtOAc); Mp = 79-83 °C;
[?] = + 41.7 (c = 1.19, CHCl25D 3);
1H NMR (400 MHz, CDCl3) ? 7.39-7.29 (m, 5H), 
5.86-5.76 (m, 2H), 4.81, (d, J = 7.1 Hz, 1H), 4.57 (d, J = 12.0 Hz, 1H), 4.53 (d, J = 
12.0 Hz, 1H), 4.31-4.26 (m, 1H) 3.74-3.68 (m, 1H), 3.64 (d, J = 4.4 Hz, 2H), 3.63-
3.58 (m, 1H); 13C NMR (100 MHz, CDCl3) ? 137.1, 128.5, 128.0, 127.8, 127.2, 120.9, 
73.3, 70.2, 56.8, 47.5; FTIR (neat) 3252 (N-H), 3032, 2922, 2866, 1653, 1498 cm-1;
HRMS (M+NH4)
+ calcd for  C12H19N2O3S 271.1116, found 271.1108.
144
 1,2-thiazine-N-carboxylic acid-3,4,5,6-tetrahydro-(3S)-[(phenylmethoxy)methyl]
-(4R,5S)-dihydroxy, 1,1-dimethylethyl ester, 1,1-dioxide (2.9) 
S
N
O O
O Ph
O
O
HO
OH
To a solution of sultam 2.6 (566 mg, 1.60 mmol), NMO (255 mg, 1.92 mmol) and
citric acid (504 mg, 2.40 mmol) in acetone (3 mL) and water (1 mL) was added  a 
4 % aqueous solution of OsO4 (0.016 mmol, 40 µL) and the reaction stirred at rt for 
12 h.  The reaction was quenched with a 10% aqueous solution of Na2S2O3 (15 mL),
extracted with CH2Cl2 (4 × 15 mL), the organic layers combined, dried over MgSO4,
filtered and concentrated under reduced pressure.  Flash chromatography (SiO2, 1:1 
Hexanes/EtOAc) afforded 598 mg (96%) of diol 2.9 as a white crystalline solid. 
Analytical data for 2.9: TLC Rf = 0.11 (1:1 Hexane/EtOAc); Mp = 105-110°C;
[?] = + 13.96 (c = 1.655, CHCl25D 3);
1H NMR (400 MHz, CDCl3) ? 7.37-7.28 (m, 5H), 
4.83 (ddd, J = 9.2, 6.0, 3.2 Hz, 1H), 4.56 (d, J = 11.6 Hz, 1H), 4.50 (d, J = 12.0 Hz,
1H), 4.33-4.28 (m, 1H), 4.18 (bs, 1H), 3.76 (dd, J = 9.6, 9.2 Hz, 1H), 3.66 (dd, J = 
10.0, 6.0 Hz, 1H), 3.52 (dd, J = 12.8, 10.4 Hz, 1H), 3.33 (dd, J = 12.8, 4.4 Hz, 1H), 
2.65 (s, 2H, O-H), 1.49 (s, 9H); 13C NMR (125 MHz, CDCl3) ? 151.8, 137.4, 128.5, 
128.1, 128.0, 85.3, 73.4, 68.5, 66.4, 65.8, 60.5, 52.3, 27.9; FTIR (neat) 3477 (O-H),
3030, 2982, 2932, 2872, 1724 cm-1; HRMS (M+Na)+ calcd for  C17H25NO7SNa
410.1250, found 410.1254. 
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1,2-thiazine-1,1-dioxide-N-carboxylicacid-3,4,5,6-tetrahydro-(3S)-
[(phenylmethoxy)methyl]-cyclic-(4R,5S)-cyclocarbonate-1,1-dimethylethyl ester
(2.10)
S
N
O O
O Ph
O
O
O
O
O
To a solution of cis-diol 2.9 (525 mg, 1.36 mmol) in CH2Cl2 (38 mL) at -78 °C was
added pyridine (3.22 g, 40.8 mmol) and triphosgene (604 mg, 2.03 mmol) in one 
portion.  After stirring for 10 min. at -78 °C the temperature was raised to 0 °C and 
the reaction stirred at that temperature for 1 h.  The crude mixture was quenched with
10 % HCl (15 mL) and extracted with CH2Cl2 (4 × 25 mL), dried over MgSO4,
filtered and concentrated under reduced pressure to afford 544 mg (97%) of carbonate 
2.10 as a white fluffy solid.  The product was used for the next reaction without 
further purification. 
Analytical data for 2.10: TLC Rf = 0.35 (1:1 Hexane/EtOAc); Mp = 55-65 °C;
[?] = + 6.26 (c = 1.405, CHCl25D 3);
1H NMR (400 MHz, CDCl3) ? 7.40-7.28 (m, 5H), 
5.17 (ddd, J = 8.8, 4.4, 2.0 Hz, 1H), 5.07 (dd, J = 8.8, 2.0 Hz, 1H), 4.99 (app q, J = 
2.8 Hz, 1H), 4.56 (d, J = 11.6 Hz, 1H), 4.47 (d, J = 11.6 Hz, 1H), 4.14 (dd, J = 15.6, 
4.4 Hz, 1H), 3.86 (dd, J = 10.8, 2.8 Hz, 1H), 3.77 (dd, J = 10.8, 3.6 Hz, 1H), 3.47 (dd, 
J = 15.2, 2.0 Hz, 1H), 1.55 (s, 9H); 13C NMR (100 MHz, CDCl3) ? 152.2, 151.1, 
136.1, 128.9, 128.6, 128.0, 86.2, 74.0, 73.8, 72.4, 70.5, 59.0, 51.6, 27.9; FTIR (neat) 
2982, 2939, 1819, 1730, 1454 cm-1; HRMS (M+Na)+ calcd for C18H23NO8SNa
436.1042, found 436.1043. 
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1, 2thiazine-N-carboxylic acid-3, 4-dihydro-(3S)-[(phenylmethoxy)methyl]-(4S)-
hydroxy-1, 1-dimethylethyl ester-1, 1-dioxide (2.11) 
S
N
O O
O Ph
O
O
OH
To a solution of carbonate 2.10 (70 mg, 0.174 mmol) in CH2Cl2 (1.7 mL) was added 
Et3N (19.3 mg, 0.19 mmol) and the reaction heated at reflux for 1h.  Flash 
chromatography (SiO2, 2:1 Hexanes/EtOAc) afforded 56.6 mg (91%) of ?-hydroxy
sultam 2.11 as a white solid.
Analytical data for 2.11: TLC Rf = 0.32 (1:1 Hexanes/EtOAc); Mp = 85-87 °C; 
[?] = -64.4 (c = 1.035, CHCl25D 3);
1H NMR (400 MHz, CDCl3) ? 7.36-7.29 (m, 5H), 
6.47 (ddd, J = 10.4, 4.8, 1.2 Hz, 1H), 6.43 (d, J = 10.8 Hz, 1H), 4.92-4.87 (m, 1H), 
4.58 (d, J = 11.6 Hz, 1H), 4.49 (d, J = 11.6 Hz, 1H), 4.39-4.35 (m, 1H), 3.70 (dd, J = 
8.8, 4.8 Hz, 2H), 2.47 (d, J = 8.5 Hz, 1H), 1.53 (s, 9H); 13C NMR (125 MHz, CDCl3)
? 151.1, 137.3, 133.9, 129.4, 128.4, 127.9, 127.8, 85.7, 73.3, 68.3, 61.4, 61.4, 27.9;
FTIR (neat) 3493, 3059, 3035, 2982, 2927, 2872, 1732, 1641 cm-1; HRMS (M+Na)+
calcd for  C17H23NO6SNa 392.1144, found 392.1150.
147
(3S, 4R)-2H-1,2thiazine-3, 4-dihydro-3[(phenylmethoxy)methyl]-4-hydroxy-1, 1-
dioxide (2.13) 
S
N
O O
O Ph
H
OH
In a procedure similar to the preparation of sulfonamide 2.7, ?-hydroxy sultam 2.11
(75.0 mg, 0.20 mmol) in CH2Cl2 (1.0 mL) was treated with TFA (0.1 mL) and the 
solution stirred at rt for 30 min.  Flash chromatography (SiO2, 1:1 Hexanes/EtOAc)
afforded 49.3 mg (92%) of sultam 2.13 as a white crystalline solid. 
Analytical data for 2.13: TLC Rf = 0.30 (1:1.5 Hezanes/EtOAc); Mp = 115-125 °C;
[?] = -15.7 (c = 0.255, CHCl25D 3);
1H NMR (400 MHz, CDCl3) ? 7.38-7.30 (m, 5H), 
6.55 (dd, J = 10.8, 2.4 Hz, 1H), 6.37 (dd, J = 10.8, 2.0 Hz, 1H), 4.78 (d, J = 12.4 Hz, 
1H), 4.58 (d, J = 11.6 Hz, 1H), 4.53 (d, J = 11.6 Hz, 1H), 4.55-4.50 (m, 1H), 3.91 (dd, 
J = 9.6, 2.0 Hz, 1H), 3.84-3.77 (m, 1H), 3.61 (dd, J = 9.6, 3.6 Hz, 1H), 2.17 (d, J = 
7.2 Hz, 1H); 13C NMR (125 MHz, Acetone-d6) ? 141.6, 138.5, 128.8, 128.2, 127.5, 
127.4, 72.9, 68.4, 62.8, 59.2; FTIR (neat) 3518, 3240, 3060, 2920, 1623, 1406 cm-1;
HRMS (M+NH4)
+ calcd for  C12H19N2O4 287.1066, found 287.1078.
148
1,2-thiazine-N-carboxylic acid-3, 4-dihydro-(3S)-[(phenylmethoxy)methyl]-(4R)-
(p-nitrophenoxy)-1,1-dimethylethyl ester-1, 1-dioxide (2.14)
S
N
O O
O Ph
O
O
O
O2N
To a solution of sultam 2.11 (50 mg, 0.14 mmol) in THF (0.70 mL) was added 
p-nitrophenol (19.0 mg, 0.14 mmol) and PPh3 (40 mg, 0.15 mmol), followed by the 
dropwise addition of DEAD (26.0 mg, 0.15 mmol, 24 µL) at rt.  The reaction was 
stirred at rt until complete consumption of sultam 2.11 (less than 1 h).  Flash 
chromatography (SiO2, 2:1 Heptane/EtOAc) afforded 30 mg (45 %) of 2.14 as an
ivory solid. 
Analytical data for 2.14: TLC Rf = 0.69 (1:1 Hexanes/EtOAc); Mp = 148-155 °C; 
[?] = +2.4 (c = 0.205, CHCl25D 3);
1H NMR (400 MHz, CDCl3) ? 8.24 (d, J = 9.2 Hz,
2H), 7.33-7.27 (m, 5H), 7.00 (d, J = 9.2 Hz, 2H), 6.47 (dd, J = 11.2, 2.4 Hz, 1H), 6.40
(ddd, J = 11.2, 1.6, 1.6 Hz, 1H), 5.50-5.48 (m, 1H), 5.27-5.21 (m, 1H), 4.55 (d, J = 
11.2 Hz, 1H), 4.49 (d, J = 11.2 Hz, 1H), 4.05 (dd, J = 10.0, 10.0 Hz, 1H), 3.89 (dd, J
= 10.4, 4.4 Hz, 1H), 1.52 (s, 9H); 13C NMR (125 MHz, CDCl3) ? 160.5, 150.8, 142.7, 
137.6, 133.6, 129.5, 128.2, 127.8, 127.7, 126.3, 115.2, 85.9, 73.5, 70.0, 65.5, 57.1, 
27.8; FTIR (neat) 2980, 2932, 2874, 1732, 1610, 1518, 1342 cm-1; HRMS (M+NH4)
+
calcd for  C23H30N3O8S 508.1754, found 508.1729.
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Trichlorooxazole-containing sultam (2.15) 
S
N
O O
O Ph
N
O
Cl3C
O
O
To a cold solution (-50 °C) of sultam 2.11 (50 mg, 0.135 mmol) in CH2Cl2 (1.35 mL)
was added Cl3CCN (20 µL) and DBU (4.1 mg, 0.027 mmol, 4.0 µL).  The reaction
was stirred until it slowly reached rt.  The reaction was quenched with saturated
NH4Cl (15 mL) and extracted with CH2Cl2 (4 × 15 mL).  The organic layers were 
combined, dried over MgSO4, filtered and concentrated under reduced pressure. 
Flash chromatography (SiO2, 2:1 Hexanes/EtOAc) afforded 66 mg (96 %) of 2.15 a
white solid.
Analytical data for 2.15: TLC Rf = 0.58 (1:1 Hexanes/EtOAc); Mp = 49-54 °C;
[?]  = +28.4 (c = 0.675, CHCl25D 3);
1H NMR (400 MHz, CDCl3) ? 7.40-7.30 (m, 5H), 
5.27 (dd, J = 10.4, 2.0 Hz, 1H), 5.18 (ddd, J = 4.4, 4.4, 2.0 Hz, 1H), 4.91 (ddd, J = 
10.0, 5.6, 2.4 Hz, 1H), 4.59 (d, J = 11.6 Hz, 1H), 4.51 (d, J = 11.6 Hz, 1H), 4.04 (dd, 
J = 14.8, 5.6 Hz, 1H), 3.79 (d, J = 4.4 Hz, 2H), 3.53 (dd, J = 14.8, 2.4 Hz, 1H), 1.52
(s, 9H); 13C NMR (125 MHz, CDCl3) 163.1, 151.2, 136.5, 128.7, 128.4, 128.0, 85.6, 
80.5, 80.5, 73.9, 70.1, 63.6, 58.9, 51.2, 27.9; FTIR (neat) 2982, 2935, 2972, 1728, 
1666, 1454, 1369, 1346 cm-1; HRMS (M+H)+  calcd for C19H24Cl3N2O6S 513.0421, 
found 513.0417.
150
1,2-thiazine-1,1-dioxide-3,4,5,6-tetrahydrohydro-(3S)-[(phenylmethoxy)methyl]-
(4S)-hydroxy-(5S)-(2,2,2-trichloro)acetamide (2.16) 
S
N
O O
O P
h
H
N
OH
Cl3C
H
O
To a solution of sultam 2.15 (24.0 mg, 0.047 mmol) in CH2Cl2 (0.5 mL) was added 
TFA (0.47 mmol, 35 µL) and the reaction stirred at rt for 1 h.  Flash chromatography
(SiO2, 1:1 Hexanes/EtOAc) afforded 19.4 mg (97%) of trichloroacetimidate 2.16 as a 
white solid.
Analytical data for 2.16: TLC Rf = 0.45 (1:1.5 Hexanes/EtOAc); Mp = 56-64 °C;
[?]  = -41.5 (c = 0.54, CHCl25D 3);
1H NMR (400 MHz, CDCl3) ? 8.51 (d, J = 8.8 Hz,
1H), 7.40-7.30 (m, 5H), 4.99 (d, J = 9.6 Hz, 1H), 4.90 (dddd, J = 8.0, 4.0, 4.0, 4.0 Hz, 
1H), 4.56 (d, J = 12.0 Hz, 1H), 4.53 (d, J = 12.0 Hz, 1H), 4.13 (dd, J = 10.4, 4.0 Hz, 
1H), 3.92 (dd, J = 9.6, 2.4 Hz, 1H), 3.63-3.60 (m, 2H), 3.45 (dd, J = 14.0, 4.0 Hz, 1H), 
3.37 (dd, J = 14.0, 4.0 Hz, 1H), 2.70 (s, 1H); 13C NMR (100 MHz, CDCl3) ? 163.9, 
137.1, 128.6, 128.2, 128.0, 92.0, 73.7, 67.2, 67.1, 55.1, 51.1, 50.3; FTIR (neat) 3470-
3447, 3362, 3064, 3032, 2935, 1713, 1630, 1454 cm-1; HRMS (M+H)+ calcd for 
C14H18Cl3N2O5S 431.0002, found 431.0026.
151
1,2-thiazine-N-carboxylic acid-3,4,5,6-tetrahydro-(3S)-[(phenylmethoxy)methyl]-
N'-phenyl-(4S,5S)-oxazolidinone-1,1-dimethylethyl ester-1,1-dioxide (2.17) 
S
N
O O
O Ph
Boc
N
O
O
Ph
To a solution of ?-hydroxy sultam 2.11 (6.0 mg, 0.016 mmol) in DCE (0.16 mL) was
added phenyl isocyanate (2.9 mg, 0.024 mmol) and Et3N (0.16 mg, 0.016 mmol).
The reaction was stirred in a pressure tube at reflux (83 °C) until complete by TLC.
Flash chromatography (SiO2, 4:1 Hexanes/EtOAc) afforded 5 mg (64%) of bicyclic 
sultam 2.17 as a white solid.
Analytical data for 2.17: TLC Rf = 0.55 (1:1 Hexane/EtOAc); Mp= 160-164 °C;
[?] = -52.9 (c = 0.17, CHCl25D 3);
1H NMR (400 MHz, CDCl3) ? 7.45-7.30 (m, 10H), 
5.09 (dd, J = 9.2, 2.0 Hz, 1H), 5.03-5.01 (m, 1H), 4.93 (ddd, J = 9.2, 4.8, 2.0 Hz, 1H),
4.59 (d, J = 11.6 Hz, 1H), 4.53 (d, J = 11.6 Hz, 1H), 3.93 (dd, J = 14.8, 4.0 Hz, 1H), 
3.89 (dd, J = 10.4, 3.6 Hz, 1H), 3.83 (dd, J = 10.8, 3.6 Hz, 1H), 3.22 (dd, J = 15.2, 2.0
Hz, 1H), 1.55 (s, 9H); 13C NMR (125 MHz, CDCl3) ? 153.5, 151.2, 136.5, 134.7,
129.7, 128.9, 128.5, 128.0, 126.7, 123.7, 85.9, 74.1, 71.0, 70.5, 59.6, 55.4, 48.0, 28.0; 
FTIR (neat) 3063, 2928, 1765, 1724, 1630, 1599, 1456 cm-1; HRMS (M+NH4)
+ calcd
for C24H32N3O7S 506.1961, found 506.1973.
152
1,2-thiazine-N-carboxylic acid-3,4,5,6-tetrahydro-(3S)-[(phenylmethoxy)methyl]-
N'-isopropyl-(4S,5S)-oxazolidinone-1,1-dimethylethyl ester-1,1-dioxide (2.18) 
S
N
O O
O Ph
Boc
N
O
O
To a solution of ?-hydroxy sultam 2.11(41.0 mg, 0.11 mmol) in DCM (0.78 mL) was
added isopropyl isocyanate (14.0 mg, 0.166 mmol, 16µL) and Et3N (3.9 mg, 0.039
mmol, 8µL).  The reaction was heated at 50 °C in a pressure tube until complete by
TLC (~24 h).  Flash chromatography (SiO2, 2:1 Hexanes/EtOAc) afforded 39.1 mg
(78%) of bicyclic sultam 2.18 as an ivory solid. 
Analytical data for 2.18: TLC Rf = 0.14 (1:1 Hexanes/EtOAc); Mp = 132-135 °C;
[?]  =-34.5 (c = 0.525, CHCl25D 3);
1H NMR (400 MHz, CDCl3) ? 7.40-7.29 (m, 5H), 
4.96 (ddd, J = 4.0, 4.0, 2.4 Hz, 1H), 4.79 (dd, J = 8.4, 2.0 Hz, 1H), 4.56 (d, J = 11.6
Hz, 1H), 4.52 (d, J = 11.6 Hz, 1H), 4.33 (ddd, J = 8.4, 4.8, 3.2 Hz, 1H), 3.94 (dd, J = 
15.2, 5.2 Hz, 1H), 3.88-3.85 (m, 1H), 3.85 (dd, J = 10.8, 4.4 Hz, 1H), 3.76 (dd, J = 
10.4, 3.6 Hz, 1H), 3.26 (dd, J = 14.8, 3.2 Hz, 1H), 1.54 (s, 9H), 1.34 (d, J =7.2 Hz, 
3H), 1.32 (d, J = 6.8 Hz, 3H); 13C NMR (125 MHz, CDCl3) ? 155.1, 151.0, 136.7, 
128.8, 128.4, 128.0, 85.7, 73.9, 71.5, 70.3, 59.1, 52.9, 50.6, 46.5, 28.0, 21.5, 20.0;
FTIR (neat) 3109, 2980, 1755, 1634, 1520, 1454 cm-1; HRMS (M+NH4)
+ calcd for 
C21H34N3O7S 472.2117, found 472.2112.
153
1,2-thiazine-N-carboxylic acid-3,4,5,6-tetrahydro-(3S)-[(phenylmethoxy)methyl]-
(4R)-hydroxy-(5R)-phenylthio-1,1-dimethylethyl ester-1,1-dioxide (2.19) 
S
N
O O
O Ph
O
O
OH
PhS
To a solution of ?-hydroxy sultam 2.11(32 mg, 0.087 mmol) in CH2Cl2 (0.87 mL)
was added PhSH (10.5 mg, 0.095 mmol, 10 µL) and DMAP (2.0 mg, 0.0174 mmol). 
The reaction was stirred at rt for 12 h and the solvent removed under reduced pressure.
Flash chromatography (SiO2, 4:1 Hexanes/EtOAc) afforded 35 mg (84%, 5.9:1
mixture of inseparable diastereomers) 2.19 as a clear oil.
Analytical data for 2.19 (major diastereomer): TLC Rf = 0.59 (1:1 
Hexanes/EtOAc); 1H NMR (400 MHz, CDCl3) ? 7.44 (dd, J = 6.0, 3.0 Hz, 2H), 7.35-
7.28 (m, 6H), 7.22 (dd, J = 8.0, 1.5 Hz, 2H), 4.95 (ddd, J = 9.0, 6.0, 2.5 Hz, 1H), 4.52
(d, J = 12.0 Hz, 1H), 4.42 (d, J = 11.5 Hz, 1H), 4.19 (d, J = 2.0 Hz, 1H), 3.87 (ddd, J
= 13.0, 3.5, 2.0 Hz, 1H), 3.74 (dd, J = 10.0, 9.0 Hz, 1H), 3.67 (dd, J = 13.5, 12.5 Hz,
1H), 3.64 (dd, J = 10.5, 5.5 Hz, 1H), 3.22 (dd, J = 13.0, 3.5 Hz, 1H), 2.61 (d, J = 3.0 
Hz, 1H), 1.50 (s, 9H); 13C NMR (125 MHz, CDCl3) ? 151.5, 137.5, 132.9, 129.7, 
128.8, 128.5, 127.9, 127.7, 85.1, 73.3, 68.2, 64.6, 61.7, 50.5, 46.0, 27.9; FTIR (neat) 
3504, 3061, 2982, 2932, 1728, 1583, 1454 cm-1; HRMS (M+NH4)
+ calcd for 
C23H33N2O6S2 497.1780, found 497.1778. 
154
1,2-thiazine-N-carboxylic acid-3,4,5,6-tetrahydro-(3R)-[(phenylmethoxy)methyl]
-(4R)-hydroxy-(5R)-benzylthio-1,1-dimethylethyl ester-1,1-dioxide (2.20) 
S
N
O O
O P
h
O
O
OH
SPh
In a procedure similar to the preparation of sultam 2.19, a solution of ?-hydroxy
sultam 2.11 (29 mg, 0.078 mmol) in CH2Cl2 (0.78 mL) was treated with PhCH2SH
(10.7 mg, 0.086 mmol, 10 µL) and Et3N (1.6 mg, 0.0156 mmol, 2.2 µL).  The 
reaction was stirred at rt for 12 h and the solvent removed under reduced pressure.
Flash chromatography (SiO2, 3:1 Hexanes/EtOAc) afforded 36.6 mg (major
diastereomer) and 1.9 mg (minor diastereomer) of 2.20 (dr ~10:1, 100% combined
yield) as clear oils.
Analytical data for 2.20 (major diastereomer): TLC Rf = 0.50 (1:1 
Hexanes/EtOAc); [?] = + 57.7 (c = 0.735, CHCl25D 3);
1H NMR (400 MHz, CDCl3)
? 7.36-7.25 (m, 10H), 4.88 (ddd, J = 8.0, 6.8, 2.4 Hz, 1H), 4.52 (d, J = 12.0 Hz, 1H), 
4.44 (d, J = 12.0 Hz, 1H), 4.00-3.98 (m, 1H), 3.80 (d, J = 13.6 Hz, 1H), 3.76 (d, J = 
13.6 Hz, 1H), 3.58 (dd, J = 8.0, 1.2 Hz, 1H), 3.57 (d, J = 13.2 Hz, 1H), 3.54 (d, J =
13.2 Hz, 1H) , 3.39 (ddd, J = 13.2, 3.2, 2.0 Hz, 1H), 3.01 (dd, J = 13.2, 3.2 Hz, 1H), 
2.57 (s, 1H), 1.48 (s, 9H); 13C NMR (125 MHz, CDCl3) ? 150.4, 136.6, 135.7, 127.9, 
127.8, 127.4, 126.9, 126.8, 126.7, 83.9, 72.1, 67.3, 63.7, 60.4, 49.5, 40.7, 34.8, 26.9;
FTIR (neat) 3504, 2980, 2930, 1726, 1602, 1454, 1138 cm-1; HRMS (M+NH4)
+ calcd 
for C24H35N2O6S2 511.1937, found 511.1939.
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1,2-thiazine-N-carboxylic acid-3,4,5,6-tetrahydro-(3S)-[(phenylmethoxy)methyl]-
(4R)-hydroxy-(5R)-butylthio-1,1-dimethylethyl ester-1,1-dioxide (2.21):
S
N
O O
O P
h
O
O
OH
S
In a procedure similar to the preparation of sultam 2.19, a solution of ?-hydroxy
sultam 2.11 (27 mg, 0.073 mmol) in CH2Cl2 (0.73 mL) was treated with BuSH 
(7.2mg, 0.080 mmol, 10 µL) and Et3N (2.2 mg, 0.0219 mmol, 3.0 µL).  The reaction 
was stirred at rt for 12 h and the solvent removed under reduced pressure.  Flash 
chromatography (SiO2, 3:1 Hexanes/EtOAc) afforded 29.6 mg (88%) of 2.21 as an 
inseparable mixture of diastereomers  (dr ~4.5:1) as a clear oil.
Analytical data for 2.21 (major diastereomer): TLC Rf = 0.50 (1:1 
Hexanes/EtOAc); 1H NMR (400 MHz, CDCl3) ? 7.35-7.29 (m, 5H), 4.97 (ddd, J = 
9.0, 5.5, 2.5 Hz, 1H), 4.60 (d, J = 12.0 Hz, 1H), 4.47 (d, J = 12.0 Hz, 1H), 4.12 (app q,
J = 2.0 Hz, 1H), 3.80 (dd, J = 9.5, 9.5 Hz, 1H), 3.67 (dd, J = 10.0, 6.0 Hz, 1H), 3.56 
(dd, J = 13.0, 13.0 Hz, 1H), 3.46 (ddd, J = 13.0, 3.0, 2.0 Hz, 1H), 3.17 (dd, J = 13.0, 
3.0 Hz, 1H), 2.61 (d, J = 2.5 Hz, 1H), 2.57 (ddd, J = 7.5, 7.5, 2.0 Hz, 2H), 1.57-1.54 
(m, 2H), 1.50 (s, 9H), 1.42-1.37 (m, 2H), 0.92 (t, J = 7.0 Hz, 3H); 13C NMR (125 
MHz, CDCl3) ? 151.4, 137.6, 128.5, 127.9, 127.8, 85.0, 73.2, 68.2, 64.6, 61.3, 50.7, 
42.6, 31.6, 31.3, 27.9, 21.9, 13.6; FTIR (neat) 2959, 2932, 1728, 1624, 1607, 1497,
1454 cm-1; HRMS (M+Na)+ calcd for C21H33NO6S2Na 482.1647, found 482.1638. 
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1,2-thiazine-1,1-dioxide-3,4,-dihydro-(3S)-[(phenylmethoxy)methyl]-(4S)-tert-
butylcarbonate (2.22) 
S
N
O O
O Ph
H
OBoc
To a solution of sultam 2.11 (25 mg, 0.067 mmol) in THF (0.67 mL) was added 
Cs2CO3 (24 mg, 0.074 mmol) and the reaction stirred at 60 °C for 1 h.  The crude 
product was filtered and purified by flash chromatography (SiO2, 4:1 Hexanes/ 
EtOAc) to afford 17.9 mg (72%) of sultam 2.22 as a clear oil.
Analytical data for 2.22: TLC Rf = 0.64 (2:1 Hexanes/EtOAc); [?] = -75.9 
(c = 0.20, CHCl
25
D
3);
1H NMR (400 MHz, CDCl3) ? 7.38-7.29 (m, 5H), 6.63 (dd, J = 
11.2, 2.0 Hz, 1H), 6.36 (dd, J = 11.2, 2.0 Hz, 1H), 5.48 (ddd, J = 12.0, 4.0, 2.0 Hz,
1H), 4.98 (d, J = 12.4 Hz, 1H), 4.58 (d, J = 11.6 Hz, 1H), 4.50 (d, J = 11.6 Hz, 1H), 
4.00 (dddd, J = 12.5, 5.0, 2.5, 2.5 Hz, 1H), 3.68 (dd, J = 10.0, 1.6 Hz, 1H), 3.59 (dd, J
= 10.0, 2.8 Hz, 1H), 1.50 (s, 9H); 13C NMR (125 MHz, CDCl3) ? 153.3, 137.0, 136.3, 
130.3, 128.6, 128.2, 128.0, 83.9, 73.7, 66.7, 66.0, 56.0, 27.7; FTIR (neat) 3285, 3063, 
2982, 1743, 1618, 1456, 1369, 1151 cm-1; HRMS (M+Na)+ calcd for C17H23NO6SNa
392.1144, found 392.1138. 
157
1,2-thiazine-1,1-dioxide-N-carboxylic acid-3, 4-dihydro-(3S)-[(phenylmethoxy)-
methyl]-1,1-dimethylethyl ester-(4S)-dimethylphosphate (2.23) 
S
N
O O
O Ph
O
O
O
P
MeO
O
MeO
To a solution of ?-hydroxy sultam 2.11 (144 mg, 0.39 mmol) in CH2Cl2 (4 mL)  at 
0 °C was added N-methylimidazole (96 mg, 1.17 mmol, 84 µL) and (MeO)2P(O)Cl
(112.6 mg, 0.78 mmol, 84 µL).  The ice bath was removed and the reaction stirred at
rt for 1 h.  The reaction was quenched with a saturated solution of NH4Cl (15 mL)
and extracted with CH2Cl2 (4 × 15 mL).  The organic layers were combined, dried 
over MgSO4, filtered and concentrated under reduced pressure.  Flash
chromatography (SiO2, 1:2 hexanes/EtOAc) afforded 159 mg (85%) of sultam 2.23 as
a clear oil. 
Analytical data for 2.23: TLC Rf = 0.37 (1:2.5 Heptane/EtOAc); [?] = -83.9 
(c = 1.355, CHCl
25
D
3);
1H NMR (500 MHz, CDCl3) ? 7.31-7.23 (m, 5H), 6.46 (d, J = 
10.6 Hz, 1H), 6.43 (ddd, J = 10.6, 5.3, 1.5 Hz, 1H), 5.06-5.02 (m, 1H), 4.93 (ddd, J = 
7.7, 5.4, 2.0 Hz, 1H), 4.51 (d, J = 11.8 Hz, 1H), 4.43 (d, J = 11.7 Hz, 1H), 3.72 (d, 
JHP =11.3 Hz, 3H), 3.69 (d, JHP = 11.3 Hz, 3H), 3.62 (dd, J = 8.4, 1.3 Hz, 2H), 1.46 (s, 
9H); 13C NMR (125 MHz, CDCl3) ? 150.6, 137.2, 131.6, 129.7 (d, JCP = 15.0 Hz),
128.5, 128.0, 127.8, 85.8, 73.4,  67.5, 65.2 (d, JCP = 20.0 Hz), 59.4 (d, JCP = 20.0 Hz), 
54.8 (d, JCP = 25.0 Hz), 54.8 (d, JCP = 20.0 Hz), 27.9; 
31P NMR (400 MHz, CDCl3) ?
158
1.77; FTIR (neat) 3833, 2981, 2959, 1736, 1647, 1456 cm-1; HRMS (M+NH4)
+ calcd 
for C19H32N2O9PS 495.1566, found 495.1560.
1,2-thiazine-N-carboxylic acid-3,6-dihydro-(3R)-[(phenylmethoxy)methyl]-(6R)-
ethyl- 1,1-dimethylethyl ester-1,1-dioxide (2.24) 
S
N
O O
O
O
OBn
To a solution of CuCN·2LiCl (1 M, 0.56 mmol) at -78° C was added Et2Zn (1 M,
0.56 mmol) and the mixture stirred at that temperature for 1.5 h.  A solution of
phosphate 2.23 (26.5 mg, 0.056 mmol) in THF (0.56 mL) was added to the ethyl 
cuprate mixture and the solution stirred until it warmed up to -20 °C.  The reaction
was quenched with a saturated solution of NH4Cl (10 mL) and extracted with CH2Cl2
(4 × 10 mL), the organic layers combined, dried over MgSO4, filtered and
concentrated.  Flash chromatography (SiO2, 7:1 Hexanes/EtOAc) afforded 15.5 mg
(74%) of sultam 2.24 as a white solid.
Analytical data for 2.24: TLC Rf = 0.69 (2:1 Hexanes/EtOAc); Mp = 60-65 °C;
[?] = + 85.7 (c = 0.68, CHCl25D 3);
1H NMR (500 MHz, CDCl3) ? 7.34-7.27 (m, 5H), 
5.93 (ddd, J = 10.8, 3.2, 3.2 Hz, 1H), 5.60 (ddd, J = 10.8, 2.0, 1.6 Hz, 1H), 5.28-5.22
(m, 1H), 4.48 (s, 2H), 3.74-3.67 (m, 3H), 2.11-2.05 (m, 1H), 1.69-1.60 (m, 1H), 1.42
(s, 9H), 1.07 (t, 7.4 Hz, 3H); 13C NMR (125 MHz, CDCl3) ? 150.7, 137.9, 128.1, 
127.6, 127.6, 125.8, 122.7, 84.4, 73.1, 70.9, 60.5, 59.9, 27.9, 21.7, 10.9; FTIR (neat) 
2978, 2935, 1716, 1616, 1456, 1169 cm-1; HRMS (M+NH4)
+ calcd for C19H31N2O5S
399.1954, found 399.1953. 
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1,2-thiazine-N-carboxylic acid-3,4,5,6-tetrahydro-(3R)-[(phenylmethoxy)methyl]
-(4R,5S)-dihydroxy-(6R)-ethyl- 1,1-dimethylethyl ester-1,1-dioxide (2.25) 
S
N
O O
O Ph
O
O
HO
OH
To a stirring solution of sultam 2.24 (10.8 mg, 0.028 mmol) in acetone (1.5 mL) and 
water (0.5 mL) was added citric acid (9.0 mg, 0.042 mmol), NMO (6.0 mg, 0.033
mmol) and 1 drop of OsO4 (4 % solution in water).  The reaction was stirred at rt for
12 h, then quenched with a 10% aqueous solution of Na2SO3 and extracted with
CH2Cl2 (4 × 15 mL).  The organic layers were combined, dried over MgSO4, filtered
and concentrated under reduced pressure.  Flash chromatography (SiO2, 1:1
Hexanes/EtOAc) afforded 9.1 mg (78%) of diol 2.25 as an ivory solid. 
Analytical data for 2.25: TLC Rf = 0.16 (1:1 Hexanes/EtOAc); Mp = 100-105 °C;
[?] = + 50.8 (c = 0.13, CHCl25D 3);
1H NMR (400 MHz, CDCl3) ? 7.37-7.30 (m, 5H), 
4.72 (ddd, J = 9.6, 5.6, 4.0 Hz, 1H), 4.56 (d, J = 12.0 Hz, 1H), 4.51 (d, J = 11.6 Hz, 
1H), 4.27 (bs, 1H), 3.98 (dd, J = 6.8, 6.0 Hz, 1H), 3.82 (dd, J = 9.6, 9.2 Hz, 1H), 3.72 
(dd, J = 9.6, 5.6 Hz, 1H), 3.38 (ddd, J = 8.0, 6.0, 6.0 Hz, 1H), 2.74 (bs, 1H), 2.51 (d, J
= 7.6 Hz, 1H), 2.04 (ddd, J = 13.6, 7.6, 7.6 Hz, 1H), 1.50 (s, 9H), 1.20 (t, J = 7.6 Hz,
3H); 13C NMR (125 MHz, CDCl3) ? 151.9, 137.4, 128.5, 128.0, 127.9, 84.9, 73.5, 
70.3, 69.7, 68.0, 63.9, 59.8, 27.9, 18.8, 11.9; FTIR (neat) 3479, 2979, 2933, 2879, 
1722, 1367, 1055 cm-1; HRMS (M+Na)+ calcd for C19H29NO7SNa 438.1563, found
438.1551.
160
1,2-thiazine-1,1-dioxide-3,4-dihydro-(3S)-[(phenylmethoxy)methyl]-(4R)-
dimethylphosphate (2.26) 
S
N
O O
O Ph
H
OMeO
P
O
MeO
To a stirring solution of sultam 2.23 (12.0 mg, 0.25 mmol) in CH2Cl2 (0.25 mL) was 
added FeCl3 (4.0 mg, 0.025 mL) in one portion and the reaction stirred at rt for 30 
min. The crude mixture was quenched with water (10 mL) and extracted with CH2Cl2
(4 × 15 mL), dried over MgSO4, filtered and concentrated under reduced pressure.
Flash chromatography (SiO2, 1:2 Hexane/EtOAc) afforded 5.6 mg (60%) of sultam 
2.26 as a white solid.
Analytical data for 2.26: TLC Rf = 0.14 (1:2 Hexanes/EtOAc); Mp = 80-84° C; 
[?] = -49.6 (c = 1.11, CHCl25D 3);
1H NMR (400 MHz, CDCl3) ? 7.37-7.32 (m, 5H), 
6.64 (dd, J = 10.8, 2.0 Hz, 1H), 6.52 (dd, J = 10.8, 2.0 Hz, 1H), 5.18 (dddd, J = 9.2, 
9.2, 2.0, 2.0 Hz, 1H), 5.00 (d, J = 12.0 Hz, 1H), 4.59 (d, J = 11.6 Hz, 1H), 4.55 (d, J = 
11.6 Hz, 1H), 4.00-3.95 (m, 1H), 3.87 (dd, J = 9.6, 2.0 Hz, 1H), 3.79 (d, JHP= 11.2 Hz,
3H), 3.75 (d, JHP = 11.2 Hz, 3H), 3.65 (dd, J = 9.6, 2.4 Hz, 1H); 
13C NMR (100 MHz, 
CDCl3) ? 137.1, 136.7, 130.4, 128.6, 128.2, 128.0, 73.7, 67.2 (d, JCP = 20.0 Hz), 66.9,
57.1 (d, JCP = 35.0 Hz), 54.9 (d, JCP = 30.0 Hz), 54.8 (d, JCP = 30.0 Hz);
31P NMR
(400 MHz, CDCl3) ? 1.60; FTIR (neat) 3232, 3119, 2957, 1610, 1454, 1155, 1092 
cm-1; HRMS (M+Na)+ calcd for C14H20NO7PSNa 400.0596, found 400.0578.
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Aziridine-Containing Sultam(2.29) 
N
S
O O
OBn
H
To a solution of sultam 2.26 (21.7 mg, 0.0575 mmol) in THF (0.58 mL) was added 
Cs2CO3 (56 mg, 0.173 mmol) and the reaction stirred at 60 °C for 1 h.  The product 
was filtered and purified by flash chromatography (SiO2, 1:1 Hexanes/EtOAc) to 
afford 15 mg (100%) of aziridine 2.29 as a light-yellow oil. 
Analytical data for 2.29: TLC Rf = 0.43 (1:2 Hexanes/EtOAc); [?]  =
-38.6 (c = 0.35, CHCl
25
D
3);
1H NMR (400 MHz, CDCl3) ? 7.38-7.31 (m, 5H), 6.96 (ddd,
J = 6.0, 1.0, 1.0 Hz, 1H), 6.40 (d, J = 6.0 Hz, 1H), 4.60 (d, J = 12.4 Hz, 1H), 4.56 (d, 
J = 12.8 Hz, 1H), 3.80 (dd, J = 11.6, 4.4 Hz, 1H), 3.68 (m, 1H), 3.58 (dd, J = 11.2, 
4.8 Hz, 1H), 2.78 (q, J = 4.0 Hz, 1H); 13C NMR (125 MHz, CDCl3) ? 136.8, 136,2,
127.6, 127.0, 126.9, 125.0, 72.6, 66.8, 55.5, 46.2; FTIR (neat) 3080, 2920, 1609 
cm-1; HRMS (M+Na)+ calcd for C12H13NO3SNa 274.0514, found 274.0515. 
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(R)-(1,1-dioxo-3,6-dihydro-[1,2]thiazin-3-yl)-methanol (2.30)
S
N
O O
OH
H
To a solution of sultam 2.8 (56 mg, 0.158 mmol) in CHCl3 (1.6 mL) was added TMSI
(95 mg, 0.475 mmol, 65 µL) and the reaction heated at 70 °C for 7 h.  The reaction
was quenched with MeOH (4 mL) and the solvent removed under reduced pressure. 
Flash chromatography (SiO2, 1:1 Hexanes/EtOAc) afforded 12 mg (47%) of sultam 
2.30 as a clear oil. 
Analytical data for 2.30: TLC Rf = 0.14 (1: 3 Hexane/EtOAc); [?] = +63.1 (c = 
0.555, EtOH); 
25
D
1H NMR (400 MHz, CDCl3) ? 5.93-5.88 (m, 1H), 5.81 (dd, J = 10.8,
2.0 Hz, 1H), 4.96 (d, J = 6.4 Hz, 1H, N-H), 4.27-4.22 (m, 1H), 3.90-3.83 (m, 2H),
3.74-3.68 (m, 2H), 2.37 (t, J = 5.6 Hz, O-H); 13C NMR (125 MHz, CDCl3) ? 126.6, 
121.7, 63.4, 58.8, 47.7; FTIR (neat) 3475, 3254, 2960, 1150 cm-1; HRMS (M+Na)+
calcd for C5H9NO3SNa 186.0201, found 186.0212. 
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(R)-(1,1-dioxo-[1,2]thiazinan-3-yl)-methanol (2.31)
S
N
O O
OH
H
A solution of 10 % Pd/C (122 mg) in 95 % EtOH (10 mL) was stirred for 15 min.
followed by the addition of sultam 2.8 (244 mg, 0.96 mmol).  The air was removed by
suction, a H2 ballon was inserted and the reaction stirred at rt for 7 h.  the product was 
filtered through celite and purified by flash chromatography (SiO2, 1:1 hexane/ 
EtOAc, then 100% EtOAc) to afford 126 mg (79%) of 2.31 as white crystals.
Analytical data for 2.31: TLC Rf = 0.26 (100% EtOAc); [?] = -14.4
(c = 0.20, MeOH); Mp = 110-115 °C;
25
D
1H NMR (400 MHz, CDCl3) ? 4.50 (d, J = 6.4 
Hz, 1H, N-H), 3.80 (dd, J = 10.8, 3.6 Hz, 1H), 3.66 (dd, J =10.8, 4.4 Hz, 1H), 3.63-
3.56 (m, 1H), 3.20 (ddd, J = 13.6, 3.6, 3.6 Hz, 1H), 2.89 (ddd, J = 13.2, 9.6, 7.2 Hz, 
1H), 2.26 (m, 2H), 1.71 (ddd, J = 14.0, 6.4, 3.2 Hz, 1H), 1.63 (bs, 1H), 1.59-1.50 (m, 
1H); 13C NMR (125 MHz, MeOD) ? 63.0, 57.4, 47.7, 25.0, 21.8; FTIR (neat) 3431,
3250, 2935, 1151 cm-1; HRMS (M+H)+ calcd for C5H12NO3S 166.0538, found
166.0540.
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(R)-2H,7H-Oxazolo[3,4?][1,2]thiazin-7-one-4?,5-dihydro-1-dioxide (2.32) 
S
N
O O
O
O
To a solution of sultam 2.30 (30 mg, 0.18 mmol) in CH2Cl2 (18 mL) at -50 °C was 
added pyridine (43 mg, 0.54 mmol, 44 µL) and triphosgene (65 mg, 0.22 mmol)
portionwise.  The reaction was stirred until it reached rt.  The reaction was quenched
with NH4Cl (15 mL) and extracted with CH2Cl2 (4 × 15 mL), dried over MgSO4,
filtered and concentrated under reduced pressure.  Flash chromatography (SiO2, 1:1 
Hexanes/EtOAc) afforded 18 mg (53 %) of carbamate 2.32 as a clear oil.
Analytical data for 2.32 TLC Rf = 0.27 (1: 2 Hexane/EtOAc); [?]  = +17.9 (c = 1.1, 
CHCl
25
D
3);
1H NMR (400 MHz, CDCl3) ? 5.95 (dddd, J = 10.4, 4.0, 4.0, 2.0 Hz, 1H),
5.89 (dddd, J = 10.4, 2.4, 1.2, 1.2 Hz, 1H), 5.12-5.10 (m, 1H), 4.53 (dd, J = 8.4, 8.4 
Hz, 1H), 4.25 (dd, J = 8.8, 2.8 Hz, 1H), 4.09 (dddd, J = 17.2, 3.2, 2.4, 2.4 Hz, 1H),
3.80 (dddd, J = 17.2, 6.0, 2.8, 1.2 Hz, 1H); 13C NMR (125 MHz, CDCl3) ? 151.2, 
126.3, 122.2, 66.6, 59.7, 48.0; FTIR (neat) 2962, 1743; HRMS (M+Na)+ calcd for
C6H7NO4SNa 211.9994, found 212.0008.
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1,2-thiazine-N-benzyl-3,6-dihydro-3-[(phenylmethoxy)methyl]-1,1-dioxide (2.33) 
S
N
O O
Ph
O Ph
To a stirring solution of sultam 2.8 (262 mg, 1.03 mmol) in THF (10.3 mL) was
added Cs2CO3 (1.0 g, 3.09 mmol) and BnBr (265 mg, 1.55 mmol, 0.18 mL) and the 
reaction stirred at 80 °C for 1 h.  The product was filtered and the solvent removed
under reduced pressure.  Flash chromatography (SiO2, 3:1 Hexane/EtOAc) afforded 
305 mg (86%) of benzyl sultam 2.33 as a light-yellow oil. 
Analytical data for 2.33:  TLC Rf = 0.34 (2:1 Hexane/EtOAc); [?] = + 92.3 (c = 1.45,
CHCl3);
1H NMR (400 MHz, CDCl3) ? 7.35-7.28 (m, 8H), 7.24-7.22 (m, 2H), 5.90 
(dddd, J = 10.4, 3.6, 2.0, 2.0 Hz, 1H),  5.79-5.74 (m, 1H), 4.52 (d, J = 14.4 Hz, 1H), 
4.44 (d, J = 12.4 Hz, 1H), 4.42 (d, J = 14.4 Hz, 1H), 4.41 (d, J = 12.4 Hz, 1H), 4.15-
4.09 (m, 1H), 3.78 (dd, J = 9.6, 6.4 Hz, 1H), 3.74 (dd, J = 9.6, 7.2 Hz, 1H), 3.64-3.62
(m, 2H); 13C NMR (125 MHz, CDCl3) ? 137.8, 135.9, 128.6, 128.4, 128.3, 127.9, 
127.6, 127.5, 126.4, 119.3, 73.2, 71.5, 61.2, 53.0, 46.4; IR (neat) 3165, 3061, 2916, 
1606 cm-1; HRMS (M+H)+ calcd for  C19H22NO3S 344.1320, found 344.1331.
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(R)-2H,7H-Oxazolo[3,4?][1,2]thiazinan-7-one-4?,5-dihydro-1-dioxide (2.34) 
S
N
O O
O
O
In a procedure similar to the preparation of carbamate 2.32, a solution of sultam 2.31
(12.5 mg, 0.076 mmol) in CH2Cl2 (1.89 mL) was treated with trtriphosgene (34 mg,
0.114 mmol) and pyridine (18 mg, 0.228 mmol, 18 µL) to afford 7 mg of carbamate
2.34 (48%) as a white crystalline solid. 
Analytical data for 2.34: TLC Rf = 0.23 (1:2 Hexanes/EtOAc); Mp =  165-170 °C; 
[?] = - 7.2 (c = 0.49, CH25D 3C(O)CH3);
1H NMR (500 MHz, CDCl3) ? 4.50-4.44 (m,
2H), 4.04-4.00 (m,1H), 3.32 (ddd, J = 13.5, 3.5, 3.5 Hz, 1H), 3.21 (ddd, J = 13.0, 13.0, 
4.5 Hz, 1H),  2.40-2.36 (m, 1H), 2.35-2.30 (m, 1H), 2.00 (dddd, J = 14.5, 4.0, 4.0, 3.0
Hz, 1H), 1.73-1.64 (m, 1H); 13C NMR (125 MHz, CDCl3) ? 150.2, 67.2, 58.3, 50.8, 
28.0, 22.9; IR (neat) 2980, 2924, 1774, 1381, 1362, 1190, 1151 cm-1; HRMS
(M+Na)+ calcd for C6H9NO4SNa 214.0150, found 214.0140.
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1,2-thiazine-3,4,5,6-tetrahydro-(3S)-[(phenylmethoxy)methyl]-(4R,5S)-
phenyldioxole-1,1-dioxide (2.35) 
S
N
O O
O Ph
H
O
O
Ph
To a solution of diol 2.9 (118 mg, 0.30 mmol), p-TsOH (11.0 mg, 0.06 mmol) and 
benzaldehyde (38 mg, 0.036 mmol) in dry benzene (3 mL) was added 4 Å molecular
sieves.  The reaction was stirred at 80 °C in a pressure tube for 12 h. The reaction 
was quenched with a saturated aqueous solution of sodium bisulfite (15 mL) and
extracted with CH2Cl2 (4 × 10 mL).  The organic layers were combined, dried over 
MgSO4, filtered and concentrated under reduced pressure.  Flash chromatography
(SiO2, 2:1 Hexanes/EtOAc) afforded 30.6 mg (major diastereomer) and 22.0 mg
(minor diastereomer) (66% combined yield; dr = 1.4:1) of 2.35 as white solids. 
Analytical data for 2.35 (major diastereomer): TLC Rf = 0.41 (1:1 
Hexanes/EtOAc);  Mp = 100-105 °C; [?] = -40.3 (c = 1.66, CHCl25D 3);
1H NMR (400 
MHz, CDCl3) ? 7.59-7.50 (m, 2H), 7.41-7.39 (m, 3H), 7.36-7.28 (m, 5H), 5.95 (s, 
1H), 4.76 (d, J = 10.0 Hz, 1H), 4.72 (q, J = 5.2 Hz, 1H), 4.52 (s, 2H), 4.39 (dd, J = 
8.8, 5.6 Hz, 1H), 3.81-3.77 (m,1H), 3.76-3.72 (m, 2H), 3.65 (dd, J = 9.6, 3.6 Hz, 1H), 
3.51 (dd, J = 15.2, 5.2 Hz, 1H); 13C NMR (125 MHz, CDCl3) ? 137.1, 136.5, 129.8,
128.7, 128.6, 128.2, 128.0, 126.5, 104.8, 75.0, 73.7, 69.4, 68.2, 55.7, 49.5; FTIR 
(neat) 3247, 3029, 2929, 1637, 1454 cm-1; HRMS (M+Na)+ calcd for C19H21NO5SNa
398.1038, found 398.1031. 
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Analytical data for minor diastereomer: TLC Rf = 0.43 (1:1 Hexanes/EtOAc); 
Mp = 112-118 °C; [?] = -65.0 (c = 1.335, CHCl25D 3);
1H NMR (400 MHz, CDCl3) ?
7.45-7.32 (10 H), 6.29 (s, 1H), 4.80 (d, J = 10.0 Hz, 1H), 4.68 (ddd, J = 4.8, 4.8, 3.2 
Hz, 1H), 4.57 (s, 2H), 4.51 (dd, J = 8.8, 5.2 Hz, 1H), 3.94 (ddd, J = 9.2, 3.2, 3.2 Hz, 
1H), 3.89 (dd, J = 9.2, 2.8 Hz, 1H), 3.76 (dd, J = 9.6, 3.2 Hz, 1H), 3.72 (dd, J = 15.2,
3.2 Hz, 1H), 3.40 (dd, J = 15.2, 4.8 Hz, 1H); 13C NMR (125 MHz, CDCl3) ? 137.0, 
136.0, 128.3, 127.6, 127.5, 127.2, 127.0, 124.9, 102.4, 72.7, 72.1, 68.9, 67.2, 53.0, 
48.2; FTIR (neat) 3451, 3031, 2929, 1637, 1459 cm-1; HRMS (M+H)+ calcd for
C19H22NO5S 376.1219, found 376.1221. 
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1,2-thiazine-N-carboxylic acid-3,4,5,6-tetrahydro-(3S)-[(phenylmethoxy)methyl]-
(4R)-hydroxy-(5S)-O-benzoyl, 1,1-dimethylethyl ester, 1,1-dioxide (2.36)
S
N
O O
Boc
O
OBn
OH
Ph
O
To a stirring cold (0 °C) solution of diol 2.9 (100 mg, 0.258 mmol) DMAP (3.0 mg,
0.0258 mmol) and Et3N (27.4 mg, 0.270 mmol, 38 µL) in CH2Cl2 (25 mL) was
slowly added a solution of benzoyl chloride (27.4 mg, 0.270 mmol, 38 µL) in CH2Cl2
(1 mL).  The reaction was stirred at 0 °C for 2 h.  The product was quenched with an 
aqueous solution of NaHCO3 (15 mL) and extracted with CH2Cl2 (4 × 15 mL).  The
organic layers were combined, dried over MgSO4, filtered and concentrated under
reduced pressure.  Flash chromatography (SiO2, 3:1 Hexanes/EtOAc) afforded 64 mg
(50 %) of benzoylated sultam 2.36 as a white solid.
Analytical data for 2.36: TLC Rf = 0.56 (1:1 Hexanes/EtOAc); Mp =120-125 °C;
[?]  = -47.6 (c = 0.45, CHCl25D 3);
1H NMR (400 MHz, CDCl3) ? 8.03 (d, J = 8.4 Hz,
2H), 7.61 (t, J = 7.6 Hz, 1H), 7.47 (t, J = 8.0 Hz, 2H), 7.34 (d, J = 4.4 Hz, 2H), 7.32-
7.28 (m, 3H), 5.63 (ddd, J = 10.4, 4.0, 2.0 Hz, 1H), 4.94 (ddd, J = 9.2, 6.4, 3.6 Hz,
1H), 4.59 (d, J = 12.0 Hz, 1H), 4.56 (d, J = 12.0 Hz, 1H), 4.50 (t, J = 2.4 Hz, 1H),
3.88 (dd, J = 10.8, 10.0 Hz, 1H), 3.84 (dd, J = 12.8, 10.8 Hz, 1H), 3.78 (dd, J = 10.0,
6.4 Hz, 1H), 3.54 (dd, J = 12.8, 4.4 Hz, 1H), 2.53 (s, 1H, O-H), 1.49 (s, 9H); 13C
NMR (125 MHz, CDCl3) ? 165.0, 151.4, 137.5, 133.9, 129.9, 128.8, 128.7, 128.5,
127.9, 127.9, 85.2, 73.5, 68.6, 68.4, 65.3, 60.4, 50.4, 27.9; FTIR (neat) 3512, 2979, 
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2955, 1726, 1600, 1452 cm-1; HRMS (M+NH4)
+ calcd for C24H33N2O8S 509.1958, 
found 509.1948.
1,2-thiazine-3,4,5,6-tetrahydro-3-[(phenylmethoxy)methyl]-4,5-dihydroxy-1,1-
dioxide (2.37) 
S
N
O O
H
HO
O
OH
To a solution of diol 2.9 (171 mg, 0.44 mmol) in CH2Cl2 (1.0 mL) was added TFA
(0.2 mL) dropwise.  The reaction was stirred at rt for 1 h at rt.  Upon completion, the 
reaction was quenched with saturated NaHCO3 (15 mL), extracted with CH2Cl2 (4 × 
15 mL), dried over MgSO4, filtered and concentrated under reduced pressure.  Flash 
chromatography (SiO2, 1:3 Hexanes/ EtOAc) afforded 112 mg (88%) of the diol 
sultam 2.37 as a white crystalline solid.
Analytical data for 2.37: TLC Rf = 0.22 (1:1 Hexanes/EtOAc); Mp = 115-117°C;
[?]  = -35.6 (c = 0.93, MeOH); 25D
1H NMR (400 MHz, CDCl3) ? 7.39-7.31 (m, 5H), 
5.01 (d, J = 8.8 Hz, 1H), 4.56 (d, J = 11.6 Hz, 1H), 4.52 (d, J = 11.6 Hz, 1H), 4.34-
4.30 (m, 1H), 3.90 (dd, J = 9.6, 3.2 Hz, 1H), 3.74 (ddd, J = 10.0, 10.0, 3.2 Hz, 1H), 
3.63 (dd, J = 12.0, 3.6 Hz, 1H), 3.61 (d, J = 9.2 Hz, 2H), 3.44 (dd, J = 14.4, 4.0 Hz, 
1H), 3.27 (dd, J = 14.4, 3.2 Hz, 1H), 2.61 (d, J = 9.6 Hz,1H); 13C NMR (125 MHz, 
CDCl3) ? 137.2, 128.6, 128.2, 128.0, 73.7, 68.3, 67.5, 66.6, 55.0, 53.3; FTIR (neat)
3460, 3444, 3256, 2930, 2872, 1607, 1497, 1454, 1155 cm-1; HRMS (M+Na)+ calcd 
for C12H17NO5SNa 310.0725, found 310.0738. 
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OACC Coupled Alanine Sultam(2.38) 
S
N
O O
O Ph
Boc
O
N
Boc
OH
To a solution of sultam 2.11 (12.0 mg, 0.032 mmol), DMAP (1.0 mg, 0.0096 mmol) 
and Boc-(L)-Alanine (7.4 mg, 0.039 mmol) in CH2Cl2 (0.1 mL) was added a solution 
of OACC (20.0 mg, 0.051 mmol) in CH2Cl2 (0.22 mL).  The reaction was stirred at rt 
for 12 h after which MP-carbonate resin (8 mg) was added and the reaction stirred for 
another 2 h.  The solvent was removed under reduced pressure, the crude mixture
mixed with silica, followed by filtration via silica plug (SiO2, 100% EtOAc) to afford 
15.9 mg (92%) of 2.38 as a clear oil.
Analytical data for 2.38: TLC Rf = 0.10 (2:1 hexanes/EtOAc); [?]  =
-105.7 (c = 0.48, CHCl
25
D
3);
1H NMR (400 MHz, CDCl3) ? 7.36-7.29 (m, 5H), 6.51 (d, J
= 10.8 Hz, 1H), 6.45 (ddd, J = 10.8, 5.6, 1.6 Hz, 1H), 5.38 (dd, J = 5.6, 2.0 Hz, 1H),
4.99 (dddd, J = 7.6, 7.6, 1.6, 1.6 Hz, 1H), 4.92 (m, 1H), 4.58 (d, J = 11.6 Hz, 1H), 
4.49 (d, J = 12.0 Hz, 1H), 4.34 (m, 1H), 3.71 (d, J = 7.6 Hz, 2H), 1.54 (s, 9H), 1.44
(9H), 1.37 (d, J = 7.2 Hz, 3H); 13C NMR (125 MHz, CDCl3) ? 172.3, 155.1, 150.6, 
137.2, 132.1, 129.3, 128.5, 128.3, 128.2, 85.8, 80.1, 73.4, 67.5, 62.9, 58.2, 49.3, 28.3,
28.0, 18.3; FTIR (neat) 3393, 2980, 1736, 1717, 1618, 1369, 1338, 1163; HRMS
(M+Na)+ calcd for C25H36N2O9SNa 563.2039, found 563.2014. 
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OACC Coupled Valine Sultam (2.39) 
S
N
O O
O Ph
Boc
O
N
Boc
O
iPr
H
In a procedure similar to the preparation of sultam 2.38, sultam 2.11 (27 mg, 0.073 
mmol), DMAP (3 mg, 0.219 mmol) and Boc-(L)-Valine (24 mg, 0.109 mmol) in 
CH2Cl2 (0.15 mL) were utilized in the coupling reaction with OACC (46 mg, 0.146
mmol) in CH2Cl2 (0.55 mL).  Filtration via silica plug (SiO2, 1:1 Hexanes/EtOAc)
afforded 44 mg (100%) of 2.39 as a clear oil. 
Analytical data for 2.39:  TLC Rf = 0.64 (1:1 hexanes/EtOAc); [?]  =
-28.8 (c = 0.48, CHCl
25
D
3);
1H NMR (400 MHz, CDCl3) ? 7.35-7.30 (m, 5H), 6.50 (d, J
= 10.4 Hz, 1H), 6.47 (ddd, J = 10.4, 6.4, 1.2 Hz, 1H), 5.37 (dd, J = 4.8, 1.6 Hz, 1H),
5.03-4.99 (m, 1H), 4.93 (d, J = 8.8 Hz, 1H), 4.58 (d, J = 11.6 Hz, 1H), 4.49 (d, J = 
12.0 Hz, 1H), 4.27 (dd, J = 8.0, 4.4 Hz, 1H), 3.70 (d, J = 7.6 Hz, 2H), 2.17-2.12 (m,
1H), 1.53 (s, 9H), 1.45 (s, 9H), 0.94 (d, J = 6.8 Hz, 3H), 0.87 (d, J = 6.8 Hz, 3H); 13C
NMR (125 MHz, CDCl3) ? 171.3, 155.6, 150.5, 137.2, 135.8, 132.0, 129.2, 128.5,
128.0, 127.9, 85.8, 80.1, 73.4, 67.5, 63.0, 58.5, 58.3; FTIR (neat) 3393, 3049, 2976, 
1735, 1717, 1653, 1391, 1369 cm-1; HRMS (M+NH4)
+ calcd for C27H44N3O9S
586.2798, found 586.2784. 
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1, 2-thiazine-N-carboxylic acid-3, 4-dihydro-(3S)-[(phenylmethoxy)methyl]-(4S)-
isobutanoate -1, 1-dimethylethyl ester-1, 1-dioxide (2.40) 
S
N
O O
O Ph
Boc
O
O
To a solution of sultam 2.11 (10.7 mg, 0.029 mmol), DMAP (1.0 mg, 0.0087 mmol) 
and isovaleric acid (3.5 mg, 0.035 mmol, 3.8 µL) in CH2Cl2 (0.1 mL) was added a
solution of OACC (19 mg, 0.046 mmol) in CH2Cl2 (0.2 mL) and the reaction stirred
at rt for 12 h.  Once complete, MP-Carbonate resin (6.5 mg) was added to the reaction
mixture and the solution stirred at rt for 2 h.  The solvent was removed, silica gel was 
added and the product filtered via SiO2 plug with 100% EtOAc.  The solvent was 
removed under reduced pressure to afford 13 mg (100 %) of 2.40 as a clear oil. 
Analytical data for 2.40: TLC Rf = 0.70 (1.5:1 hexanes/EtOAc); [?]  =
-119.7 (c = 0.68, CHCl
25
D
3);
1H NMR (500 MHz, CDCl3) ? 7.34-7.29 (m, 5H), 6.49 (d, J
= 10.5 Hz, 1H), 6.46 (ddd, J = 10.5, 5.0, 1.5 Hz, 1H), 5.36 (dd, J = 5.5, 2.0 Hz, 1H),
4.99 (dddd, J = 7.5, 7.5, 1.5, 1.5 Hz, 1H), 4.60 (d, J = 12.0 Hz, 1H), 4.49 (d, J = 12.0 
Hz, 1H), 3.71 (d, J = 8.0 Hz, 2H), 2.23 (d, J = 7.5 Hz, 2H), 2.12-2.05 (m, 1H), 1.53 (s, 
9H), 0.95 (d, J = 5.5 Hz, 3H), 0.95 (d, J = 5.5 Hz, 3H); 13C NMR (125 MHz, CDCl3)
? 172.1, 150.7, 137.3, 131.6, 129.9, 128.5, 127.9, 127.9, 85.6, 73.4, 67.6, 61.9, 58.4, 
42.9, 28.0, 25.7, 22.3, 22.3; FTIR (neat) 2960, 2932, 1736, 1647, 1456, 1371 cm-1;
HRMS (M+Na)+ calcd for C22H31NO7SNa 476.1719, found 476.1704. 
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1, 2-thiazine-N-carboxylic acid-3, 4-dihydro-(3S)-[(phenylmethoxy)methyl]-(4S)-
cyclopropanoate -1, 1-dimethylethyl ester-1, 1-dioxide (2.41)
S
N
O O
O Ph
Boc
O
O
In a procedure similar to the preparation of 2.40, a solution of sultam 2.11 (11.0 mg,
0.030 mmol), DMAP (1.0 mg, 0.009 mmol) and cyclopropane carboxylic acid (3.0
mg, 0.036 mmol, 2.8 µL) in CH2Cl2 (0.1 mL) was subjected to the coupling reaction
with OACC (19.0 mg, 0.048 mmol) in CH2Cl2 (0.2 mL) to afford 13 mg (100%) of
2.41 as a clear oil. 
Analytical data for 2.41: TLC Rf = 0.51 (1.5:1 hexanes/EtOAc); [?]  =
-137.3 (c = 0.675, CHCl
25
D
3);
1H NMR (500 MHz, CDCl3) ? 7.34-7.28 (m, 5H), 6.49 (d, 
J = 10.5 Hz, 1H), 6.46 (ddd, J = 10.5, 5.0, 1.5 Hz 1H), 5.34 (dd, J = 5.0, 1.5 Hz, 1H), 
4.99 (dddd, J = 7.0, 7.0, 1.5, 1.5 Hz, 1H), 4.57 (d, J = 12.0 Hz, 1H), 4.49 (d, J = 12.0 
Hz, 1H), 3.70 (d, J = 8.0 Hz, 2H), 1.69-1.64 (m, 1H), 1.54 (s, 9H), 1.03 (dd, J = 8.0, 
5.0 Hz, 2H), 0.92 (dd, J = 8.0, 3.0 Hz, 2H); 13C NMR (125 MHz, CDCl3) ? 172.9,
149.7, 136.3, 130.4, 128.9, 127.4, 126.9, 126.9, 84.6, 72.3, 66.6, 61.0, 57.4, 26.9, 11.7, 
8.2, 8.2; FTIR (neat) 3043, 2979, 2932, 2870, 1734, 1606, 1456 cm-1; HRMS
(M+Na)+ calcd for C21H27NO7SNa 460.1406, found 460.1394. 
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1,2-thiazine-N-carboxylic acid-3,4,5,6-tetrahydro-(3S)-[(phenylmethoxy)methyl]-
(4R)-(3-methylbutanoate)-(5R)-benzylthio-1,1-dimethylethyl ester-1,1-dioxide
(2.42)
S
N
O O
O P
h
O
O
O
SPh
O
In a procedure similar to the preparation of 2.40, sultam 2.11 (11.0 mg, 0.030 mmol) 
in CH2Cl2 (0.1 mL), DMAP (1.2 mg, 0.009 mmol) and isovaleric acid (3.4 mg, 0.036
mmol, 4 µL) were subjected to OACC coupling with OACC (19 mg, 0.048 mmol) in
CH2Cl2 (0.20 mL).  After the coupling event and scavenging of excess acid with MP-
carbonate, the product was filtered via silica plug (100 % EtOAc) and the solvent
removed under reduced pressure.  This coupling product was dissolved in CH2Cl2
(0.3 mL) followed by the addition of BnSH (4.09 mg, 0.033 mmol, 4µL) and Et3N
(0.6 mg, 0.006 mmol, 1 µL).  The reaction was stirred at reflux for 12 h.  OBAC (2
mg) was added to scavenge the excess thiol and the reaction heated at reflux for 4 h. 
Flash chromatography (SiO2, 5:1 Hexane/EtOAc) afforded 15.7 mg (91%) of 
diversified sultam 2.42 as an inseparable mixture of diastereomers (dr ~ 6:1) as a
clear oil. 
Analytical data for 2.42: TLC Rf = 0.53 (2:1 Hexanes/EtOAc);
1H NMR (500 MHz, 
CDCl3) ? 7.37-7.27 (m, 10H), 5.18 (dd, J = 7.5, 2.0 Hz, 1H), 4.72 (ddd, J = 7.0, 5.5,
2.0 Hz, 1H), 4.55 (s, 2H), 3.88 (dd, J = 10.5, 6.5 Hz, 1H), 3.82 (dd, J = 10.5, 5.5 Hz,
1H), 3.80 (d, J = 13.5 Hz, 1H), 3.75 (d, J = 13.5 Hz, 1H), 3.57 (dd, J = 14.0, 10.0 Hz, 
1H), 3.37 (dd, J = 14.0, 4.0 Hz, 1H), 3.31 (ddd, J = 11.0, 7.5, 4.0 Hz, 1h), 2.19 (dd, J
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= 8.0, 7.5 Hz, 2H), 2.10-2.05 (m, 1H), 1.49 (s, 9H), 0.96 (d, J = 7.0 Hz, 6H); 13C
NMR (125 MHz, CDCl3) ? 172.0, 150.9, 137.3, 136.8, 128.8, 128.7, 128.3, 127.8,
127.7, 127.5, 85.0, 73.4, 70.1, 70.0, 61.7, 53.1, 43.1, 41.4, 36.1, 27.8, 25.6, 22.3,
22.3; FTIR (neat) 3030, 2960, 2932, 2872 1732, 1606, 1454, 1138 cm-1; HRMS 
(M+Na)+ calcd for C29H39NO7S2Na 600.2066, found 600.2083. 
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5-norbornene-2-exo,3-exo-dimethyl phosphorochloridate (2.43) 
O
O
P
O
Cl
To a solution of 5-norbornene-2-exo,3-exo-dimethanol (159 mg, 1.03 mmol), DMAP 
(15 mg, 0.123 mmol) and Et3N (313 mg, 3.09 mmol, 0.43 mL).in CH2Cl2 (5.2 mL)
was added freshly distilled POCl3 (174 mg, 1.13 mmol, 106 µL) at 0 °C and the
reaction stirred at rt for 1 h.  The crude product was concentrated under reduced 
pressure, filtered through celite, followed by flash chromatography (SiO2, 2:1 
Heptane/EtOAc) to afford 121 mg (50%) of 2.43 as an inseparable mixture of 
diastereomers (dr = 2.8:1) as a white solid. 
Analytical data for 2.43 (major diastereomer): TLC Rf = 0.52 (1:1 
Hexanes/EtOAc);1H NMR (400 MHz, CDCl3) ? 6.26 (t, J = 1.6 Hz, 2H), 4.47-4.41 
(m, 1H), 4.39 (dd, J = 12.4, 4.4 Hz, 1H), 4.31 (dd, J = 12.4, 4.0 Hz, 1H), 4.18-4.15 (m,
1H), 2.62 (t, J = 1.6 Hz, 2H), 2.26-2.19 (m, 2H), 1.45-1.42 (m, 2H);
13C NMR (100 MHz, CDCl3) ? 137.8, 71.1 (d, JCP = 36.0 Hz), 46.2, 45.2, 42.0; 31P
NMR (400 MHz, CDCl3) ? 2.2; FTIR (neat) 3076, 2978, 1299, 1253, 1045 cm-1.
HRMS (M+H)+ calcd for C9H13ClO3P 235.0291, found 235.0286.
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Norbornenyl-Tagged Sultam (2.44)
O
O
P
O
O
S
N
O O
Boc
OBn
To a solution of sultam 2.11 (108 mg, 0.29 mmol) in CH2Cl2 (0.58 mL) was added 
N-methylimidazole (71 mg, 0.87 mmol, 69 µL) and norbornenyl monochloride 2.43
(137 mg, 0.87 mmol) and the reaction stirred at rt for 6-12 h. Flash chromatography
(SiO2, 1:1 Hexanes/EtOAc) afforded 160 mg (97%) of tagged sultam 2.44 as a 
mixture of diastereomers (dr = 2.8:1) as a white solid. 
Analytical data for 2.44: TLC Rf = 0.18 (1:1 Hexanes/EtOAc);
1H NMR (500 MHz,
CDCl3) ? 7.36-7.30 (m, 5H), 6.59 (ddd, J = 10.5, 5.5, 1.5 Hz, 1H), 6.53 (d, 10.5 Hz, 
1H), 6.22 (dd, J = 9.0, 1.0 Hz, 2H), 5.11-5.09 (m, 1H), 5.08-5.04 (m, 1H), 4.57 (d, J = 
12.0 Hz, 1H), 4.49 (d, J = 11.5 Hz, 1H), 4.44-4.46 (m, 2H), 4.25-4.13 (m, 2H), 3.73-
3.66 (m, 2H), 2.59-2.53 (m, 2H), 2.20-2.13 (m, 2H), 1.52 (s, 9H); 13C NMR (125 
MHz, CDCl3) ? 150.9, 137.4, 137.3, 137.1, 131.7, 130.1 (d, JCP = 10.0 Hz), 128.5, 
128.0, 127.9, 85.8, 73.5, 70.7 (d, JCP = 20.0 Hz), 69.9 (d, JCP = 35.0 Hz), 67.5, 64.8 (d, 
JCP = 20.0 Hz), 59.6 (d, JCP = 25.0 Hz), 44.9 (d, JCP = 15.0 Hz), 44.8, 43.4, 42.0, 41.9 
(d, JCP = 15.0 Hz), 27.9; 31P (400 MHz, CDCl3) ? -5.1, -16.4; FTIR (neat) 3050, 
2972, 1732, 1637, 1371, 1337, 1167, 1135, 1015 cm-1; HRMS (M+Na)+ calcd for 
C26H34NO9PSNa 590.1590, found 590.1584.
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ROMP Sultam (2.45) 
O
N
S
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O
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O
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To a stirring solution of norbornenyl tagged sultam 2.44 (58 mg, 0.102 mmol) in 
degassed CH2Cl2 (1.0 mL) was added 5 mol % (4.0 mg, 0.005 mmol) of Grubbs first 
generation catalyst (Cat.-B) in one portion.  The reaction was refluxed under argon
and monitored by TLC analysis.  Once polymerization was complete (~ 3 h), the 
reaction was quenched by the addition of ethyl vinyl ether (2 mL).  The mixture was 
reduced to 1/3 of the original volume and 10 mL of diethyl ether were added to 
induce precipitation.  Filtration yielded 47 mg (81%) as a gray solid.  This product 
was immediately used for the organocuprate realease strategy.
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1,2-thiazine-N-carboxylic acid-3,6-dihydro-(3R)-[(phenylmethoxy)methyl]-(6R)-
methyl- 1,1-dimethylethyl ester-1,1-dioxide (2.46) 
S
N
O O
O
O
OBn
In a procedure similar to the preparation of sultam 2.24, ROMP sultam 2.45 (26 mg,
0.046 mmol) was subjected to dimethyl cuprate addition with CuCN?2LiCl (0.46
mmol, 0.46 mL) and Me2Zn (0.46 mmol, 0.38 mL) in dry THF (0.46 mL) to afford 
after flash chromatography (SiO2, 5:1 Hexane/EtOAc) 11mg (65%) of sultam 2.46 as 
a light-yellow oil. 
Analytical data for 2.46: TLC Rf = 0.44 (2:1 Hexanes/EtOAc); [?] = +85.4 (c = 
0.35, CHCl
25
D
3);
1H (500 MHz, CDCl3) ? 7.33-7.28 (m, 5H), 5.90 (dd, J = 11.0, 2.5 Hz, 
1H), 5.49 (d, J = 11.0 Hz, 1H), 5.28 (m, 1H), 4.55 (s, 2H), 4.02-4.00 (m, 1H), 3.81-
3.74 (m, 2H), 1.49 (s, 12H); 13C (125 MHz, CDCl3) ? 150.7, 137.9, 128.4, 127.7,
125.7, 124.7, 84.5, 73.3, 70.9, 60.2, 54.7, 27.9, 13.5; FTIR (neat) 3063, 2935, 1724, 
1454, 1363, 1169 cm-1; HRMS (M+NH4)
+ calcd for C18H29N2O5S 385.1797, found 
385.1815.
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(E)-tert-butyl styrylsulfonylcarbamate (2.49) 
Ph
S
N
O O
O
O
H
To a solution of (E)-2-phenylethenesulfonamide (1.0 g, 5.46 mmol) in CH2Cl2 (6.8 
mL) containing DMAP (66 mg, 0.55 mmol) and Et3N 607 mg, 6.0 mmol, 0.84 mL) at 
rt was added a solution of BocO2 (1.37 g, 6.27 mmol, 1.44 mL) in CH2Cl2 (10.9 mL)
dropwise with stirring over 20 min.  The reaction was stirred for 2 h at rt, followed by 
removal of the solvent under reduced pressure.  The crude product was treated with 
EtOAc (80 mL) and 1N HCl (53 mL) and the organic layer washed successively with 
water (50 mL) and brine (50 mL).  The water layer was washed with CH2Cl2 (4 × 50
mL), the organic layers combined, dried over Na2SO4, filtered and concentrated under 
reduced pressure. The product was heated in heptane (20 mL), cooled down to rt and
filtered to give 1.46 g (94%) of styrylsulfonylcarbamate 2.49 as an ivory solid. 
Analytical data for 2.49: TLC Rf = 0.51(1:1 Hexanes/EtOAc); Mp = 160-166 °C;
1H NMR (400 MHz, CDCl3) ? 7.68 (d, J = 15.4 Hz, 1H), 7.54-7.52 (m, 2H), 7.46-
7.41 (m, 3H), 7.20 (s, 1H, N-H), 7.00 (d, J = 15.4 Hz, 1H), 1.48 (s, 9H); 13C NMR
(125 MHz, CDCl3) ? 149.3, 144.6, 132.1, 131.5, 129.2, 128.7, 123.9, 84.3, 28.0;
FTIR (neat) 3246, 1736, 1614, 1576 cm-1; HRMS (M+Na)+ calcd for C13H17NO4SNa
306.0776, found 306.0769. 
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(R,E)-tert-butyl 1-(benzyloxy)hex-5-en-2-yl(styrylsulfonyl)carbamate (2.51) 
Ph
S
N
O O
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In a procedure similar to the preparation of sulfonamide 2.5, a solution of sulfamoyl
carbamate 2.49 (1.42 g, 5.01 mmol) in THF (3.2 mL) was subjected to the Mitsunobu 
reaction in the presence of secondary alcohol 2.50 (1.03g, 5.01 mmol), PPh3 (1.71g, 
5.51 mmol) and DIAD (1.11 g, 5.51 mmol, 1.07 mL) to yield after flash
chromatography (SiO2, 10:1 Hexane/EtOAc) 1.93 g (82%) of sulfamoyl carbamate
2.51 as a yellow oil.
Analytical data for 2.51: TLC Rf = 0.49 (3:1 Hexanes/EtOAc); [?] = -9.1 (c = 1.06,
CHCl
25
D
3);
1H NMR (400 MHz, CDCl3) ? 7.50 (d, J = 15.5 Hz, 1H), 7.41-7.37 (m, 1H),
7.33-7.27 (m, 7H), 7.20 (d, J = 7.4 Hz, 2H), 6.98 (d, J = 15.5 Hz, 1H), 5.86 (dddd, J = 
16.8, 10.2, 6.5, 6.3 Hz, 1H), 5.08 (dd, J = 17.2, 1.6 Hz, 1H), 5.01 (dd, J = 10.2, 1.0 
Hz, 1H), 4.74-4.66 (m, 1H), 4.58 (d, J = 11.6 Hz, 1H), 4.46 (d, J = 11.6 Hz, 1H), 3.96 
(dd, J = 9.8, 9.8 Hz, 1H), 3.56 (dd, J = 9.8, 5.1 Hz, 1H), 2.28-2.16 (m, 2H), 2.14-2.03 
(m, 1H), 1.73-1.63 (m, 1H), 1.47 (s, 9H); 13C NMR (100 MHz, CDCl3) ? 150.7, 142.2, 
137.7, 137.2, 132.1, 130.5, 128.7, 128.1, 127.9, 127.3, 127.2, 125.2, 114.9, 83.7, 72.7, 
69.9, 58.0, 30.2, 29.1, 27.7; FTIR (neat) 3070, 2980, 1726, 1639, 1616, 1578, 1450, 
1353, 1145 cm-1; HRMS (M+H)+ calcd for C26H34NO5S 472.2158, found 472.2159. 
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(R,E)-N-(1-(benzyloxy)hex-5-en-2-yl)-2-phenylethenesulfonamide (2.52) 
Ph
S
N
O O
H
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In a procedure similar to the preparation of sulfonamide 2.7, a solution of sulfamoyl
carbamate 2.51 (115 mg, 0.24 mmol) in CH2Cl2 (2.0 mL) was treated with TFA (0.5 
mL) to yield after aqueous workup and  flash chromatography (SiO2, 2:1 
Heptane/EtOAc) 91 mg (100%) of sulfonamide 2.52 as an ivory solid. 
Analytical data for 2.52: TLC Rf = 0.45 (2:1 Hexanes/EtOAc); Mp = 40-43 °C; 
[?] = +18.0 (c = 1.135, CHCl25D 3);
1H NMR (400 MHz, CDCl3) ? 7.43 (d, J = 15.4 Hz, 
1H), 7.39-7.27 (m, 10H), 6.67 (d, J = 15.4 Hz, 1H), 5.77 (dddd, J = 16.8, 10.2, 6.6, 
6.6 Hz, 1H), 5.00 (dd, J = 17.1, 1.6 Hz, 1H), 4.96 (dd, J = 10.2, 1.3 Hz, 1H), 4.62 (d, 
J = 8.3 Hz, 1H), 4.50 (s, 2H), 3.53 (dd, J = 8.8, 3.4 Hz, 1H), 3.49-3.42 (m, 2H), 2.22-
2.06 (m, 2H), 1.69 (q, J = 7.4 Hz, 2H); 13C NMR (100 MHz, CDCl3) ? 140.5, 137.6,
137.5, 132.6, 130.5, 129.0, 128.4, 128.1, 127.8, 127.7, 126.2, 115.3, 73.2, 71.7, 53.3,
31.9, 29.8; FTIR (neat) 3279, 3063, 2928, 1622, 1448, 1363, 1150 cm-1; HRMS 
(M+H)+ calcd for C21H26NO3S 372.1633, found 372.1643.
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1,2-thiazepin-3,4,5-trihydro-(3R)-[(phenylmethoxy)methyl]-1,1-dioxide (2.53) 
N
S
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H
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A solution of sulfonamide 2.52 (361 mg, 0.97 mmol) in DCE (194 mL) was subjected 
to RCM with Grubbs second generation catalyst (Cat. C) (5 mol %, 41 mg, 
0.049 mmol) at reflux to afford after flash chromatography (SiO2, 3:1 
Heptane/EtOAc) 224 mg (86%) of vinylic sultam 2.53 as a yellow oil. 
Analytical data for 2.53: TLC Rf = 0.28 (1:1 Hexanes/EtOAc); [?] = -1.73 (c = 
0.925, CHCl
25
D
3);
1H NMR (400 MHz, CDCl3) ? 7.38-7.29 (m, 5H), 6.61 (dd, J = 11.1, 
1.9 Hz, 1H), 6.36 (ddd, J =11.1, 7.2, 5.5 Hz, 1H), 4.89 (d, J = 7.9 Hz, 1H), 4.55 (d, J
= 11.8 Hz, 1H), 4.50 (d, J = 11.8 Hz, 1H), 3.80-3.73 (m, 1H), 3.64-3.55 (m, 2H), 
2.65-2.57 (m, 2H), 2.04-1.99 (m, 1H), 1.94-1.87 (m, 1H); 13C NMR (100 MHz, 
CDCl3) ? 139.2, 137.4, 135.0, 128.2, 127.6, 127.5, 73.0, 72.5, 53.8, 28.5, 25.9; FTIR 
(neat) 3265, 3059, 3030, 2926, 1624, 1496, 1452, 1363 cm-1; HRMS (M+Na)+ calcd 
for C13H17NO3SNa 290.0827, found 290.0829. 
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(S)-methyl 2-(N-(tert-butoxycarbonyl)sulfamoylamino)-3-methylbutanoate (3.34) 
N
S
N
O O
HH
CO2Met-BuO
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To a stirring solution of chlorosulfonyl isocyanate (1.23 mL, 14.1 mmol) and CH2Cl2
(40 mL) at 0 °C in a 250 mL round bottom flask was added a solution of t-BuOH
(1.0 M, 1.35 mL, 14.1 mmol) in CH2Cl2 dropwise over a period of 10 min. The 
resulting solution was transferred via cannula to a mixture of H-Val-OMe?HCl (2.37
g, 14.1 mmol) and Et3N (3.94 mL, 28.3 mmol) in CH2Cl2 (40 mL) at 0 °C. The slurry
was allowed to warm to rt and stirred for an additional 2.5 h. The salts were filtered,
the organic portion was washed with H2O (2×), brine (2×), and dried over Na2SO4.
The mixture was filtered and concentrated under reduced pressure to yield 4.19 g 
(96%) of sulfamide 3.34 as a pure white solid.
Analytical data for 3.34: TLC Rf = 0.42 (2:1 Hexanes/EtOAc); Mp = 128-129 °C;
[?] = +40.6 (c = 1.00, CHCl25D 3);
1H NMR (400 MHz, CDCl3) ? 7.08 (s, 1H), 5.54 (d, 
J = 9.2 Hz, 1H), 4.04 (dd, J = 9.2, 4.9 Hz, 1H), 3.76 (s, 3H), 2.18-2.10 (m, 1H), 1.49
(s, 9H), 1.18 (d, J = 6.9 Hz, 3H), 0.91 (d, J = 6.9 Hz, 3H); 13C NMR (100 MHz, 
CDCl3) ? 171.9, 149.9, 83.8, 62.1, 52.4, 31.4, 27.9, 18.9, 17.3; FTIR (neat) 3268,
1742, 1451, 1400, 1371, 1146 cm-1; HRMS (M+H)+ calcd for C11H23N2O6S 311.1277, 
found 311.1266.
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N-[(1S)-1-(1-Benzyloxy)methyl-2-propenyl]-N-[(1,1-dimethylethoxy)carbonyl]-
N'-[(1S)-1-(1-methylethyl)-2-methoxycarbonyl]-sulfamide (3.36).
N
S
N
H
O O
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O
BnO
To a stirring solution of sulfamoyl carbamate 3.34 (400 mg, 1.30 mmol) in THF (1.0
mL) at rt under argon was added PPh3 (341 mg, 1.3 mmol) and alcohol 3.35 (231 mg,
1.30 mmol) followed by dropwise addition of DIAD (256 mL, 1.3 mmol). The
solution was stirred for 8 h and the solvent removed under reduced pressure. Flash
chromatography (20:1, heptanes/EtOAc) afforded 403 mg (67%, 6:1 mixture of 
regioisomers) of the sulfamoyl carbamate 3.36 as a clear yellow oil.
Analytical data for 3.36: TLC Rf = 0.30 (3:1 heptane/EtOAc);  [?] = +33.4 (c = 
1.246, CHCl
25
D
3);
1H NMR (400 MHz, CDCl3) ? 7.39–7.28 (m, 5H), 6.00–5.93 (m, 2H),
5.28 (dd, J = 17.4, 1.0 Hz, 1H), 5.21 (dd, J = 10.4, 1.0 Hz, 1H), 5.10 (dd, J = 14.4,7.1
Hz, 1H), 4.61 (d, J = 12.0 Hz, 1H), 4.57 (d, J = 12.0 Hz,1H), 4.03 (dd, J = 8.3, 4.4 Hz, 
1H), 3.93 (dd, J = 10.0, 8.8 Hz,1H), 3.67 (s, 3H), 3.65 (dd, J = 10.0, 6.0 Hz, 1H), 
2.14–2.06 (m, 1H), 1.52 (s, 9H), 0.99 (d, J = 6.8 Hz, 3H), 0.83 (d, J = 6.9 Hz, 3H); 
13C NMR (100 MHz, CDCl3) ? 171.4, 151.2, 137.9, 134.0, 128.3, 127.7, 127.6, 118.4, 
84.4, 72.8, 70.1, 61.8, 60.4, 52.1, 31.8, 27.9, 18.8, 17.1; FTIR (neat) 3321, 3064,
1741, 1724, 1643, 1605, 1495, 1369,1151 cm-1; HRMS (M+H)+ calcd for 
C22H35N2O7S 471.2165, found 471.2155.
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N-[(1S)-1-(1-Benzyloxy)methyl-2-propenyl]-N-[(1,1-dimethylethoxy)carbonyl]-
N'-[(1S)-1-(1-methylethyl)-2-methoxycarbonyl]-N'-2-propenyl-sulfamide (3.37).
CO2Me
BnO
t-BuO N
S
N
O OO
To a stirring solution of sulfamide 3.36 (119 mg, 0.25 mmol) in CH3CN (3 mL) in a 
pressure tube was added K2CO3 (173 mg, 1.25 mmol) and allyl bromide (216 mL, 2.5 
mmol).  The pressure tube was heated to 70 °C for 12 h.  The resulting yellow-orange
mixture was filtered by suction, and the solvent removed under reduced pressure.
Flash chromatography (8:1 heptanes/EtOAc) afforded 120 mg (92%) of diene 3.37 as 
a clear yellow oil.
Analytical data for 3.37: TLC Rf = 0.41 (3:1 heptane/EtOAc); [?]  =-37.9 (c = 0.98, 
CHCl
25
D
3);
1H NMR (400 MHz, CDCl3) ? 7.34-7.27 (m, 5H), 6.03 (dddd, J = 17.4, 10.1,
5.3, 5.3 Hz, 1H), 5.97 (ddd, J = 17.0, 10.5, 6.1 Hz, 1H), 5.29 (d, J = 17.4 Hz, 1H),
5.20 (d, J = 10.5 Hz, 1H), 5.15 (dd, J = 11.5, 1.0 Hz, 1H), 5.10-5.03 (m, 1H), 5.04
(dd, J = 10.0, 1.0 Hz, 1H), 4.57 (d, J = 12.2 Hz, 1H) 4.54 (d, J = 12.0 Hz, 1H), 4.30 
(dd, J = 16.8, 7.7 Hz, 1H), 4.24 (dd, J = 16.9, 5.2 Hz, 1H), 4.14 (d, J = 10.5 Hz, 1H),
3.89 (dd, J = 9.7, 7.7 Hz, 1H), 3.68 (s, 3H), 3.67 (dd, J = 9.9, 6.8 Hz, 1H), 2.16-2.04 
(m, 1H), 1.42 (s, 9H), 1.02 (d, J = 6.6 Hz, 3H), 0.88 (d, J = 6.7 Hz, 3H); 13C NMR
(100 MHz, CDCl3) ? 171.4, 151.1, 137.8, 135.8, 134.5, 128.2, 127.6, 127.5, 117.6, 
116.6, 83.6, 72.7, 70.6, 66.2, 60.8, 51.2, 48.8, 28.8, 27.9, 19.6, 19.2; FTIR (neat)
3081, 1726, 1640, 1367, 1140 cm-1; HRMS (M+H)+ calcd for C25H39N2O7S 511.2478, 
found 511.2460.
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2-(2S)-[(6S)-(6-Benzyloxymethyl-7-(1,1-dimethylethoxy)carbonyl-1,1-dioxo-
1,3,6,7-tetrahydro-1,2,7-thiadiazepin-2-yl)]-3-methyl-butyric acid methyl ester
(3.38).
N N
S
CO2Me
BnO
t-BuO
O O O
To a stirring solution of allylated sulfamide 3.37 (115 mg, 0.22 mmol) in degassed 
CH2Cl2 (3 mL) in a pressure tube was added (ImesH2)(PCy3)(Cl)2Ru=CHPh (9 mg,
0.011 mmol, 5 mol%). The solution was stirred at reflux for 3 h and opened up to air. 
DMSO (40 mL) was added the mixture stirred for 12 h, and the solvent concentrated.
Flash chromatography (10:1 heptanes/EtOAc) yielded 104 mg (96%) of cyclic 
sulfamide 3.38 as a clear yellow oil.
Analytical data  for 3.38: TLC Rf = 0.32 (3:1 heptanes/EtOAc); [?]  =-59.8 (c = 
0.88, CHCl
25
D
3);
1H NMR (400 MHz, CDCl3) ? 7.35–7.27 (m, 5H), 5.78-5.72 (m, 1H), 
5.55-5.50 (m, 1H), 5.04 (bs, 1H), 4.57 (s, 2H), 4.28 (d, J = 10.4 Hz, 1H), 4.15-4.10
(m, 1H), 3.86-3.79 (m, 3H), 3.64 (s, 3H), 2.20-2.11 (m, 1H), 1.49 (s, 9H), 1.00 (d, J =
6.8 Hz, 3H), 0.95 (d, J = 6.5 Hz, 3H); 13C NMR (100 MHz, CDCl3) ? 170.4, 151.1,
138.0, 128.5, 128.3, 127.6, 127.6, 125.4, 84.0, 72.8, 71.6, 65.5, 55.5, 52.0, 43.4, 28.3,
27.8, 19.2, 19.1; FTIR (neat) 3030, 1741, 1604, 1369, 1154 cm-1; HRMS (M+H)+
calcd for C23H35N2O7S 483.2165, found 483.2156. 
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2-(2S)-[(6S)-(6-Benzyloxymethyl-1,1-dioxo-1,3,6,7-tetrahydro-1,2,7-thiadiazepin-
2-yl)]-3-methylbutyric acid methyl ester (3.39). 
N N
SH
CO2Me
BnO
O O
The cyclic sulfamoyl carbamate 3.38 (64.6 mg, 0.13 mmol) was dissolved in 
TFA/CH2Cl2 (1:1). After 30 min. the reaction was quenched with saturated NaHCO3
(10 mL) and extracted with CH2Cl2 (4 × 15 mL).  The organic layers were combined,
dried over MgSO4, filtered and concentrated under reduced pressure to afford 49 mg 
(96%) of sulfamide 3.39 as a yellow oil.
Analytical data for 3.39: TLC Rf = 0.21 (3:1 heptane/EtOAc); [?] = -45.1 (c =
1.025, CHCl
25
D
3);
1H NMR (400 MHz, CDCl3) ? 7.38-7.30 (m, 5H), 5.64 (bs, 2H), 5.14 
(d, J = 10.2 Hz, 1H), 4.57 (d, J = 12.0 Hz, 1H), 4.51 (d, J = 12.0 Hz, 1H), 4.20-4.15 
(m, 2H), 4.11 (d, J = 11.0 Hz, 1H), 3.76-3.70 (m, 1H), 3.65 (s, 3H), 3.60-3.58 (m, 
2H), 2.21-2.12 (m, 1H), 1.00 (d, J = 6.7 Hz, 3H), 0.91 (d, J = 6.5 Hz, 3H); 13C NMR 
(100 MHz, CDCl3) ? 171.0, 137.4, 130.9, 128.6, 128.5, 128.0, 127.8, 73.5, 72.0, 66.1, 
51.8, 50.9, 41.0, 27.4, 19.2, 19.0; FTIR (neat) 3284, 3029, 1738, 1603, 1333, 1150
cm-1; HRMS (M+H)+ calcd for C18H27N2O5S 383.1641, found 383.1662. 
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2-(2S)-[(6S)-(7-Benzyl-6-benzyloxymethyl-1,1-dioxo-1,3,6,7-tetrahydro-1,2,7-
thiadiazepin-2-yl)]-3-methyl-butyric acid methyl ester (3.40). 
N N
SBn
CO2Me
BnO
O O
To a stirring solution of cyclic sulfamide 3.39 (49 mg, 0.13 mmol) in CH3CN (5 mL)
in a pressure tube was added K2CO3 (90 mg, 0.65 mmol) and benzyl bromide (150 µL, 
1.3 mmol). The reaction was heated to 70 °C for 12 h, filtered via suction filtration,
and purified by column chromatography (10:1 heptane/EtOAc) to afford 54 mg
(89%) of the benzylated sulfamide 3.40 as a yellow oil.
Analytical data for 3.40: TLC Rf = 0.29 (3:1 heptanes/EtOAc); [?] = -68.5 (c = 
0.80, CHCl
25
D
3);
1H NMR (500 MHz, CDCl3) ? 7.41-7.18 (m, 10H), 5.82-5.78 (m, 1H),
5.75-5.72 (m, 1H), 4.66-4.63 (m, 2H), 4.31 (s, 1H), 4.28 (d, J = 3.7 Hz, 1H), 4.22 (d, 
J = 11.9 Hz, 1H), 4.20 (d, J = 11.0 Hz, 1H), 3.99-3.94 (m, 1H), 3.82-3.76 (m, 1H),
3.72 (s, 3H), 3.54 (dd, J = 9.5, 6.0 Hz, 1H), 3.42 (dd, J = 9.5, 7.2 Hz, 1H), 2.22-2.14 
(m, 1H), 1.06 (d, J = 6.7 Hz, 3H), 0.97 (d, J = 6.5 Hz, 3H); 13C NMR (125 MHz, 
CDCl3) ? 171.8, 138.3, 137.6, 128.8, 128.4, 128.3, 128.3, 128.2, 127.5, 127.1, 126.9,
72.9, 70.9, 65.8, 55.4, 51.8, 51.0, 40.6, 27.8, 19.2, 19.1; FTIR (neat) 2962, 1740,
1496, 1454, 1334, 1150 cm-1; HRMS (M+H)+ calcd for C25H33N2O5S 473.2110, 
found 473.2110.
191
2-(2S)-[(4S,5R,6R)-(7-Benzyl-6-benzyloxymethyl-4,5-dihydroxy-1,1-dioxo-
1,3,6,7-tetrahydro-1,2,7-thiadiazepin-2-yl)]-3-methyl-butyric acid methyl ester
(3.41).
N N
SBn
CO2Me
BnO
O O
HO OH
In a procedure similar to the preparation of the sultam diol 2.9, sulfamide 3.40 (93 mg,
0.200 mmol) was subjected to dihydroxylation conditions NMO·H2O (28 mg, 0.24 
mmol), citric acid (84 mg, 0.40 mmol) and OsO4 (75 mL, 0.012 mmol, 6 mol%).
Flash chromatography (1:1 heptane/EtOAc) produced 70 mg (70%) of the sulfamide
diol 3.41 as a clear oil.
Analytical data for 3.41: TLC Rf = 0.49 (1:3 heptane/EtOAc); [?]  -37.5 (c = 0.995,
CHCl
25
D
3);
1H NMR (500 MHz, CDCl3) ? 7.39-7.09 (m, 10H), 4.58 (d, J = 14.2 Hz, 1H), 
4.39 (d, J = 7.7 Hz, 1H), 4.35 (d, J = 10.3 Hz, 1H), 4.29 (d, J = 11.8 Hz, 1H), 4.25 (d, 
J = 11.8 Hz, 1H), 4.22-4.20 (m, 1H), 4.05 (d, J = 14.2 Hz, 1H), 3.88 (d, J = 1.3 Hz, 
1H), 3.84 (dd, J = 10.2, 9.1 Hz, 1H), 3.78 (s, 3H), 3.69 (dd, J = 14.5, 5.6 Hz, 1H), 
3.42 (d, J = 14.3 Hz, 1H), 3.29-3.23 (m, 2H), 3.15 (dd, J = 9.0, 4.8 Hz, 1H), 2.21-2.13 
(m, 1H), 1.05 (d, J = 6.7 Hz, 3H), 0.97 (d, J = 6.6 Hz, 3H); 13C NMR (125 MHz, 
CDCl3) ? 172.9, 136.9, 136.6, 128.9, 128.5, 128.4, 127.9, 127.8, 127.4, 78.4, 74.1, 
73.3, 73.2, 67.4, 59.2, 55.1, 52.1, 45.8, 28.9, 19.3, 19.2; FTIR (neat) 3468, 1739,
1345, 1140 cm-1; HRMS (M+H)+ calcd for C25H35N2O7S 507.2165, found 507.2152. 
192
tert-butyl N-(benzyloxy)sulfamoylcarbamate 3.42
O
O
O
H H
N
S
N
O O
Ph
To a cold (0 °C) solution of CSI (17.8 mmol, 2.52 g) in CH2Cl2 (3 mL) was added
tert-butyl alcohol (17.8 mmol, 1.32g) dropwise via syringe and the solution stirred for 
1 h at that temperature.  This solution was then transferred via cannula to a cold
(0 °C) solution of O-benzyl hydroxylamine hydrochloride (17.8 mmol, 2.84 g) in
CH2Cl2 (25 mL) and Et3N (35.6 mmol, 3.60 g).  The reaction was stirred until it 
slowly reached rt.  Upon completion, water (100 mL) was added and the crude 
mixture extracted with CH2Cl2 (4 × 100 mL).  The organic layers were combined,
dried with Na2SO4, filtered and concentrated under reduced pressure.  Flash 
chromatography (SiO2, 10:1 Heptane/EtOAc) afforded 4.57 g (85%) of 3.42 as a 
white solid.
Analytical data for 3.42: TLC Rf = 0.49 (1:1 Heptane/EtOAc); Mp = 98 °C; 
1H
NMR (500 MHz, CDCl3) ? 7.87 (s, 1H), 7.60 (s, 1H), 7.38 (m, 5H), 4.99 (s, 2H), 1.48
(s, 9H); 13C NMR (125 MHz, CDCl3) ? 149.7, 134.8, 129.4, 128.8, 128.5, 85.0, 79.2, 
27.8; FTIR (neat) 3120, 2957, 2870, 1612, 1514, 1465, 1323, 1247, 1035, 877, 737, 
700 cm-1; HRMS (M + Na)+ calcd for C12H18N2O5Na  325.0834, found 325.0842.
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(R)-ethyl-2-((N-(benzyloxy)sulfamoyl)(tert-butoxycarbonyl)amino)propanoate
(3.43)
O
N
S
N
H
O O
Ph
EtO2C
Boc
To a solution of sulfamoyl carbamate 3.42 (4.20 mmol, 1.26 g), (S)-ethyl lactate (4.2
mmol, 496 mg) and PPh3 (4.20 mmol, 1.10 g) in THF (4.5 mL) was added DIAD (4.2 
mmol, 849 mg) dropwise via syringe.  The reaction was stirred at rt for approximately
1 h.  Flash chromatography (SiO2, 10:1 Heptane/EtOAc) provided 1.07g (64%) of 
3.43 as a clear yellow oil.
Analytical data for 3.43: TLC Rf = 0.58 (1:1 Heptane/EtOAc); [?]  = -40.0 (c = 
0.69, CHCl
25
D
3)
1H NMR (400 MHz, CDCl3) ? 8.05 (s, 1H, N-H), 7.36-7.35 (m, 5H), 
4.98 (s, 2H), 4.89 (q, J = 7.0 Hz, 1H), 4.16 (q, J = 7.0 Hz, 2H), 1.52 (d, J = 7.0 Hz,
3H), 1.46 (s, 9H), 1.20 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) ? 169.6, 
150.2, 134.7, 129.2, 128.3, 128.2, 85.5, 78.8, 61.4, 55.6, 27.5, 15.7, 13.8;  FTIR 
(neat) 3244, 2982, 1744, 1724, 1620, 1456 cm-1; HRMS (M+Na)+ calcd for 
C17H26N2O7SNa 425.1359, found 425.1340.
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(R)-ethyl 2-(N-(benzyloxy)sulfamoylamino)propanoate (3.44) 
O
N
H
S
N
H
O O
Ph
EtO2C
To a solution of 3.43 (3.38 mmol, 1.36 g) in CH2Cl2 (2 mL) was added TFA (2 mL)
dropwise via syringe.  The reaction was stirred for 1 h and quenched with a saturated 
solution of NaHCO3 (5 mL), followed by extraction with CH2Cl2 (4 × 50 mL).  The 
organic layers were combined, dried over MgSO4, filtered and concentrated under
reduced pressure.  Flash chromatography (SiO2, 6:1 Heptane/ EtOAc) afforded 1.02g 
(100%) of 3.44 as a light-yellow solid.
Analytical data for 3.44: TLC Rf = 0.42 (1:1 Heptane/EtOAc); Mp = 53-56 °C; 
[?] = -8.57 (c = 1.72, CHCl25D 3);
1H NMR (400 MHz, CDCl3) ? 7.40 (s, 1H, N-H), 
7.36-7.33 (m, 5H), 5.49 (d, J = 8.3 Hz, 1H), 4.93 (d, J = 10.9 Hz. 1H), 4.88 (d, J = 
10.9 Hz, 1H), 4.24 (quintet, J = 7.3 Hz, 1H), 4.17-4.09 (m, 1H), 4.05-3.97 (m, 1H), 
1.42 (d, J = 7.3 Hz, 3H), 1.16 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) ?
172.9, 135.3, 129.3, 128.6, 128.4, 78.8, 62.0, 52.9, 19.4, 13.8;  FTIR (neat) 3240,
3034, 2986, 1732, 1624,1454 cm-1; HRMS (M+Na)+ calcd for C12H18N2O5SNa
325.0834, found 325.0828.
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(R)-ethyl 2-(allyl(N-allyl-N-(benzyloxy)sulfamoyl)amino)propanoate (3.45) 
N N
S
O
O
O
Ph
EtO2C
To a solution of sulfamide 3.44 (2.0 mmol, 605 mg) in MeCN (25 mL) was added 
K2CO3 (10.0 mmol, 1.38 g) and allyl bromide (20.0 mmol, 2.42 g) and the reaction
heated at 80 °C for 6 h.  The product was filtered and purified by flash 
chromatography (SiO2, 10:1 Heptane/EtOAc) to afford 730 mg (95%) of 3.45 as a 
yellow oil.
Analytical data for 3.45: TLC Rf = 0.57 (1:1 Heptane/EtOAc); [?] = + 29.9 (c = 
0.855, CHCl
25
D
3);
1H NMR (400 MHz, CDCl3) ? 7.35-7.33 (m, 5H), 5.90 (m, 2H), 5.31
(dd, J = 17.2, 1.0 Hz, 1H), 5.24 (dd, J = 10.2, 1.0 Hz, 1H), 5.18 (dd, J = 17.2, 1.0 Hz,
1H), 5.11 (dd, J = 10.2, 1.0 Hz, 1H), 4.93 (d, J = 9.8 Hz, 1H), 4.86 (d, J = 9.7 Hz, 1H), 
4.63 (q, J = 7.4 Hz, 1H), 4.12-4.04 (m, 2H), 3.94-3.85 (m. 2H), 1.46 (d, J = 7.4 Hz, 
3H), 1.13 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) ? 171.7, 135.5, 135.16, 
131.8, 129.3, 128.4, 128.2, 120.0, 117.3, 78.7, 61.1, 56.7, 55.6, 49.9, 17.0, 13.8; FTIR
(neat) 3082, 2984, 1740, 1647, 1454, cm-1; HRMS (M+H)+ calcd for C18H27N2O5S
383.1641, found 383.1645. 
196
2,3,6,7-tetrahydro-1,2,7-thiazepine-1,1-dioxo-2,7-diyl-N-benzyloxy-N'-(2R)-
methyl ethanoic acid ethyl ester (3.46)
N N
S
O
O
O
Ph
EtO2C
To a degassed solution of bisallyl sulfamide 3.45 (0.19 mmol, 72.0 mg) in toluene (15
mL) was added Grubbs second generation catalyst (0.011 mmol, 6.0 mg) and the 
reaction was stirred at reflux for 4 h.  The residual ruthenium was removed by 
addition of NaHCO3 (0.275 mmol, 23.0 mg) and C14H12O4PCl (0.275 mmol, 52.0 mg)
and refluxing for 10 h.  Flash chromatography (SiO2, 8:1 Heptane/EtOAc) afforded
66 mg (97%) of 3.46 as a clear yellow oil.
Analytical data for 3.46: TLC Rf = 0.52 (1:1 Heptane/EtOAc); [?]  = -7.6 (c = 1.48, 
CHCl
25
D
3);
1H NMR (500 MHz, CDCl3) ? 7.37-7.32 (m. 5H), 6.03-5.99 (m, 1H), 5.67-
5.64 (m, 1H), 4.95 (d, J = 10.9 Hz, 1H), 4.89 (d, J = 10.8 Hz, 1H), 4.77 (q, J = 7.3 Hz,
1H), 4.16 (q, J = 7.1 Hz, 2H), 4.06 (t, J = 16.0 Hz, 2H), 3.74-3.65 (m, 2H), 1.39 (d, J
= 7.3 Hz, 3H), 1.26 (t, J = 7.5 Hz, 3H); 13C NMR (125 MHz, CDCl3) ? 171.8, 135.7,
133.3, 129.2, 128.4, 128.3, 128.2, 77.6, 61.2, 56.7, 49.7, 40.9, 17.4, 14.0; FTIR (neat) 
3031, 2982, 1740, 1610, 1456 cm-1; HRMS (M+H)+ calcd for C16H23N2O5S 355.1328, 
found 355.1322.
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2,3,4,5,6,7-hexahydro-1,2,7-thiazepine-1,1-dioxo-2,7-diyl-N-benzyloxy-N'-(2R)-
methyl ethanoic acid ethyl ester (3.48)
N N
S
O
O
O
Ph
EtO2C
To a solution of cyclic sulfamide 3.46 (0.42 mmol, 148 mg) in MeOH (10 mL) was 
added catalytic amounts of 5% Pd/C (~5 mg). After removal of air from the solution 
by suction, a H2 balloon was inserted and the reaction stirred at rt for 3 days.  The 
crude product was filtered through celite and purified by flash chromatography (SiO2,
7:1 Heptane/EtOAc) to afford 98 mg (66%) of 3.48 and 23 mg (21%) of 3.49 as clear 
yellow oils.
Analytical data for 3.48: TLC Rf = 0.55 (1:1 Heptane/EtOAc); [?]  = +7.0
(c = 0.69, CHCl
25
D
3);
1H NMR (500 MHz, CDCl3) ? 7.35-7.30 (m, 5H), 4.90 (q, J = 10.5 
Hz, 2H), 4.79 (q, J = 7.5 Hz, 1H), 4.10-4.06 (m, 1H), 4.01-3.98 (m, 1H), 3.35-3.30 (m,
1H), 3.27-3.24 (m, 2H), 3.01 (bs, 1H), 2.12 (m, 2H), 1.94-1.90 (m, 1H), 1.76 (m, 1H),
1.40 (d, J = 7.5 Hz, 3H), 1.20 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) ?
171.7, 135.8, 129.3, 128.3, 128.3, 77.6, 61.0, 57.7, 57.6, 53.9, 41.7, 27.8, 22.4, 14.0;
FTIR (neat) 3032, 2939, 1740, 1607, 1497, 1454 cm-1; HRMS (M+Na)+ calcd for 
C16H24N2O5SNa 379.1304, found 379.1308.
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2,3,4,5,6,7-hexahydro-1,2,7-thiazepine-1,1-dioxo-2,7-diyl-N'-(2R)-methyl
ethanoic acid ethyl ester (3.49) 
N N
S
O
H
O
EtO2C
Analytical data for 3.49: TLC Rf = 0.23 (1:1 Heptane/EtOAc); [?] = + 2.3 (c = 
1.08, CHCl
25
D
3);
1H NMR (500 MHz, CDCl3) ? 4.82 (t, J = 5.0 Hz, 1H), 4.60 (q, J = 5.0
Hz, 1H), 4.19 (q, J = 10.0 Hz, 2H), 4.31 (ddd, J = 15.0, 10.0, 5.0 Hz, 1H), 3.25-3.19 
(m, 3H), 1.92-1.86 (m, 2H), 1.85-1.80 (m, 1H), 1.76-1.71 (m, 1H), 1.48 (d, J = 5.0 Hz,
3H), 1.28 (t, J = 5.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) ? 172.3, 61.4, 56.6, 44.6,
42.4, 30.4, 27.4, 16.1, 14.1; FTIR (neat) 3292, 2941, 1734 cm-1; HRMS (M+H)+
calcd for C9H19N2O4S 251.1065, found 251.1060. 
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N-[[[(2-Propenyloxy)carbonyl]amino]sulfonyl]-(S)-phenylalanine methyl ester 
(4.13)
O N
S
N
O O
HH
O
Ph
OMe
O
To a stirring solution of CSI (1.97 g, 13.9 mmol) in CH2Cl2, (10 mL) at 0 °C was 
added allyl alcohol (0.95 mL, 13.9 mmol) via syringe and the reaction was stirred for 
1 h. This solution was transferred via cannula to a stirring solution of phenylalanine 
ester hydrochloride (3.0 g, 13.9 mmol) and Et3N (3.87 mL, 27.8 mmol) in CH2Cl2 (25 
mL) at 0 °C. The resulting mixture was stirred under Ar for 12 h. The product of the 
reaction was dissolved in 100 mL of H2O and extracted with CH2Cl2 (4 × 50 mL),
dried with Na2SO4, filtered and concentrated under reduced pressure. The product 
was purified by flash chromatography (SiO2, 3:1 heptane/EtOAc) to afford 2.65 g 
(56%) of carbamate 4.13 as white solid.
Analytical data for 4.13: TLC Rf = 0.38 (1:1 heptane/EtOAc); Mp = 101–102.5 °C; 
[?] = + 32.9 (c = 0.99, CHCl25D 3);
1H NMR (500 MHz, CDCl3) ? 7.33-7.27 (m, 3H 
and N–H), 7.16 (d, J = 7.0 Hz, 2H), 5.88 (dddd, J = 16.6, 11.3, 5.8, 5.6 Hz, 1H), 5.58
(d, J = 8.5 Hz, 1H), 5.34 (d, J = 17.1 Hz, 1H), 5.27 (d, J = 10.4 Hz, 1H), 4.61, (d, J = 
5.8 Hz, 2H), 4.55-4.51 (m,1H), 3.72, (s, 3H), 3.13 (d, J = 5.9 Hz, 2H); 13C NMR (125
MHz, CDCl3) ? 171.0, 150.6, 134.7, 130.9, 129.4, 128.7, 127.5, 119.5, 67.4, 57.7,
52.7, 39.0; FTIR (neat) 3271, 1740, 1732, 1647 cm-1; HRMS (M+H)+ calcd for 
C14H19N2O6S 343.0964, found 343.0957.
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N-[[[(2-Butenyloxy)carbonyl]amino]sulfonyl]-(S)-phenylalanine methyl ester 
(4.14)
O N
S
N
O O
HH
O
Ph
OM
e
O
In a procedure similar to the preparation of sulfamoyl carbamate 4.13, CSI (1.21 mL,
13.9 mmol), 3-buten-1-ol (1.2 mL, 13.9 mmol), and (L)-phenylalanine methyl ester 
hydrochloride (3.0 g, 13.9 mmol) and Et3N (3.87 mL, 27.8 mmol) were subjected to 
the aforementioned  3-component coupling conditions. Flash chromatography (SiO2,
2:1 heptane/EtOAc) afforded 3.60 g (73%) of the desired carbamate 4.14 as a white 
solid.
Analytical data for 4.14: TLC Rf = 0.38 (1:1 heptane/EtOAc); Mp = 95-97 °C; 
 [?] = + 38.3 (c = 1.05, CHCl25D 3);
1H NMR (500 MHz, CDCl3) ? 7.32-7.25 (m, 3H 
and  N–H), 7.15 (d, J = 6.8 Hz, 2H), 5.75 (dddd, J = 17.0, 10.2, 6.7, 6.7 Hz, 1H), 5.11 
(d, J = 17.1 Hz, 1H), 5.07 (d, J = 10.3 Hz, 1H), 4.51 (t, J = 5.8 Hz, 1H), 4.18 (t, J = 
6.6 Hz, 2H), 3.72 (s, 3H), 3.13 (d, J = 5.8 Hz, 2H), 2.39 (dd, J = 13.1, 6.5 Hz, 2H);
13C NMR (125 MHz, CDCl3) ? 171.0, 150.8, 134.7, 133.3, 129.4, 128.8, 127.5, 117.8, 
65.9, 57.6, 52.7, 38.8, 32.8; FTIR (neat) 3273, 2955, 1744, 1642 cm-1; HRMS
(M+H)+ calcd for C15H21N2O6S 357.1120, found 357.1099.
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N-[[[(2-Pentenyloxy)carbonyl]amino]sulfonyl]-(S)-phenylalanine methyl ester 
(4.15).
O N
S
N
O O
HH
O
Ph
OM
e
O
In a procedure similar to the preparation of sulfamoyl carbamate 4.13, CSI (1.21 mL,
13.9 mmol), 4-penten-1-ol (1.44 mL, 13.9 mmol), (L)-phenyl alanine methyl ester
hydrochloride (3.0 g, 13.9 mmol) and Et3N (3.87 mL, 27.8 mmol) were subjected to 
3-component coupling conditions. Flash chromatography (SiO2, 3:1 heptane/EtOAc) 
afforded 3.17 g (62%) of the desired carbamate 4.15 as white solid. 
Analytical data for 4.15: TLC Rf = 0.21 (2:1 heptane/EtOAc); Mp = 101–103 °C; 
[?] = + 35.0 (c = 1.03, CHCl25D 3);
1H NMR (500 MHz, CDCl3) ? 7.35-–7.25 (m, 3H), 
7.16 (d, J = 7.1 Hz, 2H), 5.77 (dddd, J = 16.9, 10.2, 6.6, 6.6 Hz, 1H), 5.58 (dd, J = 
12.6, 8.5 Hz, 1H), 5.04 (dd, J = 17.2, 1.0 Hz, 1H), 5.00 (dd, J = 10.2, 1.1 Hz, 1H),
4.52 (dd, J = 14.3, 5.9 Hz, 1H), 4.14 (t, J = 6.6 Hz, 2H), 3.72 (s, 3H), 3.13 (d, J = 5.9
Hz, 2H), 2.08 (q, J = 7.1 Hz, 2H), 1.73 (quintet, J = 7.1 Hz, 2H); 13C NMR (125 MHz, 
CDCl3) ? 171.0, 150.9, 137.0 134.7, 129.4 128.7, 127.4, 115.7, 66.5, 57.7, 52.7, 39.0, 
29.7, 27.6; FTIR (neat) 3271, 1744, 1641 cm-1; HRMS (M+H)+ calcd for 
C16H23N2O6S 371.1277, found 371.1280.
202
N-[[[(2-Propenyloxy)carbonyl]-N'-(4-methoxybenzyl)-amino]sulfonyl]-(S)-
phenylalanine methyl ester (4.16) 
O N
S
N
O O
HPMB
O
Ph
OMe
O
To a stirring solution of Ph3P (1.85 g, 7.04 mmol) in THF (4 mL) at rt was added 
PMBOH (973 mg, 7.04 mmol) via syringe and the solution stirred for 30 min. This 
mixture was transferred via cannula to a stirring solution of sulfamoyl carbamate 4.13
(2.41 g, 7.04 mmol) and DIAD (1.42 g, 7.04 mmol) in THF (5 mL) and the reaction 
was stirred for 3 h and concentrated under reduced pressure. Flash chromatography
(SiO2, 4:1 heptane/EtOAc) afforded 3.17 g (97%) of the desired alkylated sulfamoyl 
carbamate 4.16 as a yellow oil.
Analytical data for 4.16: TLC Rf = 0.49 (1:1 heptane/EtOAc); [?]  = +2.9 (c = 1.02, 
CHCl
25
D
3);
1H NMR (500 MHz, CDCl3) ? 7.35 (d, J = 8.6 Hz, 2H), 7.31–7.28 (m, 3H),
7.07 (d, J = 6.3 Hz, 2H), 6.87 (d, J = 8.5 Hz, 2H), 5.90 (dddd, J = 16.6, 11.2, 5.8, 5.4
Hz, 1H), 5.74 (d, J = 8.2 Hz, 1H), 5.36 (d, J = 17.2 Hz, 1H), 5.28 (d, J = 10.4 Hz, 1H), 
4.85 (d, J = 15.3 Hz, 1H), 4.73 (d, J = 15.3 Hz, 1H), 4.71–4.74 (m, 2H), 4.06 (dd, J = 
14.0, 5.9 Hz, 1H), 3.82 (s, 3H), 3.61 (s, 3H), 3.03 (d, J = 9.4 Hz, 2H); 13C NMR (125
MHz, CDCl3) ? 170.6, 159.4, 152.6, 136.2, 134.8, 131.0, 130.1, 129.3, 128.6, 127.3, 
119.4, 113.9, 67.4, 57.0, 55.2, 52.4, 50.3, 38.9; FTIR (neat) 3304, 2979, 1736, 1728, 
1612, 1514 cm-1; HRMS (M+H)+ calcd for C22H27N2O7S 463.1539, found 463.1566. 
203
N-[[[(2-Butenyloxy)carbonyl]-N'-(4-methoxybenzyl)-amino]sulfonyl]-(S)-
phenylalanine methyl ester (4.17) 
O N
S
N
O O
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In a procedure similar to the preparation of sulfamoyl carbamate 4.16, compound
4.14 (3.56 g, 9.99 mmol), DIAD (1.97 mL, 9.99 mmol), Ph3P (2.62 g, 9.99 mmol)
and PMBOH (1.25 mL g, 9.99 mmol) were utilized in the Mitsunobu reaction. Flash
chromatography (SiO2, 5:1 heptane/EtOAc) afforded 3.94 g (83%) of the desired 
alkylated product 4.17 as a yellow oil.
Analytical data for 4.17: TLC Rf = 0.55 (1:1 heptane/EtOAc); [?] = + 3.0 (c = 1.00, 
CHCl
25
D
3); 1H NMR (500 MHz, CDCl3) ? 7.33 (d, J = 8.5 Hz, 2H), 7.27–7.24 (m, 3H),
7.05 (d, J = 7.0 Hz, 2H), 6.84 (d, J = 8.5 Hz, 2H), 5.75–5.69 (m, 1H and N–H), 5.10 
(d, J = 17.2 Hz, 1H), 5.00 (d, J = 10.2 Hz, 1H), 4.82 (d, J = 15.2 Hz, 1H), 4.68 (d, J =
15.2 Hz, 1H), 4.24 (t, J = 6.5 Hz, 2H), 4.02 (dd, J = 14.2, 5.9 Hz, 1H), 3.80 (s, 3H), 
3.59 (s, 3H), 2.98 (d, J = 5.9 Hz, 2H), 2.40 (dd, J = 12.8, 6.4 Hz, 2H); 13C NMR (125
MHz, CDCl3) ? 170.6, 159.3, 152.8, 134.8, 134.0, 130.2, 129.4, 129.2, 128.6, 127.3, 
117.8, 113.8, 66.4, 56.9, 55.3, 52.4, 50.2, 39.0, 32.9; FTIR (neat) 3319, 3055, 2926, 
1744, 1728, 1612, 1514 cm-1; HRMS (M+NH4)
+ calcd for C23H32N3O7S 494.1961, 
found 494.1953.
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N-[[[(2-Pentenyloxy)carbonyl]-N'-(4-methoxybenzyl)-amino]sulfonyl]-(S)-
phenylalanine methyl ester (4.18) 
O N
S
N
O O
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O
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e
O
In a procedure similar to the preparation of sulfamoyl carbamate 4.16, compound
4.15 (3.0 g, 8.1 mmol), DIAD (1.59 mL, 8.1 mmol), Ph3P (2.12 g, 8.1 mmol) and
PMBOH (1.0 mL, 8.1 mmol) were utilized in the Mitsunobu reaction. Flash 
chromatography (SiO2, 4:1 heptane/EtOAc) afforded 3.08 g (78%) of the desired 
alkylated product 4.18 as a yellow oil. 
Analytical data for 4.18: TLC Rf = 0.54 (1:1 heptane/EtOAc); [?] = + 3.3 (c = 
1.01, CHCl
25
D
3);
1H NMR (500 MHz, CDCl3) ? 7.34 (d, J = 8.6 Hz, 2H), 7.31–7.27 (m, 
3H), 7.08 (d, J = 6.5 Hz, 2H), 6.87 (d, J = 8.6 Hz, 2H), 5.78 (dddd, J = 16.9, 10.2, 6.6, 
6.6 Hz, 1H), 5.73 (d, J = 5.5 Hz, 1H), 5.03 (dd, J = 16.9, 1.5 Hz, 1H), 5.00 (d, J = 9.0
Hz, 1H), 4.85 (d, J = 15.3 Hz, 1H), 4.72 (d, J = 15.3, 1H), 4.24–4.17 (m, 2H), 4.06 
(dd, J = 13.9, 5.9 Hz, 1H), 3.82 (s, 3H), 3.62 (s, 3H), 3.01 (d, J = 5.8 Hz, 2H), 2.08 
(dt, J = 7.4, 7.1 Hz, 2H), 1.75 (quintet, J = 7.1 Hz, 2H); 13C NMR (125 MHz, CDCl3)
? 170.6, 159.3, 152.8, 137.0, 134.8, 129.9, 129.3, 129.1, 128.6, 127.3, 115.6, 113.8,
67.0, 57.0, 55.2, 52.4, 50.2, 38.9, 29.7, 27.6; FTIR (neat) 3296, 1728, 1612, 1514
cm-1; HRMS (M+NH4)
+ calcd for C24H34N3O7S 508.2117, found 508.2094. 
205
N-(2-Propenyl)-N-[[[(2-propenyloxy)carbonyl]-N'-(4-methoxybenzyl)
amino]sulfonyl]-(S)-phenylalanine methyl ester (4.19) 
O N
S
N
O O
CO2Me
PMB
O
Ph
To a stirring solution of 4.16 (3.06 g, 6.62 mmol) in CH3CN (25 mL) was added
K2CO3 (9.15 g, 66.2 mmol), and allyl bromide (2.86 mL, 33.1 mmol). The reaction 
was stirred under reflux for 24 h. The product was filtered and purified by flash 
chromatography (SiO2, 5:1 heptane/EtOAc) to afford 2.01 g (60%) of the pure 
product 4.19 as a yellow oil.
Analytical data for 4.19: TLC Rf = 0.51 (1:1 heptane/EtOAc). [?] = -15.1 (c = 
1.09,CHCl
25
D
3);
1H NMR (400 MHz, CDCl3) ? 7.37 (d, J = 8.6 Hz, 2H), 7.30–7.21 (m,
3H), 7.12 (d, J = 6.9 Hz, 2H), 6.82 (d, J = 8.6 Hz, 2H), 5.97–5.85 (m, 2H), 5.35 (d, J
= 17.1 Hz, 1H), 5.28 (d, J = 10.4 Hz, 1H), 5.25 (d, J = 17.6 Hz, 1H), 5.17 (d, J = 10.2 
Hz, 1H), 4.87 (d, J = 15.4 Hz, 1H), 4.77 (d, J = 15.4 Hz, 1H), 4.65 (d, J = 5.9 Hz, 2H), 
4.55 (dd, J = 8.9, 6.2 Hz, 1H), 4.17 (dd, J = 16.7, 5.7 Hz, 1H), 4.00 (dd, J = 16.7, 6.8
Hz, 1H), 3.77 (s, 3H), 3.59 (s, 3H), 3.22 (dd, J = 13.7, 9.0 Hz, 1H), 2.97 (dd, J = 13.7,
6.2 Hz, 1H); 13C NMR (100 MHz, CDCl3) ? 170.3, 159.1, 152.5, 136.2, 134.9, 131.2, 
129.9, 129.1, 129.0, 128.4, 126.8, 119.4, 117.6, 113.6, 67.7, 61.1, 55.1, 52.0, 51.4, 
50.0, 36.8; FTIR (neat) 3350, 2982, 1732, 1649, 1612, 1585, 1514 cm-1; HRMS 
(M+H)+ calcd for C25H31N2O7S 503.1852, found 503.1863. 
206
N-(2-Propenyl)-N-[[[(2-butenyloxy)carbonyl]-N'-(4-methoxybenzyl)amino]-
sulfonyl]-(S)-phenylalanine methyl ester (4.20) 
O N
S
N
O O
CO2Me
PMB
O
Ph
In a procedure similar to the preparation of sulfamoyl carbamate 4.19, 4.17 (1.58 g, 
3.3 mmol), K2CO3 (912 mg, 6.6 mmol), and allyl bromide (0.29 mL, 3.30 mmol) was 
subjected to the allylation procedure. Flash chromatography (SiO2, 100% EtOAc)
afforded 1.68 g (98%) of 4.20 as a yellow oil.
Analytical data for 4.20: TLC Rf = 0.60 (1:1 heptane/EtOAc); [?] 25D  =  -19.8 (c = 
0.98, CHCl3);
1H NMR (500 MHz, CDCl3) ? 7.35 (d, J = 8.6 Hz, 2H), 7.29–7.22 (m, 
3H), 7.13 d, J = 7.0 Hz, 2H), 6.81 (d, J = 11.5 Hz, 2H), 5.91 (dddd, J = 16.9, 10.2, 6.3,
6.1 Hz, 1H), 5.75 (dddd, J = 17.0, 10.3, 6.7, 6.7 Hz, 1H), 5.25 (dd, J = 17.2, 1.1 Hz, 
1H), 5.16 (dd, J = 10.3, 1.0 Hz, 1H), 5.12 (dd, J = 17.2, 1.5 Hz, 1H), 5.10 (dd, J = 9.3, 
1.3 Hz, 1H), 4.83 (d, J = 15.5 Hz, 1H), 4.74 (d, J = 15.5 Hz, 1H), 4.58 (dd, J = 8.9, 
6.2 Hz, 1H), 4.20 (t, J = 6.3 Hz, 2H), 4.17 (d, J = 5.7 Hz, 1H)), 4.02 (dd, J = 16.6, 6.7
Hz, 1H), 3.77 (s, 3H), 3.59 (s, 3H), 3.22 (dd, J = 13.7, 9.0 Hz, 1H), 2.97 (dd, J = 13.7,
6.1 Hz, 1H), 2.42 (dd, J = 13.5, 6.7 Hz, 1H); 13C NMR (125 MHz, CDCl3) ? 170.4, 
159.3, 152.7, 136.3, 135.0, 133.3, 129.9, 129.2, 129.1, 128.4, 126.8, 117.8, 117.7,
113.7, 66.3, 61.2, 55.2, 52.0, 51.4, 49.9, 36.9, 33.0; FTIR (neat) 2955, 1728, 1612, 
1514 cm-1; HRMS (M+Na)+ calcd for C26H32N2O7SNa 539.1828, found 539.1834. 
207
N-(2-Propenyl)-N-[[[(2-pentenyloxy)carbonyl]-N'-(4-methoxybenzyl)amino]-
sulfonyl]-(S)-phenylalanine methyl ester (4.21) 
O N
S
N
O O
CO2Me
PMB
O
Ph
In a procedure similar to the preparation of sulfamoyl carbamate 4.19, 4.18 (513 mg,
3.3 mmol), K2CO3 (1.45 g, 10.5 mmol), allyl bromide (0.45 mL, 5.23 mmol) in
CH3CN (20 mL) was subjected to the allylation procedure. Flash chromatography
(SiO2, 4:1 heptane/EtOAc) afforded 506 mg (91%) of 4.21 as a yellow oil.
Analytical data for 4.21: TLC Rf = 0.67 (1:1 heptane/EtOAc); [?] = -20.2 (c = 
0.92, CHCl
25
D
3);
1H NMR (400 MHz, CDCl3) d 7.38 (d, J = 8.7 Hz, 2H), 7.33–7.25 (m, 
3H), 7.17 (d, J = 6.8 Hz, 2H), 6.86 (d, J = 8.7 Hz, 2H), 5.95 (dddd, J = 16.9, 10.2, 6.5, 
5.9 Hz. 1H), 5.80 (dddd, J = 16.9, 10.2, 6.6, 6.6 Hz, 1H), 5.29 (dd, J = 17.2, 1.2 Hz, 
1H), 5.20 (dd, J = 10.2, 1.1 Hz, 1H), 5.05 (dd, J = 17.1, 1.6 Hz, 1H), 5.04 (d, J = 10.0, 
1.5 Hz, 1H), 4.89 (d, J = 15.5 Hz, 1H), 4.79 (d, J = 15.5 Hz, 1H), 4.61 (dd, J = 8.9, 
6.2 Hz, 1H), 4.22 (dd, J = 16.3, 5.7 Hz, 1H), 4.19 (t, J = 7.0 Hz, 2H), 4.07 (dd, J = 
16.6, 6.7 Hz, 1H), 3.80 (s, 3H), 3.63 (s, 3H), 3.26 (dd, J = 13.7, 8.9 Hz, 1H), 3.01 (dd, 
J = 13.7, 6.2 Hz, 1H), 2.11 (q, J = 7.1 Hz, 2H), 1.79 (quintet, J = 7.0 Hz, 2H); 13C
NMR (100 MHz, CDCl3) ? 170.3, 159.1, 152.7, 136.9, 136.2, 134.9, 129.6, 129.1,
129.0, 128.3, 126.8, 117.6, 115.5, 113.6, 66.5, 61.1, 55.1, 52.0, 51.4, 49.9, 36.8, 29.6,
27.6; FTIR (neat) 1728, 1612, 1514 cm-1; HRMS (M+NH4)
+ calcd for C27H38N3O7S
548.2430, found 540.2431. 
208
(2S)-2-[3-(4-Methoxy)benzyl)-2,4,4-trioxo-3,4,6,9-tetrahydro-2H-4?6 [1,4,3,5]-
oxathiadiazonin-5-yl]-3-phenyl-propionic acid methyl ester (4.22) 
N
S
N
O
O O
CO2Me
Ph
O
PMB
Compound 4.19 (202 mg, 0.40 mmol) was dissolved in DCE (80 mL, 0.005M) and 
the solution was degassed with Ar for 15 min followed by reflux for 30 min. Cat-C 
(75 mg, 22 mol%) was added to the refluxing solution in three equal portions over a 
period of 48 h. The reaction was cooled to rt, DCE was removed under reduced 
pressure, followed the addition of DMSO (0.32 mL, 50 equiv relative to catalyst) in
CH2Cl2 (50 mL). The reaction was stirred at rt for 24 h and the solvent was removed
under reduced pressure. Flash chromatography (SiO2, 4:1 heptane/EtOAc) afforded 
124 mg (65%) of 4.22 as a yellow oil.
Analytical data for 4.22: TLC Rf = 0.47 (1:1 heptane/EtOAc); [?] = -60.6 (c = 
1.11, CHCl
25
D
3);
1H NMR (400 MHz, CDCl3) ? 7.39 (d, J = 8.9 Hz, 2H), 7.30 (d, J = 7.4 
Hz, 2H), 7.24-7.22 (m, 3H), 6.81 (d, J = 8.7 Hz, 2H), 5.74 (dd, J = 11.5 Hz, 1.7 Hz,
1H), 5.59 (dd, J = 9.2, 1.8 Hz, 1H), 5.24–5.14 (m, 1H), 4.83 (s, 2H), 4.71–4.67 (m,
1H), 4.61 (t, J = 7.3 Hz, 1H), 3.80–3.75 (m, 1H), 3.75 (s, 3H), 3.53 (s, 3H), 3.41 (dd, 
J = 14.4, 7.6 Hz, 1H), 2.98 (dd, J = 14.4, 7.6 Hz, 1H); 13C NMR (125 MHz, CDCl3) ?
170.8, 159.2, 153.1, 136.1, 132.0, 130.1, 129.0, 128.8, 128.6, 127.0, 124.5, 113.7,
64.9, 59.4, 55.2, 52.5, 50.7, 43.6, 34.8; FTIR (neat) 2950, 1740, 1612, 1514 cm-1;
HRMS (M+NH4)
+ calcd for C23H29N3O7S 492.1804, found 492.1793.
209
(2S)-2-[3-(4-Methoxybenzyl)-2,4,4-trioxo-3,4,9,10tetrahydro-2H,6H-4?6-[1,4,3,5]
oxathiadiazonin-5-yl]-3-phenyl-propionic acid methyl ester (4.23) 
N
SN
O
O
O
CO2Me
Ph
PMB
O
In a procedure similar to the preparation of cyclic sulfamoyl carbamate 4.22, 4.20
(209 mg, 0.40 mmol) and cat-C (34 mg, 10 mol%) in DCE (80 mL) was subjected to 
the RCM procedure. Flash chromatography (SiO2, 4:1 heptane/EtOAc) afforded 173 
mg (87%) of 4.23 as an ivory-colored solid. 
Analytical data for 4.23: Mp = 43-50 °C; TLC Rf = 0.16 (2:1 heptane/EtOAc); [?] 25D
= - 97.5 (c = 0.96, CHCl3);
1H NMR (500 MHz, CDCl3) ? 7.39 (d, J = 8.6 Hz, 2H),
7.31 (d, J = 7.2 Hz, 2H), 7.27–7.24 (m, 3H). 6.78 (d, J = 8.6 Hz, 2H), 5.85 (ddd, J =
10.8, 8.2, 8.0 Hz, 1H), 5.62 (ddd, J = 11.0, 11.0, 5.5 Hz, 1H), 4.82 (d, J = 15.1 Hz,
1H), 4.76 (d, J = 15.1 Hz, 1H), 4.59 (bs,1H), 4.52 (t, J = 7.4 Hz, 1H), 4.18-4.14 (m, 
1H), 4.08 (dd, J = 11.3, 1.1 Hz, 1H), 3.74 (s, 4H), 3.52 (s, 3H), 3.45 (dd, J = 14.4, 7.0
Hz, 1H), 3.00 (dd, J = 14.4, 7.8 Hz, 1H), 2.74-2.68 (m, 1H), 2.25-2.21 (m, 1H); 13C
NMR (125 MHz, CDCl3) ? 171.3, 159.2, 152.5, 136.5, 131.5, 130.3, 129.1, 129.1,
128.5, 126.9, 113.5, 65.6, 59.2, 55.2, 52.5, 50.8, 44.7, 35.0, 25.3; FTIR (neat) 1732, 
1612, 1514 cm-1; HRMS (M+NH4)
+ calcd for C24H32N3O7S 506.1961, found
506.1955.
210
(2S)-2-[3-(4-Methoxybenzyl)-2,4,4-trioxo-1-oxa-4?6-thia-3,5-diaza-cycloundec-7-
en-5-yl]-3-phenyl-propionic acid methyl ester (4.24) (hydrogenated for
characterization).
N
SN
O
O
O
CO2Me
Ph
PMB
O
2
In a procedure similar to the preparation of cyclic sulfamoyl carbamate 4.22, 4.21
(206 mg, 0.39 mmol) and cat-C (43 mg, 0.05 mmol) in DCE (78 mL) was subjected 
to the RCM procedure. Flash chromatography (SiO2, 5:1 heptane/EtOAc) afforded 
170 mg (87%) of 4.24 (1.6:1 E:Z) as a yellow oil.
Analytical data for 4.24: TLC Rf = 0.50 (1:1 heptane/EtOAc); HRMS (M+NH4)
+
calcd for C25H34N3O7S 520.2117, found 520.2091. A portion of this compound was 
immediately subjected to the following hydrogenation protocol: Cyclic sulfamoyl
carbamate 4.24 (57 mg, 0.11 mmol) was weighed into a round-bottomed flask
followed by the addition of 5% Pd/C (29 mg) and EtOAc (10 mL). The flask was 
evacuated using suction followed by the insertion of two H2 balloons. The reaction 
was stirred at rt for 2 h. The crude product was filtered through celite and
concentrated under reduced pressure to afford 54 mg (95%) of a white solid.
Analytical data for the hydrogenated product: TLC Rf = 0.49 (1:1
heptanes/EtOAc); Mp = 99-102 °C; [?] 25D = -9.7 (c = 0.82, CHCl3);
1H NMR (400
MHz, CDCl3) ? 7.44 (d, J = 8.5 Hz, 2H), 7.24-7.17 (m, 3H), 6.91 (d, J = 6.0 Hz, 2H), 
6.76 (d, J = 8.5 Hz, 2H), 5.03 (d, J = 15.0 Hz, 1H), 4.81 (d, J = 15.0 Hz, 1H), 4.22 (m, 
1H), 4.10 (t, J = 10.1 Hz, 1H), 3.90 (dd, J = 9.8, 3.7 Hz, 1H), 3.73 (s, 3H), 3.68-3.51 
(m, 2H), 3.58 (s, 3H), 3.17 (t, J = 10.5 Hz, 1H), 2.87 (dd, J = 13.3, 4.2 Hz, 1H), 2.05-
211
1.92 (m, 2H), 1.78–1.66 (m, 2H), 1.56-1.51 (m, 2H), 1.32-1.28 (m, 2H); 13C (100
MHz, CDCl3) ? 169.9, 159.2, 152.9, 136.0, 130.5, 129.1, 129.0, 128.4, 126.7, 113.6, 
69.2, 60.6, 55.1, 52.0, 51.5, 46.9, 34.9, 25.8, 23.4, 23.3, 22.1; FTIR (neat) 2953, 1743,
1726, 1612, 1514 cm-1; HRMS (M+Na)+ calcd for C25H32N2O7SNa 527.1828, found 
527.1820.
212
N-[[[(2-Propenyloxy)carbonyl]amino]sulfonyl]-(S)-valine methyl ester (4.25) 
O N
H
S
N
H
O O
CO2Me
O
To a solution of CSI (4.2 g, 29.8 mmol) in CH2Cl2 (10 mL) at 0 °C was added allyl 
alcohol (1.73 g, 29.8 mmol) via syringe. In an adjacent round-bottomed flask, valine
methyl ester hydrochloride (5.0 g, 29.8 mmol) was dissolved in CH2Cl2 (25 mL),
cooled to 0 °C, and Et3N (6.03 g, 59.6 mmol) was added via syringe. Each solution
was stirred at 0 °C under Ar for approximately 1h. The CSI/alcohol solution was
cannulated into the amino acid solution and the reaction was stirred for 12 h under Ar 
at 0 °C while slowly warming to rt. The crude product was dissolved in H2O (100 
mL) and extracted with CH2Cl2 (4 × 50 mL), dried over Na2SO4, filtered, and
concentrated under reduced pressure. Flash chromatography (SiO2, 4:1 
heptane/EtOAc) afforded 6.12 g (70%) of the desired carbamate 4.25 as white solid.
Analytical data for 4.25: TLC Rf = 0.35 (1:1 heptane/EtOAc); Mp = 93-95 °C; 
[?] = +43.6 (c = 1.03, CHCl25D 3);
1H NMR (400 MHz, CDCl3) ? 5.92 (dddd, J = 17.0, 
10.4, 5.8, 5.8 Hz, 1H), 5.67 (d, J = 9.4 Hz, 1H), 5.37 (dd, J = 17.2, 1.3 Hz, 1H), 5.29
(dd, J = 10.4, 1.1 Hz, 1H), 4.66-4.63 (m, 2H), 4.07 (dd, J = 9.4, 5.0 Hz, 1H), 3.75 (s,
3H), 2.20-2.11 (m, 1H), 1.02 (d, J = 6.8 Hz, 3H), 0.91 (d, J = 6.9 Hz, 3H); 13C NMR 
(125 MHz, CDCl3) ? 171.6, 150.7, 131.0, 119.4, 67.3, 62.2, 52.5, 31.4, 18.8, 17.2; 
FTIR (neat) 3276, 3205, 2966, 1744, 1720, 1651 cm-1; HRMS (M+H)+ calcd for 
C10H19N2O6S 295.0964, found 295.0947.
213
N-[[[[N'-(2-Propenyloxy)carbonyl]-N'-(1R)-1-ethoxycarbonyl ethyl]amino]-
sulfonyl]-(S)-valine methyl ester (4.26)
O N
S
N
H
O O
CO2Me
O
CO2Et
Compound 4.25 (2.66 g, 9.0 mmol) was dissolved in THF (3 mL) followed by the 
addition of DIAD (1.82 g, 9.0 mmol) dropwise via syringe. In an adjacent round
bottomed flask, Ph3P (2.37 g, 9.0 mmol) was dissolved in THF (4 mL) followed by
the addition of (S)-ethyl lactate (1.02 mL, 9.0 mmol) via syringe. Each solution was
stirred under Ar atmosphere at rt for 1 h after which the Ph3P/ethyl lactate solution
was cannulated into the solution of 4.25/DIAD and the resulting reaction mixture
stirred under Ar at rt for 24 h. The reaction was concentrated under reduced pressure.
Flash chromatography (SiO2, 9:1 heptane/EtOAc) afforded 2.30 g (65%) of the 
desired alkylated product 4.26 as a yellow oil.
Analytical data for 4.26: TLC Rf = 0.53 (1:1 heptane/EtOAc); [?] 25D D = +73.0 (c = 
1.18, CHCl3);
1H NMR (500 MHz, CDCl3) ? 6.08 (d, J = 7.4 Hz, 1H), 5.95 (dddd, J = 
16.6, 11.1, 5.7, 5.4 Hz, 1H), 5.39 (d, J = 17.2 Hz, 1H), 5.30 (d, J = 10.5 Hz, 1H), 4.96
(q, J = 7.0 Hz, 1H), 4.71 (t, J = 5.6 Hz, 2H), 4.23-4.17 (m, 2H), 4.12 (dd, J = 7.0, 3.5 
Hz, 1H), 3.77 (s, 3H), 2.22-2.15 (m, 1H), 1.59 (d, J = 7.0 Hz, 3H), 1.27 (t, J = 7.1 Hz,
3H), 1.02 (d, J = 6.8 Hz, 3H), 0.86 (d, J = 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3)
? 171.4, 170.0, 151.7, 131.0, 119.3, 68.1, 61.9, 61.8, 56.6, 52.5, 31.9, 18.8, 17.0, 16.5, 
14.1; FTIR (neat) 3304, 2966, 1740, 1726, 1649 cm-1; HRMS (M+H)+ calcd for
C15H27N2O8S 395.1488, found 395.1472.
214
N-(2-Propenyl)-N-[[[[N'-(2-propenyloxy)carbonyl]-N'-(1R)-1-ethoxycarbonyl-
ethyl]amino]sulfonyl]-(S)-valine methyl ester (4.27) 
N
S
N
O
O O
CO2Me
O
EtO2C
Compound 4.26 (1.10 g, 2.79 mmol) was weighed into a round-bottomed flask, 
followed by the addition of K2CO3 (771 mg, 5.58 mmol), allyl bromide (0.24 mL,
2.79 mmol) and CH3CN (25 mL). The reaction was stirred under reflux at 85 °C for 
6 h. The product was filtered and concentrated under reduced pressure. Flash
chromatography (SiO2, 6:1 heptane/EtOAc) afforded 825 mg (68%) of diene 4.27 as a 
yellow oil. 
Analytical data for 4.27: TLC Rf = 0.38 (2:1 heptane/EtOAc); [?] = -22.2 (c = 
1.05, CHCl
25
D
3);
1H NMR (500 MHz, CDCl3) ? 6.02 (dddd, J = 17.3, 10.2, 5.8, 5.8 Hz, 
1H), 5.90 (dddd, J = 16.4, 10.6, 5.8, 5.8 Hz, 1H), 5.36 (dd, J = 17.2, 1.2 Hz, 1H), 5.29 
(dd, J = 10.2, 1.0 Hz, 1H), 5.22 (dd, J = 17.3, 1.2 Hz, 1H), 5.12 (dd, J = 10.2, 1.1 Hz,
1H), 4.99 (q, J = 7.0 Hz, 1H), 4.64 (d, J = 5.8 Hz, 2H), 4.23-4.21 (m, 2H), 4.19 (d, J
= 7.1 Hz, 2H), 4.13 (d, J = 10.3 Hz, 1H), 3.70 (s, 3H), 2.22-2.14 (m, 1H), 1.61 (d, J = 
7.0 Hz, 3H), 1.26 (t, J = 7.1 Hz, 3H), 1.03 (d, J = 6.6 Hz, 3H), 0.94 (d, J = 6.6 Hz,
3H); 13C NMR (125 MHz, CDCl3) ? 171.0, 170.0, 151.9, 135.3, 131.0, 119.6, 117.5, 
67.9, 66.2, 61.7, 56.8, 51.7, 49.5, 28.9, 19.7, 19.4, 16.1, 14.0; FTIR (neat) 2968, 1742,
1647 cm-1; HRMS (M+H)+ calcd for C18H31N2O8S 435.1801, found 435.1778. 
215
(2S)-2-((1R)-1-Ethoxycarbonyl-ethyl])-2,4,4-trioxo-3,4,6,9-tetrahydro-2H-4?6-
[1,4,3,5]oxathiadiazonin-5-yl)-3-methyl-butyric acid methyl ester (4.28)
N
S
N
O
O O
CO2Me
O
EtO2C
In a procedure similar to the preparation of cyclic sulfamoyl carbamate 4.22, diene 
4.27 (24 mg, 0.055 mmol) and cat-C (4 mg, 8 mol%) in DCE (11 mL) was subjected 
to the RCM procedure. Flash chromatography (SiO2, 9:1 heptane/EtOAc) afforded 15 
mg (68%) of 4.28 as a yellow oil.
Analytical data for 4.28: TLC Rf = 0.45 (1:1 heptane/EtOAc); [?]  = -77.9 (c = 
1.00, CHCl
25
D
3);
1H NMR (400 MHz, CDCl3) ? 5.72-5.69 (m, 1H), 5.54-5.51 (m, 1H),
5.33-5.29 (m, 1H), 4.95 (q, J = 7.0 Hz, 1H), 4.89-4.85 (m, 1H), 4.73-4.69 (m, 1H), 
4.33-4.18 (m, 2H), 3.96 (d, J = 10.9 Hz, 1H), 3.57 (s, 3H), 3.57 (m, 1H), 2.37-2.27 (m, 
1H), 1.62 (d, J = 7.0 Hz, 3H), 1.31 (t, J = 7.1 Hz, 3H), 1.04 (d, J = 6.3 Hz, 3H), 0.98 
(d, J = 6.8 Hz, 3H); 13C NMR (125 MHz, CDCl3) ? 170.7, 169.7, 152.6, 130.9, 124.6, 
65.3, 61.8, 56.0, 51.8, 43.2, 29.7, 25.9, 20.5, 18.6, 15.6, 14.0; FTIR (neat) 2970, 1744,
1647, 1450, 1386 cm-1; HRMS (M+H)+ calcd for C16H27N2O8S 407.1488, found 
407.1497.
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Comments
The asymmetric unit contains one C17H23NO5S  molecule (2.6).  The oxygen
atom for the ether linkage between C(5) and C(6) has two preferred orientations [O(1) 
and O(1’)] in the crystal. This disorder produces two preferred orientations for the
methylene hydrogens adjacent to this oxygen atom.  The major orientation
[represented by atom labels without a prime(')] for the disordered atoms is occupied 
86% of the time and the minor orientation [represented by atom labels with a 
prime(')] is occupied 14% of the time.  The major orientation is represented in the
molecular plots by filled bonds and the minor orientation is represented by hollow
bonds.  All displacement ellipsoids are drawn at the 50% probability level.
Brief  Experimental Description to be Included as Text or as a Footnote at Time 
of Publication 
Colorless crystals of C17H23NO5S are, at 100(2) K, orthorhombic, space group 
P212121 – D2
4 (No. 19) (1) with a = 5.6080(4) Å, b = 11.232(1) Å, c = 28.414(2) Å, V 
= 1789.8(2) Å3 and Z =  4 molecules {dcalcd = 1.312 g/cm
3; ?a(MoK?) = 0.206 mm-1}.
A full hemisphere of diffracted intensities (1850 10-second frames with a ? scan 
width of 0.30?) was measured for a single-domain specimen using graphite-
monochromated MoK? radiation (?= 0.71073 Å) on a Bruker SMART APEX CCD
Single Crystal Diffraction System (2).  X-rays were provided by a fine-focus sealed 
x-ray tube operated at 50kV and 30mA. Lattice constants were determined with the
Bruker SAINT software package using peak centers for 7484 reflections.  A total of 
21992 integrated reflection intensities having 2?((MoK?)< 61.07? were produced 
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using the Bruker program SAINT(3); 5427 of these were unique and gave Rint = 
0.041 with a coverage which was 99.7% complete. The data were corrected 
empirically for variable absorption effects using equivalent reflections; the relative
transmission factors ranged from 0.934 to 1.000.  The Bruker software package 
SHELXTL was used to solve the structure using “direct methods” techniques.  All
stages of weighted full-matrix least-squares refinement were conducted using Fo
2 data
with the SHELXTL Version 6.10 software package(4).
The oxygen atom for the ether linkage between C(5) and C(6) has two 
preferred orientations [O(1) and O(1')] in the crystal.  This disorder produces two
preferred orientations for the methylene hydrogens adjacent to this oxygen atom.  The 
major orientation [represented by atom labels without a prime(')] for the disordered
atoms is occupied 86% of the time and the minor orientation [represented by atom 
labels with a prime(')] is occupied 14% of the time.  All ordered hydrogen atoms were 
located in a difference Fourier and included in the structural model as independent 
isotropic atoms whose parameters were allowed to vary in least-squares refinement
cycles.  The eight disordered methylene hydrogen atoms were included into the 
structural model as idealized atoms (assuming sp3-hybridization of the carbon atoms
and a C-H bond length of 0.99 Å).
The final structural model incorporated anisotropic thermal parameters for all 
nonhydrogen atoms except the minor-occupancy disordered ether oxygen atom O(1’). 
Isotropic thermal parameters were incorporated for this oxygen atom and all
hydrogen atoms.  The isotropic thermal parameters of all eight idealized hydrogen
368
atoms were fixed at values 1.2 times the equivalent isotropic thermal parameter of the
carbon atom to which they are covalently bonded.  A total of 298 parameters were 
refined using no restraints, 5427 data and weights of w = 1/ [?
2
(F
2
) + (0.0595 P)
2
],
where P = [Fo
2
 + 2Fc
2
] / 3.  Final agreement factors at convergence are:
R1(unweighted, based on F) = 0.040 for 4885 independent absorption-corrected 
“observed” reflections having 2?(MoK?)<  61.07? and I>2?(I);  R1(unweighted,
based on F) = 0.044 and wR2(weighted, based on F
2) = 0.095 for all 5427 
independent absorption-corrected reflections having 2?(MoK?)< 61.07?.  The largest
shift/s.u. was 0.001 in the final refinement cycle.  The final difference map had
maxima and minima of 0.52 and -0.35 e-/Å
3
, respectively.  The absolute configuration
was determined experimentally using anomalous dispersion of the x-rays;  the
“Flack” absolute structure parameter refined to a final value of  0.02(5).
Acknowledgment
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Table A1.  Crystal data and structure refinement for C17H23NO5S.
Empirical formula C17H23NO5S
Formula weight 353.42
Temperature 100(2) K 
Wavelength 0.71073 Å 
Crystal system Orthorhombic
Space group P212121 – D2
4 (No. 19) 
Unit cell dimensions a = 5.6080(4) Å ? = 90.000°
b = 11.232(1) Å ? = 90.000° 
c = 28.414(2) Å ? = 90.000°
Volume 1789.8(2) Å3
Z 4 
Density (calculated) 1.312 Mg/m3
Absorption coefficient 0.206 mm-1
F(000) 752 
Crystal size 0.38 x 0.28 x 0.16 mm3
Theta range for data collection 2.31° to 30.54° 
Index ranges -8 ? h ? 7, -15 ?  k ? 16, -40 ? l ? 40 
Reflections collected 21992
Independent reflections 5427 [Rint = 0.041] 
Completeness to theta = 30.54° 99.7 %
Absorption correction Empirical
Max. and min. transmission 1.000 and 0.934 
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 5427 / 0 / 298 
Goodness-of-fit on F2 0.982 
Final R indices [I>2sigma(I)] R1 = 0.040, wR2 = 0.093 
R indices (all data) R1 = 0.044, wR2 = 0.095 
Absolute structure parameter 0.02(5)
Largest diff. peak and hole 0.52 and -0.35 e-/Å3
-------------------------------------------------------------------------------------------------------
R1 = ? ||Fo| - |Fc|| / ? |Fo|
wR2 = { ? [w(Fo
2
 - Fc
2
)
2
] / ? [w(Fo
2
)
2
] }
1/2
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Table A2.  Atomic coordinates  ( x 104) and equivalent isotropic displacement
parameters (Å2 x 103) for C17H23NO5S.  U(eq) is defined as one third of the trace of 
the orthogonalized Uij tensor. 
_____________________________________________________________________
 x y z U(eq)
_____________________________________________________________________
S 755(1) 7685(1) 1492(1) 19(1)
O(1) -1583(3) 5033(1) 297(1) 27(1)
O(1') -2767(15) 5442(7) 340(2) 14(2)
O(2) 2750(2) 5658(1) 2040(1) 20(1)
O(3) 3822(2) 4661(1) 1384(1) 28(1)
O(4) 1449(2) 7896(1) 1967(1) 27(1)
O(5) -1671(2) 7865(1) 1357(1) 31(1)
N 1456(3) 6301(1) 1329(1) 22(1)
C(1) 2611(3) 8510(1) 1110(1) 24(1)
C(2) 2403(3) 8065(1) 614(1) 27(1)
C(3) 1661(3) 6997(1) 496(1) 26(1)
C(4) 1017(3) 6003(1) 825(1) 27(1)
C(5) -1487(4) 5539(2) 765(1) 44(1)
C(6) -3613(6) 4381(3) 247(1) 89(1)
C(7) -3993(4) 3979(2) -249(1) 38(1)
C(8) -2303(4) 3287(2) -476(1) 36(1)
C(9) -2692(4) 2889(2) -928(1) 40(1)
C(10) -4759(4) 3179(2) -1158(1) 42(1)
C(11) -6433(4) 3871(2) -944(1) 49(1)
C(12) -6056(4) 4264(2) -485(1) 53(1)
C(13) 2824(3) 5462(1) 1583(1) 19(1)
C(14) 4261(3) 4922(1) 2361(1) 21(1)
C(15) 3556(3) 3624(2) 2331(1) 27(1)
C(16) 3594(4) 5433(2) 2838(1) 27(1)
C(17) 6861(3) 5139(2) 2248(1) 29(1)
_____________________________________________________________________
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Table A3.   Bond lengths [Å] for  C17H23NO5S.
_____________________________________________________________________
S-O(4) 1.423(1)
S-O(5) 1.428(1)
S-N 1.669(1)
S-C(1) 1.766(2)
O(1)-C(6) 1.361(3)
O(1)-C(5) 1.448(2)
O(2)-C(13) 1.318(2)
O(2)-C(14) 1.495(2)
O(3)-C(13) 1.201(2)
N-C(13) 1.414(2)
N-C(4) 1.490(2)
C(1)-C(2) 1.499(2)
C(1)-H(1A) 0.98(2)
C(1)-H(1B) 0.89(2)
C(2)-C(3) 1.313(2)
C(2)-H(2) 0.92(2)
C(3)-C(4) 1.500(2)
C(3)-H(3) 0.90(2)
C(4)-C(5) 1.507(3)
C(4)-H(4) 0.93(2)
C(5)-H(5A) 0.99
C(5)-H(5B) 0.99
C(6)-C(7) 1.495(3)
C(6)-H(6A) 0.99
C(6)-H(6B) 0.99
C(7)-C(12) 1.375(3)
C(7)-C(8) 1.384(3)
C(8)-C(9) 1.380(3)
C(8)-H(8) 0.95(2)
C(9)-C(10) 1.370(3)
C(9)-H(9) 0.90(3)
C(10)-C(11) 1.362(3)
C(10)-H(10) 1.02(2)
C(11)-C(12) 1.392(3)
C(11)-H(11) 0.98(3)
C(12)-H(12) 1.00(3)
C(14)-C(15) 1.513(2)
C(14)-C(17) 1.513(2)
C(14)-C(16) 1.521(2)
C(15)-H(15A) 0.90(2)
C(15)-H(15B) 0.95(2)
C(15)-H(15C) 1.02(2)
C(16)-H(16A) 0.99(2)
C(16)-H(16B) 0.95(2)
C(16)-H(16C) 0.97(2)
C(17)-H(17A) 1.03(2)
C(17)-H(17B) 1.00(2)
C(17)-H(17C) 0.96(2)
_____________________________________________________________________
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Table A4.   Bond angles [°] for  C17H23NO5S.
_____________________________________________________________________
O(4)-S-O(5) 119.45(7)
O(4)-S-N 110.72(6)
O(5)-S-N 106.32(7)
O(4)-S-C(1) 109.52(8)
O(5)-S-C(1) 108.83(8)
N-S-C(1) 100.28(7)
C(6)-O(1)-C(5) 109.75(16)
C(13)-O(2)-C(14) 119.36(11) 
C(13)-N-C(4) 115.46(12)
C(13)-N-S 127.38(10)
C(4)-N-S 115.95(10)
C(2)-C(1)-S 110.93(11)
C(2)-C(1)-H(1A) 113.3(10) 
S-C(1)-H(1A) 102.6(11)
C(2)-C(1)-H(1B) 112.7(13) 
S-C(1)-H(1B) 104.7(13)
H(1A)-C(1)-H(1B) 111.9(18) 
C(3)-C(2)-C(1) 124.67(14)
C(3)-C(2)-H(2) 115.3(14) 
C(1)-C(2)-H(2) 120.0(14) 
C(2)-C(3)-C(4) 126.64(14)
C(2)-C(3)-H(3) 119.8(12) 
C(4)-C(3)-H(3) 113.5(12) 
N-C(4)-C(3) 113.03(13)
N-C(4)-C(5) 109.95(14)
C(3)-C(4)-C(5) 114.25(15)
N-C(4)-H(4) 104.3(10)
C(3)-C(4)-H(4) 110.4(11) 
C(5)-C(4)-H(4) 104.1(11) 
O(1)-C(5)-C(4) 105.96(16)
O(1)-C(5)-H(5A) 110.5 
C(4)-C(5)-H(5A) 110.5 
O(1)-C(5)-H(5B) 110.5 
C(4)-C(5)-H(5B) 110.5 
H(5A)-C(5)-H(5B) 108.7 
O(1)-C(6)-C(7) 112.33(17) 
O(1)-C(6)-H(6A) 109.1 
C(7)-C(6)-H(6A) 109.1 
O(1)-C(6)-H(6B) 109.1 
C(7)-C(6)-H(6B) 109.1 
H(6A)-C(6)-H(6B) 107.9 
C(12)-C(7)-C(8) 118.69(16) 
C(12)-C(7)-C(6) 120.6(2) 
C(8)-C(7)-C(6) 120.7(2) 
C(9)-C(8)-C(7) 120.47(19) 
C(9)-C(8)-H(8) 119.9(14) 
C(7)-C(8)-H(8) 119.7(13) 
C(10)-C(9)-C(8) 120.07(19) 
C(10)-C(9)-H(9) 119.0(15) 
C(8)-C(9)-H(9) 120.9(15) 
C(11)-C(10)-C(9) 120.40(19) 
C(11)-C(10)-H(10) 119.7(14) 
C(9)-C(10)-H(10) 119.8(14) 
C(10)-C(11)-C(12) 119.6(2) 
C(10)-C(11)-H(11) 123.6(17) 
C(12)-C(11)-H(11) 116.7(17) 
C(7)-C(12)-C(11) 120.70(19) 
C(7)-C(12)-H(12) 117.0(17) 
C(11)-C(12)-H(12) 122.3(17) 
O(3)-C(13)-O(2) 127.20(13) 
O(3)-C(13)-N 120.79(12) 
O(2)-C(13)-N 111.96(12) 
O(2)-C(14)-C(15) 110.60(12) 
O(2)-C(14)-C(17) 109.16(11) 
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C(15)-C(14)-C(17) 113.32(14) 
O(2)-C(14)-C(16) 101.29(12) 
C(15)-C(14)-C(16) 110.45(13) 
C(17)-C(14)-C(16) 111.38(14) 
C(14)-C(15)-H(15A) 114.2(13) 
C(14)-C(15)-H(15B) 111.0(12) 
H(15A)-C(15)-H(15B) 105.6(18) 
C(14)-C(15)-H(15C) 108.8(11) 
H(15A)-C(15)-H(15C) 107.9(17) 
H(15B)-C(15)-H(15C) 109.2(16) 
C(14)-C(16)-H(16A) 111.6(10) 
C(14)-C(16)-H(16B) 108.6(12) 
H(16A)-C(16)-H(16B) 111.6(17) 
C(14)-C(16)-H(16C) 110.0(13) 
H(16A)-C(16)-H(16C) 108.3(17) 
H(16B)-C(16)-H(16C) 106.6(18) 
C(14)-C(17)-H(17A) 113.6(13) 
C(14)-C(17)-H(17B) 108.2(14) 
H(17A)-C(17)-H(17B) 108.7(19) 
C(14)-C(17)-H(17C) 113.5(12) 
H(17A)-C(17)-H(17C) 106.9(17) 
H(17B)-C(17)-H(17C) 105.6(18) 
_____________________________________________________________________
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Table A5.   Anisotropic displacement parameters  (Å2 x  103) for C17H23NO5S.The
anisotropic
displacement factor exponent takes the form:  -2?2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
_____________________________________________________________________
 U11 U22 U33 U23 U13 U12
_____________________________________________________________________
S 19(1) 20(1) 18(1) -1(1) -2(1) 3(1)
O(1) 35(1) 29(1) 16(1) -3(1) -3(1) -9(1)
O(2) 23(1) 22(1) 15(1) 2(1) -1(1) 5(1)
O(3) 37(1) 26(1) 21(1) -4(1) 1(1) 8(1)
O(4) 35(1) 25(1) 21(1) -6(1) -4(1) 6(1)
O(5) 21(1) 41(1) 30(1) -1(1) -3(1) 6(1)
N 36(1) 18(1) 13(1) -2(1) -5(1) 2(1)
C(1) 23(1) 22(1) 25(1) 1(1) -2(1) -1(1)
C(2) 30(1) 28(1) 23(1) 6(1) 3(1) -2(1)
C(3) 33(1) 29(1) 15(1) 3(1) -2(1) 0(1)
C(4) 45(1) 23(1) 13(1) -1(1) -5(1) -3(1)
C(5) 61(1) 51(1) 18(1) -1(1) -4(1) -30(1)
C(6) 101(2) 129(3) 36(1) -42(1) 34(1) -86(2)
C(7) 44(1) 42(1) 29(1) -14(1) 10(1) -23(1)
C(8) 41(1) 34(1) 33(1) -2(1) -12(1) 1(1)
C(9) 52(1) 31(1) 38(1) -14(1) -3(1) 9(1)
C(10) 51(1) 44(1) 30(1) -3(1) -11(1) -12(1)
C(11) 35(1) 55(1) 57(1) 8(1) -13(1) -3(1)
C(12) 34(1) 49(1) 75(2) -21(1) 17(1) -3(1)
C(13) 21(1) 18(1) 18(1) 0(1) -1(1) -2(1)
C(14) 23(1) 22(1) 17(1) 5(1) -3(1) 3(1)
C(15) 31(1) 21(1) 27(1) 4(1) -2(1) 0(1)
C(16) 36(1) 29(1) 17(1) 3(1) -4(1) -2(1)
C(17) 23(1) 32(1) 31(1) 8(1) -3(1) -1(1)
_____________________________________________________________________
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Table A6.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters
(Å2 x 103 ) for C17H23NO5S.
_____________________________________________________________________
x y z U(eq)
_____________________________________________________________________
H(1A) 2020(30) 9328(17) 1151(6) 24(5)
H(1B) 4080(40) 8419(19) 1228(7) 35(5)
H(2) 2770(40) 8560(20) 366(8) 47(6)
H(3) 1510(30) 6803(16) 190(7) 24(4)
H(4) 1970(30) 5344(17) 770(6) 18(4)
H(5A) -1844 4924 1004 52
H(5B) -2659 6193 797 52
H(6A) -4995 4867 347 107 
H(6B) -3526 3675 455 107 
H(5'A) -1480 4729 902 52
H(5'B) -2493 6031 975 52
H(6'A) -5167 4314 410 107 
H(6'B) -2530 3797 397 107 
H(8) -870(50) 3080(20) -315(7) 48(6)
H(9) -1610(40) 2430(20) -1076(8) 48(6)
H(10) -5060(40) 2870(20) -1489(9) 56(7)
H(11) -7940(60) 4100(20) -1091(9) 72(8)
H(12) -7240(50) 4780(30) -314(10) 79(9)
H(15A) 3910(40) 3275(19) 2055(7) 34(5)
H(15B) 1880(40) 3530(17) 2371(6) 27(5)
H(15C) 4420(40) 3168(17) 2589(7) 28(5)
H(16A) 3920(30) 6296(17) 2855(6) 23(5)
H(16B) 1970(40) 5260(20) 2898(7) 35(6)
H(16C) 4500(40) 5041(19) 3085(8) 44(6)
H(17A) 7380(40) 4800(20) 1927(8) 46(6)
H(17B) 7850(40) 4760(20) 2501(8) 51(7)
H(17C) 7290(30) 5970(17) 2250(6) 25(5)
_____________________________________________________________________
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Table A7.  Torsion angles [°] for C17H23NO5S.
_____________________________________________________________________
O(4)-S-N-C(13) -8.04(16) 
O(5)-S-N-C(13) -139.22(13) 
C(1)-S-N-C(13) 107.53(14) 
O(4)-S-N-C(4) -174.77(11) 
O(5)-S-N-C(4) 54.05(13) 
C(1)-S-N-C(4) -59.21(13) 
O(4)-S-C(1)-C(2) 164.30(11) 
O(5)-S-C(1)-C(2) -63.48(13) 
N-S-C(1)-C(2) 47.84(13) 
S-C(1)-C(2)-C(3) -22.1(2) 
C(1)-C(2)-C(3)-C(4) -3.7(3) 
C(13)-N-C(4)-C(3) -128.37(15) 
S-N-C(4)-C(3) 39.98(19) 
C(13)-N-C(4)-C(5) 102.66(18) 
S-N-C(4)-C(5) -88.99(16) 
C(2)-C(3)-C(4)-N -4.0(3) 
C(2)-C(3)-C(4)-C(5) 122.7(2) 
C(6)-O(1)-C(5)-C(4) 167.7(2) 
N-C(4)-C(5)-O(1) -167.73(14) 
C(3)-C(4)-C(5)-O(1) 64.0(2) 
C(5)-O(1)-C(6)-C(7) 171.8(2) 
O(1)-C(6)-C(7)-C(12) -123.2(3) 
O(1)-C(6)-C(7)-C(8) 58.5(4) 
C(12)-C(7)-C(8)-C(9) -0.2(3) 
C(6)-C(7)-C(8)-C(9) 178.1(2) 
C(7)-C(8)-C(9)-C(10) 0.2(3) 
C(8)-C(9)-C(10)-C(11) 0.6(3) 
C(9)-C(10)-C(11)-C(12) -1.3(3) 
C(8)-C(7)-C(12)-C(11) -0.4(3) 
C(6)-C(7)-C(12)-C(11) -178.8(2) 
C(10)-C(11)-C(12)-C(7) 1.2(3) 
C(14)-O(2)-C(13)-O(3) 7.8(2) 
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C(14)-O(2)-C(13)-N -174.77(12) 
C(4)-N-C(13)-O(3) 10.0(2) 
S-N-C(13)-O(3) -156.79(13) 
C(4)-N-C(13)-O(2) -167.63(13) 
S-N-C(13)-O(2) 25.58(19) 
C(13)-O(2)-C(14)-C(15) -62.21(17) 
C(13)-O(2)-C(14)-C(17) 63.11(17) 
C(13)-O(2)-C(14)-C(16) -179.32(13) 
_____________________________________________________________________
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Comments
The asymmetric unit contains one C17H25NO7S molecule (2.9).  All 
displacement ellipsoids are drawn at the 50% probability level.
Brief  Experimental Description to be Included as Text or as a Footnote at Time 
of Publication 
Colorless needle-shaped crystals of C17H25NO7S are, at 100(2) K, monoclinic,
space group P21 – C2
2 (No. 4) (1) with a = 6.556(1) Å, b = 9.379(2) Å, c = 15.518(3)
Å, ? = 99.695(4)?, V = 940.5(3) Å3 and Z =  2 molecules {dcalcd = 1.368 g/cm3;
?a(MoK?) = 0.211 mm-1}.   A full hemisphere of diffracted intensities (1850 40-
second frames with a ? scan width of 0.30?) was measured for a single-domain
specimen using graphite-monochromated MoK? radiation (?= 0.71073 Å) on a
Bruker SMART APEX CCD Single Crystal Diffraction System (2).  X-rays were
provided by a fine-focus sealed x-ray tube operated at 50kV and 35mA.  Lattice 
constants were determined with the Bruker SAINT software package using peak
centers for 1602 reflections.  A total of 8184 integrated reflection intensities having 
2?((MoK?)< 51.99? were produced using the Bruker program SAINT(3); 3690 of 
these were unique and gave Rint = 0.084 with a coverage which was 99.9% complete.
The data were corrected empirically for variable absorption effects using equivalent 
reflections; the relative transmission factors ranged from 0.751 to 1.000.  The Bruker 
software package SHELXTL was used to solve the structure using “direct methods”
techniques.  All stages of weighted full-matrix least-squares refinement were 
conducted using Fo
2 data with the SHELXTL Version 6.10 software package(4).
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The final structural model incorporated anisotropic thermal parameters
for all nonhydrogen atoms and isotropic thermal parameters for all hydrogen 
atoms.  All hydrogen atoms were located in a difference Fourier and included 
in the structural model as independent isotropic atoms whose positional 
parameters were allowed to vary in least-squares refinement cycles.  The 
isotropic thermal parameters of all hydrogen atoms were fixed at values 1.2 
(nonmethyl) or 1.5 (methyl) times the equivalent isotropic thermal parameter
of the oxygen or carbon atom to which they are covalently bonded.  A total of 
310 parameters were refined using 1 restraint, 3690 data and weights of w = 1/
[?
2
(F
2
) + (0.0464 P)
2
], where P = [Fo
2
 + 2Fc
2
] / 3.  Final agreement factors at
convergence are:  R1(unweighted, based on F) = 0.065 for 2892 independent 
absorption-corrected “observed” reflections having 2?(MoK?)<  51.99? and 
I>2?(I);  R1(unweighted, based on F) = 0.083 and wR2(weighted, based on F2)
= 0.127 for all 3690 independent absorption-corrected reflections having 
2?(MoK?)< 51.99?.  The largest shift/s.u. was 0.000 in the final refinement
cycle.  The final difference map had maxima and minima of 0.61 and -0.56 e-
/Å
3
, respectively.  The absolute configuration was determined experimentally
using anomalous dispersion of the x-rays;  the “Flack” absolute structure
parameter refined to a final value of   –0.01(12).
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Table A8.  Crystal data and structure refinement for C17H25NO7S.
Empirical formula C17H25NO7S
Formula weight 387.44
Temperature 100(2) K 
Wavelength 0.71073 Å 
Crystal system Monoclinic
Space group P21 – C2
2 (No. 4) 
Unit cell dimensions a =   6.556(1) Å ?= 90.000° 
b =   9.379(2) Å ?= 99.695(4)° 
c = 15.518(3) Å ? = 90.000°
Volume 940.5(3) Å3
Z 2 
Density (calculated) 1.368 Mg/m3
Absorption coefficient 0.211 mm-1
F(000) 412 
Crystal size 0.14 x 0.06 x 0.02 mm3
2Theta range for data collection 2.55° to 25.99° 
Index ranges -8 ? h ? 8, -11 ? k ? 11, -19 ? l ? 19 
Reflections collected 8184
Independent reflections 3690 [Rint = 0.084] 
Completeness to theta = 25.99° 99.9 %
Absorption correction Empirical
Max. and min. transmission 1.000 and 0.751 
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 3690 / 1 / 310 
Goodness-of-fit on F2 1.016 
Final R indices [I>2sigma(I)] R1 = 0.065, wR2 = 0.121 
R indices (all data) R1 = 0.083, wR2 = 0.127 
Absolute structure parameter -0.01(12)
Largest diff. peak and hole 0.61 and -0.56 e-/Å3
-------------------------------------------------------------------------------------------------------
R1 = ? ||Fo| - |Fc|| / ? |Fo|
wR2 = { ? [w(Fo
2
 - Fc
2
)
2
] / ? [w(Fo
2
)
2
] }
1/2
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Table A9.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement
parameters (Å2 x 103) for C17H25NO7S.  U(eq) is defined as one third of  the trace of
the orthogonalized Uij tensor. 
__________________________________________________________________________
x y z U(eq)
__________________________________________________________________________
S 1469(2) 6024(1) 1155(1) 18(1)
O(1) 4685(4) 6036(4) 3631(2) 22(1)
O(2) 3701(5) 3506(3) 1594(2) 21(1)
O(3) 2406(5) 3013(3) 2827(2) 26(1)
O(4) 1293(5) 5103(3) 433(2) 26(1)
O(5) 3103(5) 7062(3) 1283(2) 25(1)
O(6) -3034(5) 8385(3) 1876(2) 29(1)
O(7) -2587(5) 5510(3) 2455(2) 24(1)
N 1570(6) 5079(4) 2083(2) 20(1)
C(1) -915(7) 6931(5) 1129(4) 25(1)
C(2) -1167(8) 7658(5) 1976(3) 21(1)
C(3) -995(7) 6529(4) 2698(3) 19(1)
C(4) 1078(7) 5798(4) 2869(3) 18(1)
C(5) 2823(7) 6761(5) 3296(3) 21(1)
C(6) 4557(8) 5166(6) 4376(3) 27(1)
C(7) 6665(7) 4935(5) 4891(3) 21(1)
C(8) 8065(8) 3983(5) 4591(3) 23(1)
C(9) 10002(9) 3809(5) 5052(4) 26(1)
C(10) 10650(8) 4537(5) 5827(3) 25(1)
C(11) 9270(8) 5452(5) 6133(3) 27(1)
C(12) 7320(8) 5641(5) 5663(3) 24(1)
C(13) 2584(7) 3746(4) 2207(3) 16(1)
C(14) 4728(7) 2091(5) 1539(3) 25(1)
C(15) 6311(8) 1856(5) 2329(4) 28(1)
C(16) 5713(10) 2296(6) 734(4) 35(1)
C(17) 3062(9) 943(7) 1390(4) 34(1)
__________________________________________________________________________
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Table A10.   Bond lengths [Å] for C17H25NO7S.
_____________________________________________________________________
S-O(4) 1.405(3)
S-O(5) 1.437(3)
S-N 1.682(4)
S-C(1) 1.774(5)
O(1)-C(5) 1.417(5)
O(1)-C(6) 1.429(6)
O(2)-C(13) 1.314(5)
O(2)-C(14) 1.497(5)
O(3)-C(13) 1.205(5)
O(6)-C(2) 1.387(6)
O(6)-H(6O) 0.78(6)
O(7)-C(3) 1.418(5)
O(7)-H(7O) 0.81(5)
N-C(13) 1.414(5)
N-C(4) 1.477(5)
C(1)-C(2) 1.514(7)
C(1)-H(1A) 1.04(5)
C(1)-H(1B) 0.85(5)
C(2)-C(3) 1.532(6)
C(2)-H(2) 0.93(5)
C(3)-C(4) 1.506(6)
C(3)-H(3) 0.94(5)
C(4)-C(5) 1.520(6)
C(4)-H(4) 1.00(5)
C(5)-H(5A) 0.99(5)
C(5)-H(5B) 0.99(5)
C(6)-C(7) 1.491(7)
C(6)-H(6A) 1.07(5)
C(6)-H(6B) 1.04(5)
C(7)-C(12) 1.372(7)
C(7)-C(8) 1.415(7)
C(8)-C(9) 1.358(7)
C(8)-H(8) 0.85(5)
C(9)-C(10) 1.385(7)
C(9)-H(9) 0.94(5)
C(10)-C(11) 1.388(7)
C(10)-H(10) 0.93(6)
C(11)-C(12) 1.373(7)
C(11)-H(11) 0.95(5)
C(12)-H(12) 1.00(5)
C(14)-C(15) 1.484(7)
C(14)-C(16) 1.512(7)
C(14)-C(17) 1.523(8)
C(15)-H(15A) 0.94(6)
C(15)-H(15B) 0.85(6)
C(15)-H(15C) 0.98(5)
C(16)-H(16A) 0.89(6)
C(16)-H(16B) 0.93(7)
C(16)-H(16C) 1.00(6)
C(17)-H(17A) 0.91(6)
C(17)-H(17B) 1.03(6)
C(17)-H(17C) 0.93(6)
_____________________________________________________________________
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Table A11.   Bond angles [°] for C17H25NO7S.
_____________________________________________________________________
O(4)-S-O(5) 119.0(2)
O(4)-S-N 110.19(18)
O(5)-S-N 108.6(2)
O(4)-S-C(1) 108.9(2)
O(5)-S-C(1) 108.2(2)
N-S-C(1) 100.4(2)
C(5)-O(1)-C(6) 114.0(4) 
C(13)-O(2)-C(14) 120.3(3) 
C(2)-O(6)-H(6O) 123(4) 
C(3)-O(7)-H(7O) 107(4) 
C(13)-N-C(4) 117.0(4) 
C(13)-N-S 122.2(3)
C(4)-N-S 119.0(3)
C(2)-C(1)-S 114.9(4)
C(2)-C(1)-H(1A) 110(2) 
S-C(1)-H(1A) 107(3) 
C(2)-C(1)-H(1B) 116(3) 
S-C(1)-H(1B) 99(3) 
H(1A)-C(1)-H(1B) 109(4) 
O(6)-C(2)-C(1) 110.4(4) 
O(6)-C(2)-C(3) 112.1(4) 
C(1)-C(2)-C(3) 108.5(4) 
O(6)-C(2)-H(2) 113(3) 
C(1)-C(2)-H(2) 109(3) 
C(3)-C(2)-H(2) 104(3) 
O(7)-C(3)-C(4) 110.0(3) 
O(7)-C(3)-C(2) 108.2(4) 
C(4)-C(3)-C(2) 113.4(4) 
O(7)-C(3)-H(3) 110(3) 
C(4)-C(3)-H(3) 102(3) 
C(2)-C(3)-H(3) 114(3) 
N-C(4)-C(3) 112.2(4)
N-C(4)-C(5) 112.2(4) 
C(3)-C(4)-C(5) 113.4(3) 
N-C(4)-H(4) 100(3) 
C(3)-C(4)-H(4) 109(3) 
C(5)-C(4)-H(4) 109(3) 
O(1)-C(5)-C(4) 114.4(4) 
O(1)-C(5)-H(5A) 101(3) 
C(4)-C(5)-H(5A) 110(3) 
O(1)-C(5)-H(5B) 109(3) 
C(4)-C(5)-H(5B) 106(3) 
H(5A)-C(5)-H(5B) 117(4) 
O(1)-C(6)-C(7) 110.0(4) 
O(1)-C(6)-H(6A) 108(3) 
C(7)-C(6)-H(6A) 117(3) 
O(1)-C(6)-H(6B) 105(3) 
C(7)-C(6)-H(6B) 108(3) 
H(6A)-C(6)-H(6B) 108(4) 
C(12)-C(7)-C(8) 117.8(4) 
C(12)-C(7)-C(6) 121.5(5) 
C(8)-C(7)-C(6) 120.6(4) 
C(9)-C(8)-C(7) 120.2(5) 
C(9)-C(8)-H(8) 121(4) 
C(7)-C(8)-H(8) 118(4) 
C(8)-C(9)-C(10) 121.4(5) 
C(8)-C(9)-H(9) 126(3) 
C(10)-C(9)-H(9) 112(3) 
C(9)-C(10)-C(11) 118.7(5) 
C(9)-C(10)-H(10) 123(3) 
C(11)-C(10)-H(10) 119(3) 
C(12)-C(11)-C(10) 120.0(5) 
C(12)-C(11)-H(11) 123(3) 
C(10)-C(11)-H(11) 117(3) 
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C(7)-C(12)-C(11) 121.9(5) 
C(7)-C(12)-H(12) 119(3) 
C(11)-C(12)-H(12) 119(3) 
O(3)-C(13)-O(2) 128.4(4) 
O(3)-C(13)-N 120.5(4) 
O(2)-C(13)-N 111.1(4) 
C(15)-C(14)-O(2) 110.0(4) 
C(15)-C(14)-C(16) 111.4(5) 
O(2)-C(14)-C(16) 101.2(4) 
C(15)-C(14)-C(17) 113.9(4) 
O(2)-C(14)-C(17) 108.5(4) 
C(16)-C(14)-C(17) 111.1(4) 
C(14)-C(15)-H(15A) 108(3) 
C(14)-C(15)-H(15B) 115(4) 
H(15A)-C(15)-H(15B) 102(5) 
C(14)-C(15)-H(15C) 110(3) 
H(15A)-C(15)-H(15C) 107(4) 
H(15B)-C(15)-H(15C) 114(5) 
C(14)-C(16)-H(16A) 111(4) 
C(14)-C(16)-H(16B) 108(3) 
H(16A)-C(16)-H(16B) 108(5) 
C(14)-C(16)-H(16C) 111(3) 
H(16A)-C(16)-H(16C) 114(5) 
H(16B)-C(16)-H(16C) 105(5) 
C(14)-C(17)-H(17A) 111(4) 
C(14)-C(17)-H(17B) 109(3) 
H(17A)-C(17)-H(17B) 108(5) 
C(14)-C(17)-H(17C) 110(4) 
H(17A)-C(17)-H(17C) 111(5) 
H(17B)-C(17)-H(17C) 108(5) 
__________________________________________________________________________
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Table A12.   Anisotropic displacement parameters (Å2 x 103) for C17H25NO7S.  The 
anisotropic displacement factor exponent takes the form:  -2?2[ h2 a*2U11 + ...  + 2 h k 
a* b* U12 ]
_____________________________________________________________________
 U11 U22  U33 U23 U13 U12
_____________________________________________________________________
S 20(1) 12(1) 21(1) 5(1) 4(1) 3(1)
O(1) 21(2) 20(2) 28(2) 4(2) 8(1) 3(2)
O(2) 26(2) 9(2) 28(2) 1(1) 10(2) 8(1)
O(3) 40(2) 13(2) 25(2) 7(2) 9(2) 4(2)
O(4) 31(2) 22(2) 25(2) 4(2) 5(2) 4(2)
O(5) 22(2) 19(2) 34(2) 7(1) 7(2) 4(1)
O(6) 20(2) 17(2) 50(2) -4(2) 6(2) 3(1)
O(7) 21(2) 17(2) 35(2) -4(1) 10(2) -1(1)
N 28(2) 13(2) 20(2) 5(2) 11(2) 7(2)
C(1) 15(2) 19(3) 42(3) 12(2) 7(2) 5(2)
C(2) 21(3) 14(2) 30(3) -3(2) 6(2) 1(2)
C(3) 22(3) 13(2) 23(2) -6(2) 3(2) -4(2)
C(4) 27(2) 4(2) 23(2) -2(2) 9(2) 2(2)
C(5) 22(3) 14(2) 26(3) -2(2) 3(2) 2(2)
C(6) 32(3) 28(3) 22(3) 2(2) 6(2) -5(2)
C(7) 27(3) 14(2) 22(2) 4(2) 7(2) -3(2)
C(8) 30(3) 17(2) 24(3) -4(2) 7(2) -5(2)
C(9) 29(3) 14(3) 39(3) 4(2) 17(2) 5(2)
C(10) 23(3) 20(2) 33(3) 12(2) 4(2) -2(2)
C(11) 44(3) 11(2) 25(3) 1(2) 6(2) -7(2)
C(12) 28(3) 13(2) 31(3) 2(2) 11(2) 0(2)
C(13) 18(3) 10(2) 20(2) -1(2) 1(2) 2(2)
C(14) 35(3) 10(2) 28(3) -7(2) 6(2) 14(2)
C(15) 24(3) 13(3) 45(3) -6(2) 3(2) 8(2)
C(16) 44(4) 28(3) 33(3) -8(3) 13(3) 14(3)
C(17) 37(3) 25(3) 37(3) -9(3) -2(2) 10(3)
_____________________________________________________________________
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Table A13.   Hydrogen coordinates ( x 104) and isotropic displacement parameters
(Å2 x 103) for C17H25NO7S.
_____________________________________________________________________
x y z U(eq)
_____________________________________________________________________
H(6O) -4100(90) 8020(60) 1720(40) 34
H(7O) -3560(80) 5750(50) 2680(30) 28
H(1A) -2080(70) 6190(60) 950(30) 30
H(1B) -860(80) 7480(60) 700(30) 30
H(2) -30(80) 8240(50) 2150(30) 26
H(3) -1080(70) 6900(50) 3250(30) 23
H(4) 1000(70) 4950(50) 3260(30) 21
H(5A) 3280(70) 7390(50) 2850(30) 25
H(5B) 2300(70) 7240(50) 3790(30) 25
H(6A) 3670(80) 4240(50) 4160(30) 32
H(6B) 3720(70) 5780(50) 4760(30) 32
H(8) 7710(80) 3600(60) 4090(30) 28
H(9) 11070(80) 3260(60) 4880(30) 32
H(10) 12010(80) 4490(50) 6130(30) 30
H(11) 9730(70) 5880(60) 6690(30) 32
H(12) 6350(70) 6320(50) 5890(30) 28
H(15A) 7070(80) 1040(70) 2230(30) 41
H(15B) 7250(90) 2490(60) 2420(30) 41
H(15C) 5650(90) 1660(60) 2830(40) 41
H(16A) 6640(90) 3000(70) 810(40) 52
H(16B) 6400(90) 1460(70) 640(40) 52
H(16C) 4630(100) 2400(60) 200(40) 52
H(17A) 2040(90) 1180(70) 940(40) 51
H(17B) 3710(100) 0(70) 1230(40) 51 
H(17C) 2520(90) 790(70) 1900(40) 51
__________________________________________________________________________
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Table A14.  Torsion angles [°] for C17H25NO7S.
________________________________________________________________
O(4)-S-N-C(13) 35.7(4) 
O(5)-S-N-C(13) -96.3(4) 
C(1)-S-N-C(13) 150.4(4) 
O(4)-S-N-C(4) -160.3(3) 
O(5)-S-N-C(4) 67.7(4) 
C(1)-S-N-C(4) -45.7(4) 
O(4)-S-C(1)-C(2) 164.6(3) 
O(5)-S-C(1)-C(2) -64.7(4) 
N-S-C(1)-C(2) 48.9(4) 
S-C(1)-C(2)-O(6) 177.5(3) 
S-C(1)-C(2)-C(3) -59.4(5) 
O(6)-C(2)-C(3)-O(7) 62.1(5) 
C(1)-C(2)-C(3)-O(7) -60.0(5) 
O(6)-C(2)-C(3)-C(4) -175.6(4) 
C(1)-C(2)-C(3)-C(4) 62.2(5) 
C(13)-N-C(4)-C(3) -141.5(4) 
S-N-C(4)-C(3) 53.7(4) 
C(13)-N-C(4)-C(5) 89.5(5) 
S-N-C(4)-C(5) -75.3(4) 
O(7)-C(3)-C(4)-N 62.5(5) 
C(2)-C(3)-C(4)-N -58.8(5) 
O(7)-C(3)-C(4)-C(5) -169.1(4) 
C(2)-C(3)-C(4)-C(5) 69.7(5) 
C(6)-O(1)-C(5)-C(4) -69.1(5) 
N-C(4)-C(5)-O(1) -64.2(5) 
C(3)-C(4)-C(5)-O(1) 167.4(4) 
C(5)-O(1)-C(6)-C(7) -157.0(4) 
O(1)-C(6)-C(7)-C(12) 104.4(5) 
O(1)-C(6)-C(7)-C(8) -75.0(6) 
C(12)-C(7)-C(8)-C(9) -1.3(7) 
C(6)-C(7)-C(8)-C(9) 178.1(5) 
C(7)-C(8)-C(9)-C(10) 0.8(7) 
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C(8)-C(9)-C(10)-C(11) 0.5(7) 
C(9)-C(10)-C(11)-C(12) -1.2(7) 
C(8)-C(7)-C(12)-C(11) 0.6(6) 
C(6)-C(7)-C(12)-C(11) -178.9(4) 
C(10)-C(11)-C(12)-C(7) 0.7(7) 
C(14)-O(2)-C(13)-O(3) 8.7(7) 
C(14)-O(2)-C(13)-N -173.3(4) 
C(4)-N-C(13)-O(3) 25.3(6) 
S-N-C(13)-O(3) -170.4(3) 
C(4)-N-C(13)-O(2) -152.8(4) 
S-N-C(13)-O(2) 11.5(5) 
C(13)-O(2)-C(14)-C(15) -64.6(5) 
C(13)-O(2)-C(14)-C(16) 177.6(4) 
C(13)-O(2)-C(14)-C(17) 60.6(5) 
________________________________________________________________
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Table A15.  Hydrogen bonds for C17H25NO7S [Å and °]. 
_____________________________________________________________________
D-H...A d(D-H) d(H...A) d(D...A) <(DHA)
_____________________________________________________________________
 O(6)-H(6O)...O(5)#1 0.78(6) 2.05(6) 2.831(5) 179(6)
 O(7)-H(7O)...O(1)#1 0.81(5) 2.04(5) 2.805(4) 159(5)
_____________________________________________________________________
Symmetry transformations used to generate equivalent atoms:  #1:  x-1, y, z.
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Comments
The asymmetric unit contains one C12H15NO4S molecule (2.13).  All 
displacement ellipsoids are drawn at the 50% probability level.
Brief  Experimental Description to be Included as Text or as a Footnote at Time 
of Publication 
Colorless crystals of C12H15NO4S are, at 100(2) K, monoclinic, space group
P21 – C2
2 (No. 4) with a = 6.406(1) Å, b = 9.788(1) Å, c = 9.865(1) Å, ? = 95.112(2)?,
V = 616.1(1) Å3 and Z =  2 molecules {dcalcd = 1.452g/cm
3; ?a(MoK?) = 0.269 mm-1}.
A full hemisphere of diffracted intensities (1850 10-second frames with a ? scan 
width of 0.30?) was measured for a single-domain specimen using graphite-
monochromated MoK? radiation (?= 0.71073 Å) on a Bruker SMART APEX CCD
Single Crystal Diffraction System (2).  X-rays were provided by a fine-focus sealed 
x-ray tube operated at 50kV and 30mA. Lattice constants were determined with the
Bruker SAINT software package using peak centers for 3642 reflections.  A total 
7585 integrated reflection intensities having 2?((MoK?)< 61.00? were produced 
using the Bruker program SAINT(3); 3673 of these were unique and gave Rint = 
0.037 with a coverage which was 99.5% complete. The data were corrected 
empirically for variable absorption effects using equivalent reflections; the relative
transmission factors ranged from 0.964 to 1.000.  The Bruker software package 
SHELXTL was used to solve the structure using “direct methods” techniques.  All
stages of weighted full-matrix least-squares refinement were conducted using Fo
2 data
with the SHELXTL Version 6.10 software package(4).
403
The final structural model incorporated anisotropic thermal parameters for all 
nonhydrogen atoms and isotropic thermal parameters for all hydrogen atoms.  All
hydrogen atoms were located in a difference Fourier and included in the structural 
model as independent isotropic atoms whose parameters were allowed to vary in 
least-squares refinement cycles.  A total of 223 parameters were refined using 1 
restraint, 3673 data and weights of w = 1/ [?
2
(F
2
) + (0.0483 P)
2
], where P = [Fo
2
 + 
2Fc
2
] / 3.  Final agreement factors at convergence are:  R1(unweighted, based on F) =
0.039 for 3532  independent absorption-corrected “observed” reflections having 
2?(MoK?)<  61.00? and I>2?(I);  R1(unweighted, based on F) = 0.040 and 
wR2(weighted, based on F
2) = 0.088 for all 3673 independent absorption-corrected 
reflections having 2?(MoK?)< 61.00?.  The largest shift/s.u. was 0.000 in the final
refinement cycle.  The final difference map had maxima and minima of 0.58 and 
-0.25 e-/Å
3
, respectively.
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Table A16.  Crystal data and structure refinement for C12H15NO4S.
Empirical formula C12H15NO4S
Formula weight 269.31
Temperature 100(2) K 
Wavelength 0.71073 Å 
Crystal system Monoclinic
Space group P21 – C2
2 (No. 4) 
Unit cell dimensions a = 6.406(1) Å ? = 90.000°
b = 9.788(1) Å ? = 95.112(2)° 
c = 9.865(1) Å ? = 90.000°
Volume 616.1(1) Å3
Z 2 
Density (calculated) 1.452 Mg/m3
Absorption coefficient 0.269 mm-1
F(000) 284 
Crystal size 0.32 x 0.22 x 0.05 mm3
Theta range for data collection 2.94 to 30.50° 
Index ranges -8 ? h ? 9, -13 ? k ? 13, -13 ? l ? 13 
Reflections collected 7585
Independent reflections 3673 [Rint = 0.037] 
Completeness to theta = 30.50° 99.5 %
Absorption correction Empirical
Max. and min. transmission 1.000 and 0.964 
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 3673 / 1 / 223 
Goodness-of-fit on F2 1.024 
Final R indices [I>2sigma(I)] R1 = 0.039, wR2 = 0.088 
R indices (all data) R1 = 0.040, wR2 = 0.088 
Absolute structure parameter 0.05(6)
Largest diff. peak and hole 0.58 and -0.25 e-/Å
3
_____________________________________________________________________
R1 = ? ||Fo| - |Fc|| / ? |Fo|
wR2 = { ? [w(Fo
2
 - Fc
2
)
2
] / ? [w(Fo
2
)
2
] }
1/
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Table A17.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement
parameters (Å2 x 103) for C12H15NO4S. U(eq) is defined as one third of  the trace of 
the orthogonalized Uij tensor. 
_____________________________________________________________________
 x y z U(eq)
_____________________________________________________________________
S -4116(1) 2422(1) -1569(1) 15(1)
O(1) 44(2) 3656(1) 1890(1) 17(1)
O(2) 156(2) 5891(1) -1050(1) 21(1)
O(3) -4016(2) 953(1) -1581(1) 22(1)
O(4) -6124(2) 3066(2) -1819(1) 23(1)
N(1) -3007(2) 2910(2) -107(2) 15(1)
C(1) -2489(3) 3067(2) -2751(2) 17(1)
C(2) -936(3) 3919(2) -2362(2) 17(1)
C(3) -416(3) 4482(2) -958(2) 14(1)
C(4) -2200(3) 4323(2) -36(2) 14(1)
C(5) -1490(3) 4653(2) 1434(2) 17(1)
C(6) 835(3) 3849(2) 3273(2) 19(1)
C(7) 2474(3) 2774(2) 3605(2) 16(1)
C(8) 4042(3) 2570(2) 2724(2) 19(1)
C(9) 5543(3) 1557(2) 2997(2) 21(1)
C(10) 5498(3) 747(2) 4154(2) 20(1)
C(11) 3976(3) 954(2) 5039(2) 21(1)
C(12) 2458(3) 1965(2) 4762(2) 19(1)
_____________________________________________________________________
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Table A18.   Bond lengths [Å] for C12H15NO4S.
________________________________________________________________
S-O(4)   1.434(1) 
S-O(3) 1.439(1)
S-N(1) 1.622(2)
S-C(1) 1.749(2)
O(1)-C(6) 1.425(2)
O(1)-C(5) 1.428(2)
O(2)-C(3) 1.432(2)
O(2)-H(2O) 0.76(3)
N(1)-C(4) 1.476(2)
N(1)-H(1N) 0.77(3)
C(1)-C(2) 1.328(2)
C(1)-H(1) 0.96(2)
C(2)-C(3) 1.500(2)
C(2)-H(2) 0.90(2)
C(3)-C(4) 1.530(2)
C(3)-H(3) 0.91(2)
C(4)-C(5) 1.515(2)
C(4)-H(4) 0.96(2)
C(5)-H(5A) 0.94(2)
C(5)-H(5B) 0.94(2)
C(6)-C(7) 1.502(2)
C(6)-H(6A) 0.88(2)
C(6)-H(6B) 1.00(3)
C(7)-C(12) 1.390(2)
C(7)-C(8) 1.400(2)
C(8)-C(9) 1.391(3)
C(8)-H(8) 0.91(3)
C(9)-C(10) 1.391(3)
C(9)-H(9) 0.91(2)
C(10)-C(11) 1.381(3)
C(10)-H(10) 1.01(2)
C(11)-C(12) 1.397(3)
C(11)-H(11) 0.98(2)
C(12)-H(12) 0.95(2)
_____________________________________________________________________
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Table A19.   Bond angles [°] for  C12H15NO4S.
_____________________________________________________________________
O(4)-S-O(3) 118.49(8)
O(4)-S-N(1) 109.82(8)
O(3)-S-N(1) 106.57(8)
O(4)-S-C(1) 107.79(8)
O(3)-S-C(1) 108.99(8)
N(1)-S-C(1) 104.28(8)
C(6)-O(1)-C(5) 112.76(13)
C(3)-O(2)-H(2O) 104(2) 
C(4)-N(1)-S 116.21(12)
C(4)-N(1)-H(1N) 109.8(19) 
S-N(1)-H(1N) 109.8(19)
C(2)-C(1)-S 120.65(14)
C(2)-C(1)-H(1) 121.9(12) 
S-C(1)-H(1) 117.5(12)
C(1)-C(2)-C(3) 126.56(16)
C(1)-C(2)-H(2) 119.3(13) 
C(3)-C(2)-H(2) 114.1(13) 
O(2)-C(3)-C(2) 109.40(14)
O(2)-C(3)-C(4) 110.15(14)
C(2)-C(3)-C(4) 113.30(14)
O(2)-C(3)-H(3) 103.6(12) 
C(2)-C(3)-H(3) 112.8(12) 
C(4)-C(3)-H(3) 107.1(12) 
N(1)-C(4)-C(5) 108.58(14)
N(1)-C(4)-C(3) 110.14(13)
C(5)-C(4)-C(3) 111.78(14)
N(1)-C(4)-H(4) 105.3(13) 
C(5)-C(4)-H(4) 112.0(13) 
C(3)-C(4)-H(4) 108.8(12) 
O(1)-C(5)-C(4) 107.17(13) 
O(1)-C(5)-H(5A) 107.8(13) 
C(4)-C(5)-H(5A) 110.5(13) 
O(1)-C(5)-H(5B) 109.9(13) 
C(4)-C(5)-H(5B) 112.1(13) 
H(5A)-C(5)-H(5B) 109.2(18) 
O(1)-C(6)-C(7) 107.36(14) 
O(1)-C(6)-H(6A) 110.9(14) 
C(7)-C(6)-H(6A) 110.8(15) 
O(1)-C(6)-H(6B) 106.4(13) 
C(7)-C(6)-H(6B) 112.7(14) 
H(6A)-C(6)-H(6B) 109(2) 
C(12)-C(7)-C(8) 119.10(16) 
C(12)-C(7)-C(6) 121.51(16) 
C(8)-C(7)-C(6) 119.38(15) 
C(9)-C(8)-C(7) 120.22(16) 
C(9)-C(8)-H(8) 121.7(16) 
C(7)-C(8)-H(8) 118.0(16) 
C(8)-C(9)-C(10) 120.05(17) 
C(8)-C(9)-H(9) 118.9(13) 
C(10)-C(9)-H(9) 120.9(13) 
C(11)-C(10)-C(9) 120.15(17) 
C(11)-C(10)-H(10) 119.3(12) 
C(9)-C(10)-H(10) 120.6(12) 
C(10)-C(11)-C(12) 119.91(17) 
C(10)-C(11)-H(11) 119.1(13) 
C(12)-C(11)-H(11) 120.9(13) 
C(7)-C(12)-C(11) 120.57(18) 
C(7)-C(12)-H(12) 120.9(13) 
C(11)-C(12)-H(12) 118.6(13)
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_____________________________________________________________________
Table A20.   Anisotropic displacement parameters  (Å2 x 103) for C12H15NO4S. The 
anisotropic displacement factor exponent takes the form:  -2?2[ h2 a*2U11 + ...  + 2 h k 
a* b* U12 ] 
_____________________________________________________________________
 U11 U22  U33 U23 U13 U12
_____________________________________________________________________
S 12(1) 15(1) 18(1) -1(1) 1(1) -2(1)
O(1) 17(1) 16(1) 16(1) -2(1) -2(1) 4(1)
O(2) 22(1) 12(1) 27(1) 3(1) -4(1) -5(1)
O(3) 23(1) 16(1) 27(1) -2(1) 2(1) -6(1)
O(4) 13(1) 30(1) 26(1) -2(1) 0(1) 1(1)
N(1) 14(1) 13(1) 17(1) 0(1) 1(1) 0(1)
C(1) 18(1) 16(1) 16(1) -1(1) 4(1) -1(1)
C(2) 16(1) 17(1) 19(1) 2(1) 3(1) -1(1)
C(3) 13(1) 11(1) 18(1) 1(1) 0(1) -1(1)
C(4) 13(1) 12(1) 17(1) -1(1) 1(1) 2(1)
C(5) 17(1) 14(1) 18(1) -2(1) 1(1) 3(1)
C(6) 21(1) 20(1) 16(1) -1(1) 1(1) 3(1)
C(7) 16(1) 16(1) 16(1) -1(1) -1(1) -1(1)
C(8) 19(1) 21(1) 18(1) 5(1) 2(1) 0(1)
C(9) 17(1) 24(1) 22(1) 1(1) 2(1) 3(1)
C(10) 20(1) 20(1) 19(1) 0(1) -4(1) 2(1)
C(11) 27(1) 20(1) 14(1) 3(1) -2(1) -1(1)
C(12) 23(1) 21(1) 14(1) -2(1) 2(1) -1(1)
_____________________________________________________________________
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Table A21.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters
(Å2 x 103) for C12H15NO4S.
_____________________________________________________________________
x y z U(eq)
_____________________________________________________________________
H(2O) -740(40) 6200(30) -1500(30) 34(8)
H(1N) -2120(40) 2410(30) 130(20) 27(6)
H(1) -2770(30) 2790(20) -3680(20) 13(5)
H(2) -110(30) 4240(20) -2990(20) 11(5)
H(3) 750(30) 4090(20) -519(19) 8(4)
H(4) -3350(30) 4880(20) -380(20) 17(5)
H(5A) -2620(30) 4580(20) 1980(20) 14(5)
H(5B) -920(30) 5530(20) 1530(20) 18(6)
H(6A) -180(40) 3780(20) 3820(20) 17(5)
H(6B) 1420(40) 4790(30) 3340(20) 26(6)
H(8) 4030(40) 3110(30) 1970(30) 27(6)
H(9) 6480(30) 1390(20) 2380(20) 14(5)
H(10) 6580(30) 0(20) 4360(20)
 21(6) 
H(11) 3970(30) 380(20) 5850(20) 16(5)
H(12) 1410(40) 2080(20) 5380(20) 20(6)
_____________________________________________________________________
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Table A22.  Torsion angles [°] for C12H15NO4S.
________________________________________________________________
O(4)-S-N(1)-C(4) -72.9(1) 
O(3)-S-N(1)-C(4) 157.6(1) 
C(1)-S-N(1)-C(4) 42.3(1) 
O(4)-S-C(1)-C(2) 108.2(2) 
O(3)-S-C(1)-C(2) -122.0(2) 
N(1)-S-C(1)-C(2) -8.5(2) 
S-C(1)-C(2)-C(3) -2.9(3) 
C(1)-C(2)-C(3)-O(2) -139.7(2) 
C(1)-C(2)-C(3)-C(4) -16.4(2) 
S-N(1)-C(4)-C(5) 172.6(1) 
S-N(1)-C(4)-C(3) -64.7(2) 
O(2)-C(3)-C(4)-N(1) 171.4(1) 
C(2)-C(3)-C(4)-N(1) 48.5(2) 
O(2)-C(3)-C(4)-C(5) -67.8(2) 
C(2)-C(3)-C(4)-C(5) 169.3(1) 
C(6)-O(1)-C(5)-C(4) -179.7(1) 
N(1)-C(4)-C(5)-O(1) 57.2(2) 
C(3)-C(4)-C(5)-O(1) -64.5(2) 
C(5)-O(1)-C(6)-C(7) -178.0(1) 
O(1)-C(6)-C(7)-C(12) -130.3(2) 
O(1)-C(6)-C(7)-C(8) 48.9(2) 
C(12)-C(7)-C(8)-C(9) 0.8(3) 
C(6)-C(7)-C(8)-C(9) -178.4(2) 
C(7)-C(8)-C(9)-C(10) -0.4(3) 
C(8)-C(9)-C(10)-C(11) -0.6(3) 
C(9)-C(10)-C(11)-C(12) 1.0(3) 
C(8)-C(7)-C(12)-C(11) -0.4(3) 
C(6)-C(7)-C(12)-C(11) 178.9(2) 
C(10)-C(11)-C(12)-C(7) -0.5(3) 
________________________________________________________________
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Table A23.  Hydrogen bonds for C12H15NO4S [Å and °]. 
_____________________________________________________________________
D-H...A d(D-H) d(H...A) d(D...A) <(DHA)
_____________________________________________________________________
 N(1)-H(1N)...O(2)#1 0.77(3) 2.10(3) 2.859(2) 168(2)
_____________________________________________________________________
Symmetry transformations used to generate equivalent atoms:  #1 –x;  y-1/2;  -z.
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